MARK J. BENNETT 2672
ATTORNEY GENERAL
STATE OF HAWAII

Civil No. 06-1-0720-04 EEH
(Complex Litigation)

FIRST CIRCUIT
STATE OF HAWAII
FILED
2007 JUL -3 PM 12: 07
F. OTAKE
CLERK

LEXISNEXIS® FILE & SERVE
15457758
E-SERVICE
Jul 3 2007 3:47PM

MINER, BARNHILL & GALLAND, P.C.
CHARLES BARNHILL, JR. (WI Bar No. 1015932)
44 East Mifflin Street, Suite 803
Madison, Wisconsin 53703
Telephone: (608) 255-5200
Facsimile: (608) 255-5380
E-mail: cbarnhill@lawmbg.com

SPECIAL DEPUTY ATTORNEY GENERAL
ATTORNEY FOR PLAINTIFF

MINER, BARNHILL & GALLAND, P.C.
GEORGE F. GALLAND, JR. (IL Bar No. 0906646)
ROBERT S. LIBMAN (IL Bar No. 6282259)
14 East Erie Street
Chicago, Illinois 60601
Telephone: (312) 751-1170
Facsimile: (608) 255-5380
Email: ggalland@lawmbg.com
E-mail: rlibman@lawmbg.com

BEASLEY, ALLEN, CROW, METHVIN, PORTIS & MILES, P.C.
W. DANIEL "Dee" MILES, III (AL Bar No. MIL060)
CLINTON C. CARTER (AL Bar No. CAR112)
272 Commerce Street
P.O. Box 4160
Montgomery, Alabama 36103-4160
Telephone: (334) 269-2343
Facsimile: (334) 954-7555
E-mail: dee.miles@beasleyallen.com
E-mail: clint.carter@beasleyallen.com

P. JEFFREY ARCHIBALD (WI Bar No. 1006299)
1914 Monroe Street
Madison, Wisconsin 53711
Telephone: (608) 661-8855
Facsimile: (608) 661-0067
E-mail: archibaldlaw@tds.net

I do hereby certify that this is a full, true, and correct copy of the original on file in this office.
Clerk Circuit Court, First Circuit

SUMMONS DENIED
LEGAL DOCUMENTS BR

MICHAEL WINGET-HERNANDEZ (TX Bar No. 2176950)
3112 Windsor Road, Suite 228
Austin, Texas 78703
Telephone: (512) 474-4095
Facsimile: (512) 697-0080
Email: m.winget.hernandez@gmail.com

PRICE, OKAMOTO, HIMENO & LUM
WARREN PRICE, III 1212
KENNETH T. OKAMOTO 2068
RICK J. EICHOR 1588
707 Richards Street, Suite 728
Honolulu, Hawaii 96813
Telephone: (808) 538-1113
Facsimile: (808) 533-0549
E-mail: wprice@pohlhawaii.com
E-mail: kokamoto@pohlhawaii.com
E-mail: reichor@pohlhawaii.com

ATTORNEYS FOR PLAINTIFF

IN THE CIRCUIT COURT OF THE FIRST CIRCUIT

STATE OF HAWAI'I

State of Hawaii, Plaintiff, vs. Abbott Laboratories Inc.; Alpharma USPD, Inc.; Apothecon, Inc.; AstraZeneca Pharmaceuticals LP, AstraZeneca LP; Aventis Pharmaceuticals, Inc.; Aventis Behring LLC n/k/a ZLB Behring LLC; Barr Laboratories, Inc.; Baxter Healthcare Corporation; Ben Venue Laboratories, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Roxane, Inc. f/k/a Roxane Laboratories, Inc.; Bristol-Myers Squibb Co.; Centocor, Inc.; Dey, Inc.; Forest Pharmaceuticals, Inc.; SmithKline Beecham Corporation d/b/a GlaxoSmithKline; Hoffman-LaRoche, Inc.;	Civil No. 06-1-0720-04 EEH (Complex Litigation) SECOND AMENDED COMPLAINT; EXHIBITS "1 to 3"; SUMMONS TO ANSWER SECOND AMENDED COMPLAINT; DEMAND FOR JURY TRIAL; CERTIFICATE OF SERVICE

Hospira, Inc.; Ivax Corporation; Ivax Pharmaceuticals Inc.; Janssen, LP f/k/a Janssen Pharmaceutica, LP; Johnson & Johnson, Inc.; McNeil-PPC, Inc.; Merck & Co., Inc.; Mylan Laboratories, Inc.; Mylan Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, LP; Par Pharmaceutical Cos., Inc.; Pfizer, Inc.; Pharmacia Corporation; Purepac Pharmaceutical Co.; Roche Laboratories, Inc.; Sandoz, Inc.; Schering-Plough Corporation; Sicor Pharmaceuticals, Inc. f/k/a Gensia Sicor Pharmaceuticals, Inc.; TAP Pharmaceutical Products, Inc.; Teva Pharmaceuticals USA, Inc.; Warrick Pharmaceuticals Corporation; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Doe Corporations 1-100; Doe Entities 1-100.

Defendants.

TABLE OF CONTENTS

Page

I. INTRODUCTION 1

II. PARTIES 2

A. Plaintiff 2

B. Defendants 3

III. FACTUAL BACKGROUND 10

A. The Market for Prescription Drugs 10

B. The Purpose of the Medicaid Program and How it Responds to the Complexity of the Drug Markets 12

C. Defendant's Corruption of the Government Medicaid Programs 15

IV. DEFENDANTS' EXACERBATION OF THE COMPLEXITIES OF THE MARKET AND AFFIRMATIVE CONCEALMENT OF THEIR WRONGDOING 18

V. THE GOVERNMENTAL INVESTIGATIONS OF DEFENDANTS' CONDUCT 22

VI. THE INJURY TO GOVERNMENTAL HEALTH PLANS CAUSED BY DEFENDANTS' FALSE WHOLESALE PRICES 26

A. The Hawaii Medicaid Program 26

B. The Medicare Program 28

VII. DEFENDANTS' CONDUCT INTENTIONALLY DISREGARDED ESTABLISHED LAW 30

VIII. TOLLING 30

Count I – False Claims 31
Count II – Unfair or Deceptive Acts or Practices 31
Count III – Unfair Competition 32
Count IV – Deceptive Trade Practices Act 32
Count V – Intentional and / or Negligent Misrepresentation 33
Count VI – Unjust Enrichment 33

SECOND AMENDED COMPLAINT

I. INTRODUCTION

1. This case is an enforcement action brought by the State of Hawaii under State law on behalf of its Medicaid program, as well as Hawaii residents who are Medicare beneficiaries, against Defendant Drug Companies who have caused the submission of false claims and engaged in unfair or deceptive acts or practices in the sale, pricing and marketing of their prescription drug products. The State of Hawaii brings this action exclusively under the common law and statutes of the State of Hawaii. No federal claims are asserted. No aspect of the claims asserted herein is brought pursuant to any federal law, including either Medicare or ERISA, nor is any aspect of the claims asserted herein brought for the purpose of interpreting a federal contract or the terms of an ERISA plan.

2. The Defendant Drug Companies' fraudulent pricing and marketing of their prescription drugs have impacted elderly, disabled, and poor Hawaii citizens covered by Medicaid and Medicare by causing them to pay grossly excessive prices for the Defendants' prescription drugs. Defendants have taken advantage of the enormously complicated and non-transparent market for prescription drugs to engage in an unlawful scheme to cause Hawaii and its citizens to pay inflated prices for prescription drugs. The scheme involves the publication by Defendants of phony "average wholesale prices," which become the basis for calculating the cost at which "providers" - the physicians, clinics, and pharmacies who provide these prescription drugs to patients - are reimbursed by Plaintiff. Defendants reinforce this basic tactic with other deceptive practices described in this Second Amended Complaint, including the use of secret discounts and rebates to providers and the use of various devices to keep secret the prices at which their drugs are

currently available in the marketplace to other purchasers. By willfully engaging in this scheme, Defendants have succeeded in having Plaintiff finance windfall profits to these providers. Defendants attempt to profit from their scheme by using the lure of these windfall profits competitively to encourage providers to buy their drugs instead of competing in the marketplace solely on the basis of legitimate factors such as price and the medicinal value of their drugs.

3. Fair and honest drug pricing is a matter of great importance to the State and its citizens. Expenditures by the State and its agencies for prescription drug reimbursement have increased dramatically in the past several years as a result, in part, of Defendants' fraudulent pricing scheme. Each year Hawaii spends millions of dollars on prescription drugs under the Hawaii Medicaid program. The cost of prescription drug services in the Hawaii Medicaid program has seen dramatic increases rising from $25.4 million in 1997 to $117 million in 2004, an increase of over 350%.

4. This exponential increase in prescription drug costs in recent years has contributed to a health care funding crisis within the State that requires action to ensure fair dealing between the Defendants and the State and Hawaii Medicare beneficiaries.

II. PARTIES

A. Plaintiff

5. This action is brought by the State of Hawaii for violations of 1) the Hawaii False Claims Act, Unfair Competition, Deceptive Trade Practices, Non-Disclosure, and Unjust Enrichment, and 2) as parens patriae on behalf of Medicare beneficiary purchasers for Unfair or Deceptive Acts or Practices and/or Unfair Competition, Deceptive Trade Practices, declared unlawful by Hawaii Revised Statutes ("H.R.S.") §480-2, H.R.S. §480-13 and H.R.S. § 481A-3(a)(9), (11) and (12) and Unjust

Enrichment. No claim is asserted for Medicare beneficiaries who made flat insurance co-payments and those whose co-payment was reimbursed in full by a third-party insurer.

6. The Attorney General is authorized to bring this action on behalf of the State of Hawaii and its agencies by virtue of H.R.S. §28-1. The Attorney General is authorized to bring this case for indirect purchasers based upon unfair or deceptive acts or practices and/or unfair competition declared unlawful by H.R.S. §480-2 by virtue of H.R.S. §480-14.

B. Defendants

7. Defendants are all pharmaceutical companies whose fraudulent schemes, including the publication of excessive and inflated prices for prescription drugs, as described in this Second Amended Complaint, have caused to be presented to officers and/or employees of the State of Hawaii false or fraudulent claims for payment or approval of certain drugs to get these false or fraudulent claims paid or approved by the State of Hawaii Medicaid program, and have resulted in Hawaii and its citizens paying for drugs at inflated prices, as detailed below.

8. At all times material to this civil action, each Defendant has transacted business in the State of Hawaii by, including but not limited to, selling directly or through wholesalers its drugs, including those identified in this Second Amended Complaint, to purchasers within the State of Hawaii.

9. Defendant Abbott Laboratories Inc. ("Abbott") is a Delaware corporation with its principal place of business located at 100 Abbott Park Road, Abbott Park, IL 60064-6400.

10. The following two Defendants are hereinafter referred to as the Alpharma group:

(a) Defendant Alpharma USPD, Inc. ("Alpharma") is a Delaware corporation in the business of manufacturing and selling pharmaceuticals. Alpharma's principal place of business is located at One Executive Drive, Ft. Lee, NJ 07024; and

(b) Defendant Purepac Pharmaceutical Co. ("Purepac") is a Delaware corporation in the business of manufacturing and selling pharmaceuticals. Purepac's principal place of business is located at 14 Commerce Drive, Suite 301, Cranford, NJ 07016. Purepac is a wholly owned subsidiary of Alpharma, Inc.

11. Defendants AstraZeneca Pharmaceuticals LP and AstraZeneca LP ("AstraZeneca") are related Delaware corporations with their principal place of business located at 1800 Concord Pike, Wilmington, DE 19850.

12. The following two Defendants are referred to as the Aventis group:

(a) Defendant Aventis Pharmaceuticals, Inc. is a Delaware corporation with its principal place of business is located at 300-400 Somerset Corporate Boulevard, Bridgewater, NJ 08807-2854; and

(b) Defendant Aventis Behring, LLC n/k/a ZLB Behring LLC is headquartered at 1020 First Avenue, King of Prussia, PA 19406-2854.

13. Defendant Barr Laboratories, Inc. ("Barr") is a Delaware corporation with its principal place of business located at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677.

14. Defendant Baxter Healthcare Corporation ("Baxter") is a Delaware corporation with its principal place of business located at One Baxter Parkway, Deerfield, IL 60015.

15. The following three Defendants are hereinafter referred to as the Boehringer group:

(a) Defendant Boehringer Ingelheim Pharmaceuticals, Inc. ("Boehringer Pharm"), a wholly owned subsidiary of Boehringer Ingelheim Corp. ("Boehringer"), is a Connecticut corporation engaged in the business of manufacturing and selling pharmaceuticals. Boehringer Pharm's principal place of business is located at 900 Ridgebury Road, Ridgefield, CT 06877; and

(b) Defendant Boehringer Ingelheim Roxane, Inc. ("BIRI"), f/k/a Roxanne Laboratories, Inc., a wholly-owned subsidiary of Boehringer, is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. BIRI's principal place of business is located at 1809 Wilson Road, Columbus, OH 43216-6532; and

(c) Defendant Ben Venue Laboratories, Inc. ("Ben Vue") is a wholly owned subsidiary of Boehringer Ingelheim Corporation and is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Ben Venue's principal place of business is located at 300 Northfield Road, Bedford, OH 44146. Ben Venue is also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to Bedford Laboratories.

16. Defendant Bristol-Myers Squibb Co. ("Bristol-Myers") is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Bristol-Myers' principal place of business is located at 345 Park Avenue, New York, NY 10154-0037. Bristol-Myers is also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to E.R. Squibb & Sons, Inc. and Apothecon, Inc.

17. Defendant Dey, Inc. ("Dey") is a Delaware corporation with its principal place of business located at 2751 Napa Valley Corporate Drive, Napa, CA 94558.

18. Defendant Forest Pharmaceuticals, Inc. ("Forest") is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Forest's principal place of business is located at 909 Third Avenue, New York, NY 10022.

19. Defendant SmithKline Beecham Corporation d/b/a GlaxoSmithKline ("GlaxoSmithKline"), is a Delaware corporation with its principal place of business located at One Franklin Plaza, Philadelphia, PA 19102.

20. Defendant Hoffman-LaRoche, Inc. ("Hoffman-LaRoche") is a New Jersey corporation with its principal place of business located at 340 Kingsland Street, Nutley, NJ 07110-1199. Hoffman LaRoche is also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to Roche Laboratories, Inc.

21. Defendant Hospira, Inc. ("Hospira") is a corporation organized under the laws of Delaware, with its principal offices located at 275 N. Field Drive, Lake Forest, IL. 60045, Hospira is the successor to Abbott's Hospital Products Division.

22. The following five Defendants are hereinafter referred to as the Johnson & Johnson group:

(a) Defendant Johnson & Johnson, Inc. ("J&J") is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. J&J's principal place of business is located at One Johnson & Johnson Plaza, New Brunswick, NJ 08933; and

(b) Defendant Janssen, LP f/k/a Janssen Pharmaceutica, LP ("Janssen"), a wholly-owned subsidiary of J&J, is a New Jersey limited partnership engaged in the business of manufacturing and selling pharmaceuticals. Janssen's principal place of business is located at 1125 Trenton-Harbourton Road, Titusville, NJ 08560; and

(c) Defendant Ortho Biotech Products, LP ("Ortho Biotech"), a wholly owned subsidiary of J&J, is a New Jersey limited partnership engaged in the business of manufacturing and selling pharmaceuticals. Ortho Biotech's principal place of business is located at 700 U.S. Highway 202, Raritan, NJ 08869; and

(d) Defendant McNeil-PPC, Inc. ("McNeil"), a wholly owned subsidiary of J&J, is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. McNeil's principal place of business is located at 7050 Camp Hill Road, Ft. Washington, PA 19034. McNeil Consumer & Specialty Pharmaceuticals ("McNeil Cons") is a division of McNeil; and

(e) Defendant Centocor, Inc. ("Centocor") is a wholly owned subsidiary of Defendant Johnson & Johnson with its principal place of business located at 800/850 Ridgeview Drive, Horsham, PA 19044. The principal drug it markets is Remicade for autoimmune conditions.

23. Defendant Merck & Co., Inc. ("Merck") is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. Merck's principal place of business is located at One Merck Drive, Whitehouse Station, NJ 08889-0100.

24. The following two Defendants are hereinafter referred to as the Mylan group:

(a) Defendant Mylan Laboratories, Inc. ("Mylan") is a Pennsylvania corporation engaged in the business of manufacturing and selling pharmaceuticals, mainly through its subsidiaries. Mylan's principal place of business is located at 1500 Corporate Drive, Suite 400, Canonsburg, PA 15317; and

(b) Defendant Mylan Pharmaceuticals, Inc. ("Mylan Pharm"), a wholly owned subsidiary of Mylan, is a West Virginia corporation engaged in the business of manufacturing and selling pharmaceuticals. Mylan Pharm's principal place of business is located at 1500 Corporate Drive, Suite 400, Canonsburg, PA 15317.

25. The following two Defendants are hereinafter referred to as the Novartis group:

(a) Defendant Novartis Pharmaceuticals Corp. ("Novartis") is a New Jersey corporation engaged in the business of manufacturing and selling pharmaceuticals. Novartis' principal place of business is located at One Health Plaza, East Hanover, NJ 07936; and

(b) Defendant Sandoz, Inc. ("Sandoz"), formerly known as Geneva Pharmaceuticals, Inc., is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Sandoz's principal place of business is located at 506 Carnegie Center, Princeton, NJ 08540.

26. Defendant Par Pharmaceutical Cos., Inc. ("Par") is a Delaware corporation with its principal place of business located at One Ram Ridge Road, Spring Valley, NY 10977. Par is also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to Par Pharmaceutical, Inc.

27. Defendant Pfizer, Inc. ("Pfizer") is a Delaware corporation with its principal place of business located at 235 E. 42nd Street, New York, NY 10017. In April, 2003, Pfizer acquired Pharmacia Corporation. Pfizer is also being sued for the conduct of its subsidiaries and/or divisions, including but not limited to Warner-Lambert, Pfizer-Warner-Lambert, and Parke-Davis.

28. The following two Defendants are hereinafter referred to as the Schering group:

(a) Defendant Schering-Plough Corp. ("Schering-Plough") is a New Jersey corporation with its principal place of business located at 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530. Schering-Plough has engaged in the practices described in this Second Amended Complaint under its own name and through its wholly-owned subsidiary, Warrick Pharmaceutical Industries, Ltd.; and

(b) Defendant Warrick Pharmaceuticals Corporation ("Warrick"), is a Delaware corporation with its principal place of business located at 12125 Moya Boulevard, Reno, NV 89506-2600. Warrick is a wholly owned subsidiary of Defendant Schering-Plough and has been since its formation in 1993. Warrick manufactures generic pharmaceuticals.

29. Defendant TAP Pharmaceutical Products, Inc. ("TAP") is a Delaware corporation headquartered at Bannackburn Lake Office Plaza, 2355 Waukegan Road, Deerfield, IL 60015. TAP is jointly owned by Abbott Laboratories and Takeda Chemical Industries, Ltd.

30. The following four Defendants are referred to as the Teva Group:

(a) Defendant Teva Pharmaceuticals USA, Inc. ("Teva US") is a Delaware corporation engaged in the business of manufacturing and selling pharmaceuticals. Teva's principal place of business is located at 650 Cathill Road, Sellersville, PA 18960. Teva US is a subsidiary of an Israeli corporation, Teva Pharmaceutical Industries, Ltd. ("Teva Ltd."); and

(b) Defendant Ivax Corp. ("Ivax"), which became a wholly owned subsidiary of Teva Ltd. on January 26, 2006, is a Florida (formerly Delaware) corporation engaged in the business of manufacturing and selling pharmaceuticals. Ivax's principal place of business is located at 4400 Biscayne Boulevard, Miami, FL 33137; and

(c) Defendant Ivax Pharmaceuticals Inc. ("Ivax Pharm"), a wholly owned subsidiary of Ivax, is a Florida corporation engaged in the business of manufacturing and selling pharmaceuticals. Ivax Pharm's principal place of business is located at 4400 Biscayne Boulevard, Miami, FL 33137; and

(d) Defendant Sicor Pharmaceuticals, Inc., f/k/a Gensia Sicor Pharmaceuticals, Inc., is a Delaware corporation with its principal place of business located at 19 Hughes, Irvine, CA 92618-1902. Sicor is owned by Teva Ltd.

31. The following three Defendants are hereinafter referred to as the Watson group:

(a) Defendant Watson Pharmaceuticals, Inc. ("Watson") is a Nevada corporation engaged in the business of manufacturing and selling pharmaceuticals. Watson's principal place of business is located at 311 Bonnie Circle, Corona, CA 92880; and

(b) Defendant Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc. ("Watson Pharma"), a wholly-owned subsidiary of Watson Pharmaceuticals, Inc. since 2000, is a Delaware corporation. Watson Pharma's principal place of business is located at 311 Bonnie Circle, Corona, CA 92880; and

(c) Defendant Watson Laboratories, Inc. ("Watson Labs"), a wholly-owned subsidiary of Watson Pharmaceuticals, Inc., is a Nevada corporation with its principal place of business located at 311 Bonnie Circle, Corona, CA 92880.

32. This Court has jurisdiction over Plaintiff's claims as they involve claims arising exclusively under Hawaii statutes and the parens patriae authority of the Attorney General to act on behalf of the State of Hawaii and its citizens.

III. FACTUAL BACKGROUND

A. The Market for Prescription Drugs

33. The market for prescription drugs is extremely complex. It is composed of over 65,000 separate National Drug Codes ("NDCs") and is non-transparent. (There is a separate NDC number for each dosage and package size of each drug manufactured by each manufacturer.) The essential structure of the prescription drug market is as follows: The drugs themselves are manufactured by enormous and hugely profitable companies such as Defendants. Defendants sell the drugs (with varying numbers of intermediaries, primarily wholesalers, involved in the process) to physicians, clinics, and pharmacies. These physicians, clinics, and pharmacies are called "providers." The providers then in essence resell the drugs to those requiring them when the drugs are prescribed for, administered or dispensed to those patients.

34. In the case of Medicare and Medicaid programs, the price that is paid for the patient's prescribed drug ultimately will be paid in whole or in large part by a government entity, and in the case of Medicare, the Medicare beneficiary pays a 20 percent co-payment. These entities are known as the "payers" or "third party payers." In the case of Medicare and Medicaid programs the reimbursement is made directly to the provider, not to the patient.

35. This market structure means that the prescription drug market differs in two crucial respects from most markets.

36. First, in most markets, the ultimate consumer determines the product demand. This is not the case for prescription drugs. In the prescription drug market, the decision to use a prescription drug is made by the physicians, by the hospitals in which the patient is treated, home health care agencies, long term care pharmacies or

(with respect to the decision to use generic drugs versus brand-name drugs) a pharmacy. Since prescription drugs are dispensed only on a physician's order, the physician has the principal say in what drug will be chosen for the patient. However, hospitals, particularly teaching hospitals, also have considerable influence over this choice. If a hospital decides to put one drug as opposed to a competing drug on its "formulary" (the list of drugs that the hospital pharmacy stocks), the result will be that the physicians (particularly residents and attending physicians who are employed by the hospital) will likely order that drug rather than a competing drug. Likewise, although pharmacists do not prescribe drugs, pharmacists can exert an important influence over the choice of which drug the patient will purchase where there is a choice between buying different generic versions of the same drug.

37. A second difference of the prescription drug market from other markets is that in ordinary markets, the ultimate consumer of the product pays for it directly. In the prescription drug market, however, most payments are made by "payers" through private or public insurance programs.

38. The structure of the prescription drug market produces the following fundamental fact that underlies Defendants' unlawful scheme. If a Defendant Drug Manufacturer can cause a "payer" to reimburse for the Defendant's drug at a higher price than the price the provider paid to buy the drug from the Defendant, there will be a "spread" between the two prices, and that "spread" is retained by the provider as profit. The larger the "spread" that can be created for a particular drug, the greater the incentive the provider has for choosing, or for influencing the choice of, that drug rather than a drug from a competing manufacturer.

B. The Purpose of the Medicaid Program and How it Responds to the Complexity of the Drug Markets

39. The purpose of Hawaii's Medicaid program is to provide medical assistance to the State's neediest citizens.

40. Hawaii, through its Medicaid program, is a huge purchaser of drugs, currently purchasing over $110 million annually. Although participation by the Defendants in the Hawaii Medicaid program is purely voluntary, because of the size of the Hawaii Medicaid program all Defendants have chosen to participate and sell drugs to Hawaii's Medicaid participants. Thus, Hawaii may at any given time have to reimburse a pharmacist for any of the drugs from any of the Defendants—a universe of many thousands of drugs.

41. Hawaii's task is further complicated in that Federal law places limits on what Hawaii may pay for any particular drug. According to 42 CFR § 447.331, Hawaii may reimburse pharmacists at "the lower of the — 1) Estimated acquisition costs plus reasonable dispensing fees established by the agency; or 2) Providers' usual and customary charges to the general public." 42 CFR § 447.331. The "estimated acquisition cost" ("EAC") means the agency's estimate of the price generally and currently paid by providers for a drug marketed or sold by a particular manufacturer or labeler in the package size of drug most frequently purchased by providers." 42 CFR § 447.301. Thus, pursuant to federal law, the highest price Hawaii can pay for a drug is the estimated acquisition cost of that drug to a provider. Hawaii currently estimates the EAC as the AWP minus 10.5%.

42. Defendants have hidden the wholesale prices at which they sell their drugs, and their knowledge about the prices at which wholesalers sell their drugs to providers, (as described in more detail herein) thus depriving Hawaii of access to the pricing information it needs to estimate accurately the acquisition cost of Defendants' drugs. Because neither Hawaii nor any other state has the knowledge base required to accurately estimate Defendants' drug prices, entire businesses have grown up to provide pricing information to the states and others. Two of these are of particular importance in this case. They are First DataBank and the Redbook. These compendiums purport to supply accurate price information on Defendants' drugs through information obtained from Defendants themselves.

43. Hawaii, as have most other states, has chosen First DataBank as its primary price source. First DataBank purports to supply the states with accurate information about the average wholesale price ("AWP") of all drugs that it receives from the drug manufacturers themselves. As First DataBank explained the concept of the Average Wholesale Price to its customers in September 1991:

> Average Wholesale Price (AWP) is perhaps the most misunderstood concept in the pharmaceutical industry. The purpose of this article is to describe what is meant by AWP and to explain some of the underlying concepts involved in the acquisition, determination and maintenance of First DataBank's AWP.
>
> AWP represents an average price that a wholesaler would charge a pharmacy for a particular product. The operative word is *average*. AWP never means that every purchase of that product will be exactly at that price. There are many factors involved in pricing at the wholesale level that can modify the prices charged even among a group of customers from the same wholesaler. AWP was developed because there had to be some price that all parties could agree upon if machine processing was to be possible.

> At First DataBank, all pricing information is received in hard copy from the manufacturers. Catalogs, price updates, and other information reach us by fax, Federal Express, or U.S. mail. In the past two years, fax transmission has streamlined the acquisition of data to a large extent.
>
> Exhibit 1.

For virtually the entire time period relevant hereto, First DataBank has represented that its published prices reflect actual average wholesale prices.

44. Because Hawaii, like most states, has no consistent source of systematic information about providers' acquisition cost for the drugs that it reimburses, Hawaii has relied on the prices reported to First DataBank by Defendants and published by First DataBank to estimate the acquisition cost of most of its drugs. Consistent with the explanation of AWP by First DataBank that some providers pay less than the published AWP and some more – that the AWP is only an average of wholesale prices - Hawaii set its reimbursement at AWP minus 10.5% for most of the relevant period. Hawaii also pays a separate dispensing fee to providers. It has never been Hawaii's intention to pay more for a drug than the cost of that drug to a provider.

45. As a practical matter, Hawaii, as most other states, is dependent on the First DataBank pricing reports for the maintenance of its Medicaid claims processing system. Hawaii contracts with ACS, a company whose business is to electronically process on a real-time basis the claims for drugs prescribed, or administered to, Hawaii Medicaid participants. At the time a prescription is presented to a pharmacy, the pharmacy submits a real-time claim to ACS electronically through what is called a Point-of-Sale ("POS") claims processing system. Upon receipt, the POS system monitors the reimbursement claim for eligibility, covered drugs, Medicaid cost containment policies and pricing. ACS then sends a real time response that includes the authorized

payment. Thereafter ACS sends Remittance and Status Reports ("R&S") to Medicaid certified providers for paid real-time claims.

46. First DataBank sends its updated AWPs for the thousands of NDC codes listed in its database to ACS on a weekly basis and this information is entered into the system. These prices become the basis for Hawaii's reimbursements to providers. There is no other electronic source for this information.

47. Thus, Hawaii is functionally dependent on the accuracy of the data supplied by First DataBank, and supplied to First DataBank by the Defendants, in meeting its obligation to pay providers no more than the actual acquisition cost of their drugs.

C. Defendant's Corruption of the Government Medicaid Programs

48. Defendants have defeated the intent of the Medicaid Program to pay providers at a rate no greater than their acquisition cost by reporting false and inflated AWPs to First DataBank and/or by reporting prices which, they knew, because of the manner of First DataBank's operations, would misrepresent Defendants' true wholesale prices. One purpose of this scheme was and is to create the spread between the true wholesale price of a drug and the false and inflated AWP reported by First DataBank and thereby increase the incentive for providers to choose the drug for their patients, or, at a minimum, to counteract the same tactic used by a competitor.

49. The higher the spread between the AWP and the wholesale price the provider actually pays, the more profit a provider can make. Defendants often market their products by pointing out (explicitly and implicitly) that their drug's spread is higher than a competing drugs'.

50. One example of how Defendants market this spread is Adriamycin, one of the drugs used in treating breast cancer. Defendant Pharmacia reported an AWP of $241.36 for Adriamycin in April 2000 when the drug was actually selling at wholesale for as low as $33.43, creating a "spread" of $207.93. These spreads were then advertised to oncology providers in promotions that emphasized a wide margin of profit.

51. All of the Defendants have inflated their reported average wholesale prices of their drugs and those of their subsidiaries to levels far beyond any real average wholesale price of their drugs and those of their subsidiaries. One high-ranking industry executive has described it as the industry practice to do so.

52. In 2004, high-ranking executives of Defendants Roxanne, Dey, Aventis and Barr testified in Congress that the AWP was not a legitimate price. And, Defendant Dey's chief financial officer testified before Congress as follows: "Why doesn't Dey lower its AWP on generic drugs? The simple answer is that given the system that now exists our customers won't buy from us if we lower our AWP."

53. Dey brought a lawsuit against First DataBank, the publisher of the medical compendium that Hawaii Medicaid relies on for prescription drug pricing, because it published the actual average wholesale price of Dey's drugs instead of the false average wholesale price sent to the publisher by Dey. Dey's principal allegation in that lawsuit was that the publication of its actual prices for drugs was inconsistent with the practice in the industry of accepting and publishing reported, inflated AWPs, and that such publication put Dey at a competitive disadvantage because it had no "spread" to advertise.

54. Attached as Exhibit 2 to this Second Amended Complaint is a list of drugs manufactured by the Defendants and/or their subsidiaries that the U.S. Department of Justice, after an extensive investigation, found to have inflated AWPs. The U.S. Department of Health and Human Services concluded, with respect to all drugs utilized in the Medicare Program that "[a] general conclusion reached in reviewing GAO [General Accounting Office] and OIG [Office of Inspector General] data is that there is a level of overstatement in the listed AWP for *all* drugs. . . . ." Payment Reform for Part B Drugs, 68 Fed. Reg. 50,430 (August 20, 2003) (emphasis added).

55. Examples of the Defendants' practices of inflating AWPs include:

Manufacturer/Drug	2000 AWP	2000 Available Price	Spread	% Spread
Baxter Dextrose	$542.88	$86.40	$456.48	528%
Ben Venue/Bedford Labs Etoposide, 20 ml.	$550.00	$45.13	$504.87	1119%
Pharmacia/Upjohn Methylprednisolone Sodium Succinate (Solu-Medrol)	$21.90	$5.51	$16.39	297%

56. Plaintiff has secured the false prices Defendants caused to be published from First DataBank, the business that supplies Hawaii, and most other states, with pricing information for use in its Medicaid program. Hawaii has also secured data showing the true average wholesale prices of Defendants' drugs from AmeriSourceBergen, a major drug wholesaler. (The Defendants have not produced comprehensive pricing data because discovery is just starting.) Attached as Exhibit 3 is a chart containing a summary of falsely reported and actual wholesale prices for various of Defendants drugs. Exhibit 3 compares the false prices published in First DataBank to

the true average annual wholesale prices of the major wholesaler for each year from 2001 - 2004, where such data are available.

57. Defendants have similarly illegally and deceptively misrepresented and inflated the wholesale acquisition cost ("WAC") of their drugs making it appear that any reduction in the purchase price beyond the listed WAC would result in a loss to the wholesaler and was, hence, unachievable, when in fact the WAC was secretly discounted by the Defendants to purchasers other than the Medicaid and Medicare programs through an elaborate charge back system.

IV. DEFENDANTS' EXACERBATION OF THE COMPLEXITIES OF THE MARKET AND AFFIRMATIVE CONCEALMENT OF THEIR WRONGDOING

58. Defendants have been able to succeed in their drug pricing scheme for more than a decade by exacerbating the complexities of the incredibly huge, and dauntingly complex, drug market, and by purposely concealing their pricing scheme from Hawaii and other payers, as set forth below.

59. The published wholesale price of the thousands of NDC numbered drugs may, and often does, change at any time. As a consequence, just to track the current published prices of drugs utilized by a state's citizen requires resources and expertise that Hawaii and most other states do not have.

60. Defendants have further exacerbated the inherent complexities of the drug market by utilizing marketing schemes that conceal the true price of their drugs in the following different ways.

61. First, Defendants sell their drugs in a unique manner that hides the true price of their drugs. This scheme works as follows. Upon agreeing on a quantity and price of a drug with a provider, or group of providers, the Defendants purport to sell the

agreed upon drugs to wholesalers with whom they have a contractual arrangement, at a price they call the Wholesale Acquisition Cost ("WAC"). The WAC may be higher than the price agreed upon by the provider and the drug manufacturer. The wholesaler then ships the product to the provider, charging the provider the (lower) price originally agreed upon by the drug manufacturer and the provider. When the wholesaler receives payment from the provider, it charges the manufacturer for the difference between the price agreed-to between the manufacturer and the provider and the WAC, and sends a bill to the manufacturer, called a "charge back," for the difference between the WAC and the price actually paid by the provider. These charge backs, (or shelf adjustments, or other economic inducements) are kept secret, so that it appears that the wholesaler actually purchased the drug at the higher WAC price. The effect of this practice is to create the impression that the "wholesale price" of the drug is higher than it really is. Defendants hide other actual price reductions by directly paying providers market share rebates that are calculated long after the actual provider dates of the drugs.

62. Second, Defendants further inhibit the ability of Hawaii and other ultimate purchasers to learn the true cost of their drugs by wrapping the sales agreements they negotiate with providers in absolute secrecy, terming them trade secrets and proprietary, to preclude providers from telling others the actual price they paid.

63. Third, Defendants further obscure their true prices for their drugs with their policy of treating different so-called classes of trade differently. Thus, for the same drug, pharmacies are given one price, hospitals another and doctors yet another.

64. Fourth, some Defendants have hidden their real drug prices by providing free drugs and phony grants to providers as a further means of discounting the overall

price of their drugs. For example, Defendant TAP pled guilty to a federal criminal indictment for engaging in such conduct and paid $875 million in fines and damage, and Defendant AstraZeneca paid $355 million to settle federal fraud charges that it induced doctors to falsely bill Medicare and Medicaid.

65. Defendants have hidden their motives for utilizing an inflated AWP from the public. Indeed, one official, a high ranking employee of Dey, even went so far as to lie under oath about Dey's marketing of its spread. Only with the disclosure of materials secured by litigants in recent discovery has it become apparent that one reason Defendants were intentionally manipulating the nation's drug reimbursement system was to compete for market share on the basis of a phony price spread, instead of the true selling price of their drugs or the medicinal efficacy of these drugs to their users.

66. Defendants have further concealed their conduct by making sure that all of the entities purchasing drugs directly from the Defendants (and, hence, knowledgeable about the true price of their drugs) have had an incentive to keep Defendants' scheme secret. Defendants' scheme permits all providers, pharmacies, physicians, and hospitals/clinics, to make some profit off of Defendants' inflated spread, because they are all reimbursed in some manner on the basis of the AWP for at least some of the drugs they sell or administer. For providers, therefore, the greater the difference between the actual price and the reported AWP, the more money they make. Thus, providers willingly sign drug sales contracts requiring them to maintain secrecy about the prices they pay for drugs.

67. Defendants have continuously concealed the true price of their drugs and continued to publish deceptive AWPs and WACs as if they were real, representative prices. Indeed, in the 2000 Edition of *Novartis' Pharmacy Benefit Report*, an industry trade publication, the glossary defines AWP as follows:

> Average wholesale price (AWP) – A published suggested wholesale price for a drug, based on the average cost of the drug to a pharmacy from representative sample of drug wholesalers. There are many AWPs available within the industry, AWP is often used by pharmacies to price prescriptions. Health plans also use AWP – usually discounted – as the basis for reimbursement of covered medications.

Novartis Pharmacy Benefit Report: Facts and Figures, 2000 Edition, East Hanover, NJ, Novartis Pharmaceuticals Corporation, p. 43.

68. Defendants' unlawful scheme has completely corrupted the market for prescription drugs. Instead of competing on prices and medicinal value alone, the Defendants have deliberately sought to create a powerful financial incentive for providers to prescribe drugs based primarily on the spread between the true price of a drug and its published AWP or WAC. Creating incentives for providers to prescribe drugs based on such a spread is inconsistent not only with Hawaii statutes, but also its public policy. Large price spreads on higher priced drugs encourage providers to prescribe more expensive drugs instead of their lower priced substitutes thereby increasing the cost of healthcare, and competition on the basis of such spreads has the potential to influence (consciously or unconsciously) providers to prescribe less efficacious drugs over ones with greater medicinal value. Because of Defendants' concealment of their scheme, Hawaii and its citizens have unknowingly underwritten this perversion of competition in the drug market. In sum, Defendants have been, and continue to be, engaged in an insidious, deceptive scheme that is causing Hawaii and

its citizens to pay scores of millions of dollars a year more than they should for their prescription drugs, and may well be inducing some providers to prescribe less efficacious drugs.

V. THE GOVERNMENTAL INVESTIGATIONS OF DEFENDANTS' CONDUCT

69. The first governmental investigation of Defendants' conduct began in 1995 when a small infusion pharmacy, Ven-a-Care of the Florida Keys, filed sealed *qui tam* actions with the Federal Government and in Texas, Florida, California and Illinois alleging that certain Defendants were intentionally inflating the reported AWPs of certain drugs, primarily physician administered drugs.

70. In 1997, in response to the Ven-a-Care Complaint, the Federal Government issued subpoenas to certain of the Defendants including Dey, Abbott and Warrick seeking pricing information from them.

71. In 2000, Congress began its investigation of the pricing practices of some of the Defendants in connection with the Medicare Part B program based on the materials it received through its subpoenas. As part of this investigation U.S. Representative Pete Stark, on September 28, 2000, wrote to the President of the Pharmaceutical Research and Manufacturers of America (of which most of the Defendants are members) as follows:

> Drug company deception costs federal and state governments, private insurers and others billions of dollars per year in excessive drug costs. This corruptive scheme is perverting the financial integrity of the Medicare program and harming beneficiaries who are required to pay 20% of Medicare's current limited drug benefit. Furthermore, these deceptive, unlawful practices have a devastating financial impact upon the states' Medicaid Program....
>
> The evidence I have obtained indicates that at least some of your members have knowingly and deliberately falsely inflated their representations of the average wholesale price ("AWP"), wholesaler acquisition cost ("WAC") and direct price ("DP") which are utilized by the Medicare and Medicaid programs in establishing drug reimbursements to providers. The evidence

> clearly establishes and exposes the drug manufacturers themselves that were the direct and sometimes indirect sources of the fraudulent misrepresentation of prices. Moreover, this unscrupulous "cartel" of companies has gone to extreme lengths to "mask" their drugs' true prices and their fraudulent conduct from federal and state authorities. I have learned that the difference between the falsely inflated representations of AWP and WAC versus the true prices providers are paying is regularly referred to in your industry as "the spread." . . .
>
> The evidence is overwhelming that this "spread" did not occur accidentally but is the product of conscious and fully informed business decisions by certain PhRMA members....

146 Cong. Rec. E1622 (daily ed. September 28, 2000) (September 28, 2000 letter from House Committee on Ways and Means, Subcommittee on Health, to Alan F. Holmer, President, Pharmaceutical Research and Manufacturers of America, Washington, D.C.

72. On December 21, 2000, Congress passed the Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 ("BIPA"), Pub. L. No. 106-554, § 429(c) (2000) which required a comprehensive study of drug pricing.

73. Continuing Congress' investigation of Medicare Part B pricing in 2001 Congressman Stark wrote to Defendant Bristol-Myers on February 22, 2001 outlining numerous apparent illegal pricing practices:

> The evidence clearly shows that Bristol has intentionally reported inflated prices and has engaged in other improper business practices in order to cause its customers to receive windfall profits from Medicare and Medicaid when submitting claims for certain drugs. The evidence further reveals that Bristol manipulated prices for the express purpose of expanding sales and increasing market share of certain drugs where the arranging of a financial benefit or inducement would influence the decisions of healthcare providers submitting the Medicare and Medicaid claims.

147 Cong. Rec. E244-45 (daily ed. February 28, 2001).

74. In 2003, the House Committee on Energy and Commerce expanded Congress' Medicare investigation into pricing practices in the state Medicaid program. On June 26, 2003, Chairman Billy Tauzin (R.-La.) and Oversight and Investigations

Subcommittee Chairman James Greenwood (R.-Pa.) wrote as follows to 26 drug companies, including many of the Defendants here:

> The Committee on Energy and Commerce is conducting an investigation into pharmaceutical reimbursements and rebates under Medicaid. This inquiry builds upon the earlier work by this Committee on the relationship between the drug pricing practices of certain pharmaceutical companies and reimbursements rates under the Medicare program. In that investigation, the Committee uncovered significant discrepancies between what some pharmaceutical companies charged providers for certain drugs and what Medicare then reimbursed those providers for dispensing those drugs. This price difference resulted in profit incentives for providers to use the drugs of specific companies as well as higher costs to the Medicare system and the patients it serves. For example, we learned that one manufacturers sold a chemotherapy drug to a health care provider for $7.50, when the reported price for Medicare was $740. The taxpayer therefore reimbursed the doctor almost $600 for dispensing the drug and the cancer patient had a $148 co-payment. Such practices are unacceptable in the view of the Committee, which is why we are in the process of moving legislation to address these abuses.
>
> The Committee has similar concerns regarding drug prices in Medicaid, which has a substantially larger pharmaceutical benefit than Medicare.

House Committee on Energy and Commerce Press Release, Tauzin, Greenwood Expand Medicaid Fraud Investigation (June 26, 2003) at http://energycommerce.house.gov/108/News/06262003_1002.htm.

75. This investigation is continuing. On December 7, 2004, the House Subcommittee of Oversight and Investigation of the Commerce and Energy Committee conducted a hearing on "*Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much.*" In his opening remarks, Chairman Joe Barton (R-TX) stated:

> Data obtained by the committee from five of the largest retail pharmacy chains reveals that during the period of July 1, 2002 to June 20, 2003, the average acquisition costs for seven widely prescribed generic drugs was 22 cents, while the average Medicaid reimbursement just for those drugs alone was 56 cents, more than double the cost . . . .

Medicaid Prescription Drug Reimbursement: Why the Government Pays Too Much: Hearing Before the House Subcomm. on Oversight and Investigations, No. 108-126, at 5 (2004) available at http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?IPaddress=162.140.64.52&filename=97275.pdf&directory=/disk2/wais/data/108_house_hearings (opening statement of Joe Barton, Chairman, House Subcomm. on Oversight and Investigations).

76. The importance to Hawaii and the other states of the information being sought by this investigation was explained by Henry Waxman during the December 2004 House Committee on Energy and Commerce hearings on Medicaid pricing practices. Congressman Waxman explained that even though the federal government had access to the manufacturers' actual average manufacturers prices ("AMPs"), the states did not:

> the drug industry was powerful, and they succeeded in securing a provision in the basic legislation that kept the Best Price and the AMP information a secret. Can you imagine that? The federal government knew this information, but we kept it a secret from the states. This has proved to be a costly error. Without this crucial piece of information, states who were, after all, responsible for establishing the reimbursement rate for prescription drugs could not set their reimbursement rates appropriately. As a result, [the states] continued to rely on the average wholesale price minus the arbitrary amount because they did not have the information needed to set a more appropriate reimbursement rate.

Id. at 23. (Emphasis added).

77. Concomitant with Congress' investigation, the United States Department of Justice and the National Association of Medicaid Fraud Control Units (NAMFCU) conducted their own much more limited investigation into 400 of the 50,000 NDC numbers state Medicaid programs reimbursed in 2000 concluding that some drug manufacturers were reporting inflated average wholesale prices for certain of these drugs.

78. As a result of all these investigations many states began to investigate on their own Defendants' drug pricing practices leading to lawsuits in some 20 separate states including Hawaii. Notwithstanding these investigations and lawsuits Defendants continue to publish, or participate in the publication of, inflated wholesale prices and continue to hide the true prices of their drugs including opposing discovery of the actual prices of these drugs in litigation.

VI. THE INJURY TO GOVERNMENTAL HEALTH PLANS CAUSED BY DEFENDANTS' FALSE WHOLESALE PRICES

A. The Hawaii Medicaid Program

79. Medicaid is a joint federal and state health care entitlement program authorized by federal law, with mandatory and optional provisions for eligibility and benefits covered, including prescription drugs. Plaintiff State of Hawaii, via the Department of Human Services ("DHS"), administers Hawaii's Medicaid program and reimburses physicians and pharmacies for drugs prescribed for, and dispensed to, Medicaid recipients. Hawaii Medicaid also pays the 20% co-payment for prescription drugs for Hawaii Medicare beneficiaries who are also qualified to receive Medicaid benefits.

80. In 2004 there were approximately 43,189 individual recipients of Hawaii's Medicaid drug services. The cost of drug services in the Hawaii Medicaid program have seen dramatic increases rising from slightly over $20.7 million in 1997 to slightly over $112.5 million in 2004, an increase of over 500%.

81. In its report to the Legislature on Act 259, Part III, Section 39 Prescription Drugs for Fee for Service Clients, the DHS reported expending $63,255,737 for medication in calendar year 2000. There were approximately 35,000 eligible recipients.

In its report to the Twenty-Third Hawaii State Legislature in 2005, DHS reported that it spent $112,575,993.82 for all prescription drugs in fiscal year 2004 in its Med-Quest program.

82. Hawaii's Medicaid program provides services through various programs such as the Fee-For-Service program that provides services to qualified persons who are aged 65 and over, or certified blind or disabled under which payment is made directly to the provider, and the Med-Quest program that provides coverage for all other qualified persons under a managed care program.

83. With some exceptions, reimbursement to pharmacies and physicians for drugs covered by the Hawaii Medicaid program is made at the AWP minus a percentage (currently 10.5%), plus a dispensing fee.

84. For a minority of the drugs purchased by Hawaii, the state sets its reimbursement rate at either the Federal Upper Limit ("FUL") or at a rate established by the State Maximum Acquisition Cost ("SMAC") Program. For multi-source drugs that have at least three suppliers, the Center for Medicaid Services ("CMS") generally establishes federal upper limits of FULs, defined as 150% of the least costly therapeutic equivalent (using all national compendia) that can be purchased by pharmacies in quantities of 100 tablets or capsule or, in the case of liquids, the commonly listed size. 42 C.F.R. § 447.332. As a practical matter CMS relies on the published AWPs to set most of its FULs. The states may also set reimbursement rates for these drugs at rates lower than the FUL pursuant to the State SMAC program and Hawaii has done so in a number of instances.

85. At all relevant times, each Defendant was aware of Hawaii's Medicaid reimbursement formulas and Hawaii's reliance on the Defendants reported AWPs.

86. By publishing false and inflated wholesale prices, and by keeping their true wholesale prices secret, Defendants have knowingly enabled providers of drugs to Medicaid recipients to charge Hawaii false and inflated prices for these drugs, and interfered with Hawaii's ability to set reasonable reimbursement rates for these drugs. As a consequence, Hawaii's Medicaid program has paid more for prescription drugs than it would have paid if Defendants had published their true wholesale prices.

B. <u>The Medicare Program</u>

87. Medicare is a health insurance program created by the federal government for the elderly and disabled and other eligible persons. 42 U.S.C. 1395, *et. seq*. Typically, individuals become eligible for Medicare health insurance benefits if they are over 65 years of age, disabled, or have end stage renal disease. There are two major components of the Medicare Program, Part A and Part B.

88. Medicare Part B is an optional program that provides coverage for some healthcare services for Hawaii's participating elderly and disabled citizens not covered by Part A. 42 U.S.C. 1395j through 1395w-4. Medicare Part B is supported by government funds and premiums paid by eligible individuals who choose to participate in the program.

89. At issue here is Medicare Part B's limited benefit for drugs which are provided either: (a) incident to a physician's service and cannot generally be self-administered; or (b) in conjunction with the medical necessity of an infusion pump or nebulizer or other durable medical device payable under Medicare's DME benefit equipment ("DME").

90. In order to calculate the portion Medicare recipients must pay for Part B benefits, the Medicare program has looked to the falsely-reported AWPs. The starting point is the calculation of the "allowable cost." From 1992 until 1997, the methodology for calculating the allowable cost of Medicare Part B drugs was 100% of the published AWP. From 1997 until January 1, 2004, the methodology for calculating the allowable cost of brand name (single-source) drugs was 95% of the published AWP. During this same time period, for multiple-source drugs, the allowable cost was calculated as 95% of the lower of (a) the median AWP for all sources of the generic forms of the drug or (b) the lowest brand-name product AWP. 42 C.F.R. §405.517. From January 1, 2004 until January 1, 2005, the methodology for calculating the allowable cost was 85% of the published AWP. Medicare pays 80% of the allowable cost. The remaining 20% is paid as a co-payment by the Medicare Part B beneficiary, or for individuals eligible for Medicaid (known as "dual eligibles"), by the Medicaid program. In addition, Medicare Part B beneficiaries are required to pay an annual deductible amount before Part B benefits are payable.

91. Because Medicare Part B participants must pay 20 percent of the allowable cost, which is based on the AWP, for their medications, and because Defendants have published false and inflated AWPs for their drugs, Medicare Part B participants are paying substantially more for their co-pay than they would pay if Defendants published their true wholesale prices. Indeed, with respect to some drugs, the 20% co-pay for the Medicare Part B participant is greater than the cost of the drug.

VII. DEFENDANTS' CONDUCT INTENTIONALLY DISREGARDED ESTABLISHED LAW

92. Defendants have a duty to deal completely honestly with the State of Hawaii and they know it.

93. Moreover, it is long-settled law that it is unlawful for a seller to cause to be circulated a price at which no, or few, sales are actually expected, whether it is called a list price, suggested price, or benchmark price. *E.g.*, *FTC v. Colgate-Palmolive Co.*, 380 U.S. 372 (1965); *FTC v. The Crescent Publishing Group, Inc.*, 129 F. Supp.2d 311 (S.D.N.Y. 2001). Defendants either knew of this law or acted in reckless and conscious disregard of it.

94. Congressional hearings have excoriated the pharmaceutical industry for causing untrue AWPs to be published.

95. Defendants have violated their duty to Hawaii and its citizens by intentionally misrepresenting their reported prices. By manipulating the AWP and keeping secret the true AWP, Defendant Drug Manufacturers inflated the prescription drug prices thus causing Hawaii and its citizens to overpay for their drug purchases.

VIII. TOLLING

96. Any applicable statute of limitation has been tolled by Defendants' knowing and active concealment and or as a continuing violation. Because of their knowing, affirmative, and/or active concealment of the fraudulent nature of the published AWPs, Defendants are estopped from relying on any statutes of limitations.

Count I – False Claims

(On Behalf of the State of Hawaii)

97. Defendant Drug Manufacturers knowingly caused to be presented to an officer or employee of the State a false or fraudulent claim for payment, and/or caused to be made or used a false record or statement and/or conspired to defraud the State by getting a false or fraudulent claim allowed or paid in violation of H.R.S. § 661-21 (a)(1), (2) and (3).

Count II – Unfair or Deceptive Acts or Practices

(On Behalf of Hawaii Medicare Beneficiaries and State of Hawaii)

98. Plaintiff re-alleges and incorporates all the above allegations.

99. The AWP scheme constitutes an unfair or deceptive act or practice in violation of Chapter 480, H.R.S.

H.R.S. § 480-2 provides in part:

> (a) Unfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce are unlawful.

100. Defendants violated this section by, including but not limited to, intentionally engaging in a scheme to falsify the true AWP of their drugs, reporting false, misleading and inflated pricing information on their drugs to national reporting services while at the same time concealing actual AWP pricing information. The reporting services in turn published the Defendants' inflated pricing information to substantial numbers of persons, including but not limited to, the Medicare/Medicaid program, in connection with the promotion of the sale of, or to increase the consumption of, Defendants' prescription drugs. This conduct caused the beneficiaries to overpay, and allowed Defendants to increase their market share.

Count III – Unfair Competition

(On Behalf of Medicare Beneficiaries and the State of Hawaii)

101. Plaintiff re-alleges and incorporates all the above allegations.

102. The AWP Scheme constitutes an unfair competition act in violation of Chapter 480, Hawaii Revised Statutes.

103. Defendants violated this section by, including but not limited to, intentionally engaging in a scheme to falsify the true AWP of their drugs, reporting false, misleading and inflated pricing information on their drugs to national reporting services while at the same time concealing actual AWP pricing information. The reporting services in turn published the Defendants' inflated pricing information to substantial numbers of persons, including but not limited to, the Medicare/Medicaid program, in connection with the promotion of the sale of, or to increase the consumption. This conduct caused the beneficiaries and the State to overpay, and allowed defendants to increase their market share.

Count IV – Deceptive Trade Practices Act

(On Behalf of Medicare Beneficiaries and the State of Hawaii)

104. Plaintiff re-alleges and incorporates all the above allegations.

105. H.R.S. § 481A-3 provides:

(a) A person engages in a deceptive trade practice when, in the course of the person's business, vocation, or occupation, the person:

(9) Advertises goods or services with the intent not to sell them as advertised;

(11) Makes false or misleading statements of fact concerning the reasons for, existence of, or amounts of price reductions;

(12) Engages in any other conduct that similarly creates a likelihood of confusion or misunderstanding.

106. Defendants violated these sections and thereby committed a per se violation of H.R.S. § 480-2 by, including but not limited to, intentionally engaging in a scheme to falsify the true AWP of their drugs, reporting false, misleading and inflated pricing information on their drugs to national reporting services while at the same time concealing actual AWP pricing information. The reporting services in turn published the Defendants' inflated pricing information to substantial numbers of persons, including but not limited to, the Medicare/Medicaid program, in connection with the promotion of the sale of or to increase the consumption of Defendants' prescription drugs and thereby caused Hawaii and its citizens to overpay for Defendants' drugs.

Count V – Intentional and / or Negligent Misrepresentation

(On Behalf of the State of Hawaii)

107. Plaintiff re-alleges and incorporates all the above allegations.

108. Defendants intentionally and/or negligently caused to be published false and incorrect pricing information, as described above, in trade publications.

109. Defendants engaged in this scheme with the intent that others, including the State of Hawaii's Medicaid Program, use it in their business transactions.

110. Plaintiff State of Hawaii's Medicaid Program relied upon the false and incorrect AWP information, as alleged above, and was damaged by overpaying for Defendants' drug products.

Count VI – Unjust Enrichment

(On Behalf of Medicare Beneficiaries and the State of Hawaii)

111. Plaintiff re-alleges and incorporates all the above allegations.

112. Defendant Drug Manufacturers knew that pharmacies and physicians who obtained Medicare/Medicaid reimbursement for Defendants' drug products were not

entitled to improperly inflated reimbursement rates that were based on Defendants' false pricing information.

113. As a result of the excessive payments to health care providers of all or part of the "spread," Defendants were unjustly enriched at the expense of the State of Hawaii and its citizens.

114. Defendants knew they were not entitled to the profits that resulted from the sales obtained through the use of the spreads they created, and should be required to make restitution of all such amounts obtained through the use of such spreads.

WHEREFORE, Plaintiff and the Attorney General on behalf of its citizens, ask the Court for the following relief and seek judgment against the Defendant Drug Manufacturers as follows:

a. That general and special damages be awarded to the State of Hawaii and Hawaii Medicare beneficiaries.

b. That mandatory treble damages be awarded pursuant to H.R.S. §§ 480-13, 480-14, 661-21 or alternatively punitive damages.

c. That qualifying Medicare beneficiaries be awarded the statutory minimum damages of $5,000 per incident for unfair and deceptive acts and practices against elderly persons pursuant to H.R.S.§ 480-13(b).

d. That the Court award costs of suit, pre-judgment and post-judgment interest, and attorneys' fees pursuant to H.R.S.§ 480-13 and 480-14, 661-21 or as otherwise allowed by law; and such other relief as this Court deems just and proper.

e. That the Court assesses civil penalties pursuant to H.R.S. § 480-13.5 or 661-21 or as otherwise allowed by law.

f. That the Court enjoins the Defendant Drug Manufacturers from continuing the deceptive or unfair acts or practices complained of herein.

g. That the Court grants such other and further relief or equitable relief that it deems just and proper.

Dated: Honolulu, Hawaii, JUL 3 - 2007.

RICK J. EICHOR
ATTORNEY FOR PLAINTIFF

CHARLES BARNHILL, JR.
SPECIAL DEPUTY ATTORNEY GENERAL

GEORGE F. GALLAND, JR.
ROBERT S. LIBMAN
W. DANIEL "Dee" MILES, III
CLINTON C. CARTER
P. JEFFREY ARCHIBALD
MICHAEL WINGET-HERNANDEZ
WARREN PRICE, III
KENNETH T. OKAMOTO

ATTORNEYS FOR PLAINTIFF

Exhibit "1"

VOL 6 NO 9

First DataBank

SEPTEMBER 1991

Monthly Interest

Understanding AWP

Average Wholesale Price (AWP) is perhaps the most misunderstood concept in the pharmaceutical industry. The purpose of this article is to describe what is meant by AWP and to explain some of the underlying concepts involved in the acquisition, determination and maintenance of First DataBank's AWP.

AWP represents an average price which a wholesaler would charge a pharmacy for a particular product. The operative word is *average*. AWP never means that every purchase of that product will be exactly at that price. There are many factors involved in pricing at the wholesale level which can modify the prices charged even among a group of customers from the same wholesaler. AWP was developed because there had to be some price which all parties could agree upon if machine processing was to be possible.

At First DataBank, all pricing information is received in hard copy from the manufacturers. Catalogs, price updates, and other information reach us by fax, Federal Express, or U.S. mail. In the past two years, fax transmission has streamlined the acquisition of data to a large extent.

First DataBank has established specific contact people within each major drug manufacturer/labeler's organization. When pricing or other questions arise, we know who to ask for reliable information. Knowing who to talk to prevents misinformation and keeps problems to a minimum. Usually it is our contact people who send information to us when there are price changes or other product changes. We make sure that we are placed on the priority mailing list so that we receive the information before the trade. Because personnel movement within a corporation is the norm, we continually work to keep our contact list current.

Once the information is received, we often have to interpret what the data represents. There can be confusing or contradictory factors, not to mention hard to read fax's and typographical errors. Our data entry experts have experience as pharmacy technicians or in related fields. With their knowledge and proficiency, potential errors are detected before they become part of the database. As an example, occasionally a manufacturer which normally sends us wholesale net pricing will inadvertently send direct or suggested list prices. It is up to the staff to recognize the error and ask the manufacturer to send the correct information.

The pricing information which we receive can be in the form of wholesale net, direct, or suggested wholesale prices (see Figure 1). It is our task to convert these prices into AWP. There are several ways in which AWP's are derived. Large manufacturers such as Merck have a one price policy for all purchasers whether wholesale or direct. They supply their published direct prices to which we must determine a markup factor and arrive at an AWP. Others supply wholesale net prices only. In order to determine an appropriate markup, it is necessary to survey wholesalers. The accompanying sidebar (see next page) describes this process in detail. Wholesaler surveys are an important part of what First DataBank does to establish realistic AWP pricing.

Some manufacturers do not sell products through wholesalers but supply a suggested wholesale price, which is

(continued on page 2)

How Drugs are Purchased



Figure 1

The Monthly Interest

Editor.....Jim Wilson
Publisher.....Joe Hirschmann
Editorial Assistant.....Amy Ream
Contributors: Ed Edelstein, Virginia Halsey, Pamela Catling, Jerry Roberts, Linda Sekino, Beth Rader
Published monthly by First DataBank
Copyright 1991 The Hearst Corporation

Exhibit "1"

regarded as the AWP. Others apply different markup factors to each product or type of product and supply suggested wholesale prices which wholesalers use as their AWP. Many generic suppliers fall into this category (see Figure 2).

Maintenance of pricing is perhaps the most challenging task of all. It is necessary to constantly remind manufacturers that their pricing data must be supplied on time. With the advent of on-line claims processing, pricing must be there when the update occurs. Some manufacturers do not release their price updates until the effective date so that purchasers cannot take the opportunity of purchasing at the old price just before the increase. We have made an all-out effort to apprise the manufacturers of our deadlines so that they do not miss the monthly schedule. We are beginning to see results in this effort.

Data acquisition is a difficult, exacting task which requires constant vigilance. Reporting AWP is an important function of First DataBank and we take this responsibility seriously.

Wholesaler Surveys

First DataBank recognizes that the pharmaceutical industry is constantly evolving. New companies and new products are introduced almost daily. We understand that when product distribution changes within or between manufacturers, wholesaler pricing structures may change. These industry changes have made the wholesaler survey fundamental in maintaining current pricing data.

At First DataBank, wholesaler surveys are done for two reasons: to establish an Average Wholesale Price (AWP) markup for a new company that does not provide a Suggested Wholesale Price (SWP), or to confirm that the markup that First DataBank utilizes for AWP is representative of the wholesaler industry. A survey may be performed on a single NDC number or for a manufacturer's entire line of products. In either case, each wholesaler is surveyed on a number of products within each manufacturer.

The number of surveys performed is increasing. First DataBank surveys at minimum five drug wholesalers that represent over two-thirds of the total dollar volume of drug wholesalers. The markup that First DataBank utilizes is representative of wholesalers on a national level. Because individual wholesalers may mark up each manufacturer differently, a weighted average, not a consensus average, is calculated. That is, the market share held by the wholesalers surveyed affects the markup proportionally. Wholesalers with higher drug dollar volumes have more weight in the determination of the final markup. Thus, a higher degree of certainty is achieved.

In most cases, the results from surveys match what First DataBank is using. In the instances that they do not, it is policy that First DataBank will change the markup on file to report marketplace reality.

First DataBank "AWP" Calculation Process



Figure 2

Price Declines And Balance Sheets

Although the expected movement of AWP's is upward, there is an occasional decline without a corresponding change in wholesale net or direct prices. Such an occurrence usually results when two companies merge into a single entity. Seeking to merge two pricing methods into a unified whole, some products exhibit an AWP drop.

Pharmacies holding inventories of these products had expected to sell their inventory based on current or future AWP. Consequently, when billing third parties at AWP, the stock on hand will produce less profit than expected.

The accounting method most commonly used is to carry inventory at the lower of cost or market value. The selling price does not enter into the picture until the product is actually sold. If the selling price decreases below actual cost, then the carrying value drops correspondingly. Conversely, if the selling price does not decrease below actual cost, then the carrying value does not drop, but the effects are felt in future cash flow and profitability.

As long as mergers and acquisitions continue in the pharmaceutical industry, we can expect occasional AWP decreases.

Reality and AWP

If you were ever confused by the AWP for the product Corgard you are not alone. AWP pricing is an increasingly confusing business, and it's especially so when a particular product's AWP does not behave as expected. Unfortunately, non-standard pricing in the pharmaceutical industry is becoming the norm. The following examples will clarify some of these issues.

The confusion often originates from the current atmosphere of frequent mergers and acquisitions in the pharmaceutical industry. When two companies merge, the pricing philosophy of the larger becomes dominant. Product swapping and habitual changes in marketing strategies - what has been called the 'blending' of the industry - further complicate the situation.

Let's go back to the example of Corgard which this article opened with. Last year Bristol-Meyers acquired Squibb, which manufactures Corgard. The new entity, Bristol-Meyers Squibb, moved Corgard (along with Corzide) to the Bristol Labs line of products. First DataBank responded by revising the AWP's to reflect the accepted Bristol Labs' markup. (See page one for a discussion of markups.)

However, Corgard still has an NDC number recognizable in the industry as a Squibb product, i.e. it has a labeler code of 00003. Although the distributor changed, and thus the AWP, the NDC number remained the same. Since any particular labeler code is no longer strictly associated with only one distributor, two products with the same labeler may have AWP's calculated from totally different markups.

Although the occasional wholesaler may still be treating these drugs as Squibb products, this is the exception. First DataBank always publishes the surveyed AWP.

Capoten, Prolixin and Rauzide, among other products in the U.S. Squibb Group, recently exemplified another type of pricing change. This division of Squibb introduced prices to the wholesalers where previously only direct pricing was available. After thoroughly researching wholesalers' responses, we instituted a new markup procedure. We were careful to include every product affected in order to minimize the occurrences of pricing changes.

In some cases the reason behind such a change may be invisible to someone who sees only the results. In other cases a new Manufacturer Name or a change to the Labeler Identifier field provides the key. Regardless, there is much consideration to ensure that the AWP reflects reality.

Bob Matutat Promoted to Manager of Professional Services



Bob Matutat has been promoted to Manager of the Professional Services Department. His new responsibilities include overseeing the creation and maintenance of all NDDF™, MDF, clinical, DUR and Canadian products. He will also continue his involvement in the implementation and modification of all products in order to ensure that the customers requirements are being met at the clinical level.

Bob graduated from the University of California, Berkeley with a B.A. in Political Science, received his Doctorate at the UCSF School of Pharmacy and completed a hospital pharmacy residency at the University of Illinois Medical Center, Chicago. In addition, Bob has 10 years of hospital experience at two major medical centers including three years in drug information and four years in a clinical pharmacy position. He joined First DataBank in [illegible] of 1987 as Staff Pharmacist, [illegible]

We congratulate [illegible] advancement and [illegible] and look forward to watching [illegible] future successes.

Arkansas Medicaid

Arkansas Prior Authorization (AR*PA) is now available [illegible] Definitions are as follows

0 = Prior authorization is not required
1 = Prior authorization is required

Colorado Medicaid

Colorado Prior Authorization will be changed from 0-2 definitions to 0-3 definitions. The new PA code [illegible]

3 = Prior authorization is required if drug is dispensed through an outpatient pharmacy.

Exhibit “2”

Program Memorandum Intermediaries/Carriers	Department of Health and Human Services (DHHS) HEALTH CARE FINANCING ADMINISTRATION (HCFA)
Transmittal AB-00-86	Date: SEPTEMBER 6, 2000

CHANGE REQUEST 1232

SUBJECT: An Additional Source of Average Wholesale Price Data in Pricing Drugs and Biologicals Covered by the Medicare Program

The purpose of this Program Memorandum (PM) is to provide you with an alternative source of average wholesale price data (attached) for some drugs and biologicals covered by the Medicare program. The first attachment includes data for 32 drugs that you are to consider in determining the Medicare payment allowances for your January 2001 quarterly update. The second attachment includes data for 14 oncology drugs and 3 clotting factors that are not to be implemented in that same quarterly update.

The payment allowance for drugs and biologicals covered by the Medicare program is described in PM AB-99-63. That PM states that drugs and biologicals not paid on a cost or prospective payment basis are paid based on the lower of the billed charge or 95 percent of the average wholesale price reflected in sources such as the Red Book, Blue Book, or Medispan. Examples of drugs that are paid on this basis are drugs furnished incident to a physician's service, drugs furnished by pharmacies under the durable medical equipment benefit, covered oral anti-cancer drugs, and drugs furnished by independent dialysis facilities that are not included in the end stage renal disease composite rate payment. While the Blue Book is no longer available, another publication, Price Alert, is available. Also, there are electronic versions of the same data.

The data in the attachments have come from the United States Department of Justice (DOJ) and the National Association of Medicaid Fraud Control Units (NAMFCU). They are an alternative source of average wholesale price data for certain drugs, which has recently become available to HCFA. These data have been compiled for about 400 national drug codes (NDC) representing about 50 different chemical compounds. These data are from wholesalers' catalogs that list the prices at which the wholesaler sells the respective products. The DOJ has indicated that these are more accurate wholesale prices for these drugs. Furthermore, the DOJ has indicated that because purchasers often receive further discounts below the advertised wholesale catalog price, either from a wholesaler or from the drug manufacturer directly, actual acquisition costs may be lower. The DOJ indicates that some physicians and suppliers obtain drugs at prices lower than the wholesale catalog prices through Group Purchasing Organizations (GPO). For example, the DOJ data from wholesale catalogs indicates an average wholesale price of $22 for one albuterol sulfate NDC which is substantially less than the $73 average wholesale price in the Redbook and compares to $15 from a GPO. These data are generally consistent with findings from OIG reports.

There has been correspondence with some members of congress on this subject. Under separate cover, we will send you a letter from the Administrator to Members of Congress, which places in context the issue of pricing drugs covered under the existing Medicare drug benefit and this new source.

DOJ and NAMFCU have provided these data to First Data Bank, a company that compiles average wholesale prices for most State Medicaid programs. On May 1, 2000, First Data Bank provided these new average wholesale prices to State Medicaid programs. Some States have already implemented these new average wholesale prices while others have not.

Exhibit "2"

You are to consider these alternative wholesale prices as another source in determining your January, 2001 quarterly update for the 32 drugs (Attachment 1), as per PM AB-99-63. These drugs account for 75 percent of Medicare spending and 70 percent of savings (based on DOJ data) for the drugs on the complete DOJ list. However, we have some concern about access to care related to the DOJ's wholesale prices for 14 chemotherapy drugs and 3 clotting factors (Attachment 2), due to other Medicare payment policies associated with the provision of these drugs for the treatment of cancer and hemophilia. Therefore, you are not to consider at this time using the DOJ data for these drugs (Attachment 2) to establish your Medicare allowances while we further review these concerns and develop alternative policies. For the drugs shown in Attachment 2, use your usual source of average wholesale prices in your next quarterly update.

The data in these attachments *may not* represent all of the NDCs for a drug or biological in applying the pricing rules described in PM AB-99-63; if you decide to use these data, then you must use solely these data as the source of average wholesale prices in establishing your Medicare payment allowances for the drugs in Attachment 1.

You are to report by October 15, 2000, your usual source as well as the source you intend to use for the January 2001 updates. Also, you are to provide a list of what the updates would be for the source(s) you identify as usual and for January 2001 updates, and the percentage difference, if any, for all the drugs listed in Attachment 1 and 2 (source for drugs in Attachment 2 can not be DOJ data). You are to submit these reports electronically to a special mailbox being established for this purpose. The e-mail address for this mailbox is DOJAWP@hcfa.gov.

For the drugs in Attachment 1, we may provide additional guidance by the end of October, which could affect your January 2001 updates. We will provide guidance in subsequent correspondence that concerns your future drug updates, and on Medicare allowances for the drugs listed in Attachment 2 as any necessary adjustments to other payments related to the provision of these drugs are being carried out. We will also convey how we plan to adjust Medicare allowances under the outpatient prospective system for drugs that are both subject to the AWP rules and paid on a passthrough basis.

The enclosed data show a price for each NDC that is an average of the wholesale prices in the catalogs of the various wholesale companies that are also shown. The DOJ indicates that these wholesalers have toll-free numbers (included in Attachment 1) and the capacity to supply drugs via overnight delivery to any place in the country. If you decide to use these data and if a physician or supplier indicates that they cannot obtain one of these products for the average wholesale price in this new source, you may explain to the physician or supplier that one or more of the wholesale companies in the attachment have indicated to the DOJ that they supply these drugs at or below these prices. You may give the physician or supplier the name and toll-free number of the wholesaler(s). You may also give the name and telephone number of the manufacturer of the drug (available in the Red Book) as DOJ has indicated that manufacturers often supply the drugs directly. Some of the manufacturers also have web pages on the Internet. Physicians or suppliers who are members of a GPO might also obtain these drugs through that organization at or below these average wholesale prices. However, you should not imply in any way that the physician or supplier is required to change their procedure for obtaining drugs. Further, you should indicate that you are not advocating the use of these sources and do not assume any liability for the choice of source by the physician or supplier.

Sections 1842(o) and 1833(a)(1)(S) of the Social Security Act (the Act) require the Medicare program to set payment allowances for drugs and biologicals at the lower of the actual amount billed or 95 percent of the average wholesale price. The attached data represent another source of average wholesale prices for the products on the attached list. Therefore, use of this new source of average wholesale prices in Attachment 1 is not an inherent reasonableness adjustment under paragraphs (8) and (9) of section 1842(b) of the Act.

The procedure for processing intermediary claims has not changed. As described in PM AB-97-25, all carriers will continue to furnish free of charge their drug payment allowance updates for all drugs and biologicals directly to the fiscal intermediaries in their jurisdiction. Carriers should contact the fiscal intermediaries to determine the preferred method of transmission. Carriers are to send this information to all fiscal intermediaries with whom they routinely deal. To further clarify, fiscal intermediaries must use each carrier's drug payment allowances for claims submitted under that carrier's jurisdiction.

Attachments (3)

The effective date for this (PM) is September 8, 2000.

The implementation date for this PM is September 8, 2000.

These instructions should be implemented within your current operating budget.

This PM may be discarded September 1, 2001.

If you have any questions contact Robert Niemann at 410-786-4531.

Attachment 1 – If you decide to use these data, use solely these data to update the HCPCS billing codes that correspond to the drugs on this list.

Drug Name	Prod/Mfr	Measurements	NDC	Wholesaler	Average Wholesale (AWP)
Acetylcysteine	(Abbott Hosp.)/SOL, IH	10%, 30 ml, 3s	00074-3307-03	MK	$21.90
Acetylcysteine	(Abbott Hosp.)/SOL, IH	20%, 4 ml, 30 ml, 3s	00074-3308-03	MK, BB	$18.75
Acetylcysteine	(Dey)/SOL, IH	10%, 4ml, 12s	49502-0181-04	MK	$25.80
Acetylcysteine	(Dey)/SOL, IH	10%, 10 ml, 3s	49502-0181-10	MK	$15.27
Acetylcysteine	(Dey)/SOL, IH	10%, 30 ml, 3s	49502-0181-30	MK	$41.97
Acetylcysteine	(Dey)/SOL, IH	20%, 100 ml, ea	49502-0182-00	MK	$75.90
Acetylcysteine	(Dey)/SOL, IH	20%, 4 ml, 12s	49502-0182-04	MK	$31.08
Acetylcysteine	(Dey)/SOL, IH	20%, 10 ml, 3s	49502-0182-10	MK	$18.57
Acetylcysteine	(Dey)/SOL, IH	20%, 30 ml, 3s	49502-0182-30	MK	$50.64
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 4 ml, 10s	61703-0203-04	MK,BB	$13.50
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 30 ml, 10s	61703-0203-31	BB	$91.00
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 4 ml, 10s	61703-0204-04	MK, BB	$19.50
Acetylcysteine	(Faulding)/SOL, IH (VIAL)	10%, 30 ml, 10s	61703-0204-31	MK	$91.00
Acyclovir Sodium	(Abbott Hosp.)/(Vial, Flip-top)	500 mg, 10s	00074-4427-01	BB, MK	$349.05
Acyclovir Sodium	(Abbott Hosp.)/(Vial, Flip-top)	1000 mg, 10s	00074-4452-01	BB, MK	$700.10
Acyclovir Sodium	(App)/INJ, LJ (Vial)	50 mg/ml, 10 ml	63323-0325-10	MK	$15.00
Acyclovir Sodium	(App)/INJ, LJ (Vial)	50 mg/ml, 20 ml	63323-0325-20	MK	$28.00
Acyclovir Sodium	(App)/PDI	15s, 500 mg, ea	63323-0105-10	MK	$37.15
Acyclovir Sodium	(App)/PDI	15s, 1000 mg, ea	63323-0105-20	MK	$75.13
Acyclovir Sodium	(Bedford)/PDI, LJ (S.D.V.)	500 mg, 10s	55390-0612-10	BB, ASD, R	$207.00
Acyclovir Sodium	(Bedford)/PDI, LJ (S.D.V.)	1000 mg, 10s	55390-0613-20	BB, ASD, R, OS	$401.75
Acyclovir Sodium	(Faulding)/PDI, LJ	500 mg, 10s	61703-0311-20	R	$89.00
Acyclovir Sodium	(Faulding)/PDI, LJ	1000 mg, 10s	61703-0311-43	R	$179.50
Acyclovir Sodium	(Fujisawa/APP)/PDI, LJ (VIAL)	500 mg, 10s	63323-0105-10	BB, MK	$371.50
Acyclovir Sodium	(Fujisawa/APP)/PDI, LJ (VIAL)	1000 mg, 10s	63323-0110-20	BB, MK	$751.80
Acyclovir Sodium	(Fujisawa/APP)/PDI, LJ (VIAL)	500 mg, 10s	63323-0325-10	BB	$150.00
Acyclovir Sodium	(Fujisawa/APP)/PDI, LJ (VIAL)	1000 mg, 10s	63323-0325-20	BB, MK	$280.00
Acyclovir Sodium	(Genslo)/PDI, LJ (VIAL)	500 mg, 10s	00703-8104-03	BB	$100.00
Acyclovir Sodium	(Genslo)/PDI, LJ (VIAL)	1000 mg, 10s	00703-8105-03	BB	$186.00
Albuterol Sulfate	(Dey)/SOL, IH	0.5%, 20 ml	49502-0196-20	BB, MK	$5.91
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3 ml, 25s, UD	49502-0697-03	BB, MK	$9.17
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3ml, 30s, UD	49502-0697-33	BB, MK	$11.01
Albuterol Sulfate	(Dey)/SOL, IH	0.083%, 3ml, 60s, UD	49502-0697-60	BB, MK	$22.01
Albuterol Sulfate	(Schein)/SOL, IH	0.5%, 20 ml	00364-2530-55	BB, MK	$7.62
Albuterol Sulfate	(Warrick)/SOL IH	0.083%, 3ml, 60s	59930-1500-06	BB, MK, AND	$21.92
Albuterol Sulfate	(Warrick)/SOL IH	0.083%, 3ml, 25s, UD	59930-1500-08	BB, MK, AND	$9.16
Albuterol Sulfate	(Warrick)/SOL IH	0.5%, 20 ml	59930-1515-04	BB, MK	$5.65
Amikacin Sulfate	(Abbott Hosp.)/(Vial, Flip-top)	50 mg/ml, 2 ml, 10s	00074-1955-01	BB	$125.00
Amikacin Sulfate	(Abbott Hosp.)/(Vial, Flip-top)	250 mg/ml, 2 ml, 10s	00074-1956-01	BB, MK	$150.00

Amikacin Sulfate	(Abbott Hosp.)/(Vial, Flipiop)	250 mg/ml, 4 ml, 10s	00074-1957-01	BB, MK	$320.00
Amikacin Sulfate	(Apothecon) Amikin/INJ, IJ (Vial)	250 mg/ml, 2 ml	00015-3020-20	FI, MK	$17.31
Amikacin Sulfate	(Apothecon) Amikin/INJ, IJ (Vial)	250 mg/ml, 4 ml	00015-3023-20	FI, MK	$34.49
Amikacin Sulfate	(Bedford)/INJ, IJ (S.D.V., P.F.)	250 mg/ml, 2 ml, 10s	55390-0226-02	BB, MK, FI	$65.33
Amikacin Sulfate	(Bedford)/INJ, IJ (S.D.V., P.F.)	250 mg/ml, 4 ml, 10s	55390-0226-04	BB, MK, FI	$125.33
Amikacin Sulfate	(Faulding Pharm.)/INJ, IJ (VIAL)	50 mg/ml, 2 ml, 10s	61703-0201-07	MK	$295.00
Amikacin Sulfate	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 4 ml, 10s	61703-0202-04	BB, MK	$890.00
Amikacin Sulfate	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 2 ml, 10s	61703-0202-07	BB, MK	$450.00
Amikacin Sulfate	(Faulding Pharm.)/INJ, IJ (VIAL)	250 mg/ml, 3 ml, 10s	61703-0202-08	MK	$600.00
Amikacin Sulfate	(Gensia)/INJ, IJ (S.D.V.)	50 mg/ml, 2 ml, 10s	00703-9022-03	BB, OS	$72.68
Amikacin Sulfate	(Gensia)/INJ, IJ (S.D.V.)	250 mg/ml, 2 ml, 10s	00703-9032-03	BB, MK	$70.00
Amikacin Sulfate	(Gensia)/INJ, IJ (Vial)	250 mg/ml, 4 ml, 10s	00703-9040-03	BB	$140.00
Amphotericin B	(Apothecon) Fungizone/PDI, IJ	50 mg, ea	00003-0437-30	FI	$6.20
Amphotericin B	(Gensia)/PDI, IJ (S.D.V.)	50 mg, ea	00703-9785-01	BB	$9.80
Amphotericin B	(Pharmacia/Upjohn) Amphocin/PDI, IJ	50 mg, ea	00013-1405-44	ASD	$16.00
Calcitriol	(Abbott Hosp) Calcijex/INJ, IJ (AMP)	1mcg/ml 1ml, 100s	00074-1200-01	FI	$1,079.00
Calcitriol	(Abbott Hosp) Calcijex/INJ, IJ (AMP)	2 mcg/ml 1 ml, 100s	00074-1210-01	FI	$2,009.35
Cimetidine Hydrochloride	(Abbott Hosp.)/INJ, IJ	300 mg/50 ml, 50 ml, 48s	00074-7447-16	MK	$120.00
Cimetidine Hydrochloride	(Abbott Hosp.)/INJ, IJ (ADD-VANTAGE)	150 mg/ml, 2 ml, 25s	00074-7446-02	MK, BB	$35.00
Cimetidine Hydrochloride	(Abbott Hosp.)/INJ, IJ (VAIL FLIPTOP)	150 mg/ml, 2 mg/ml, 2 ml, 10s	00074-7444-01	ASD, BB, MK, OTH, FI	$11.72
Cimetidine Hydrochloride	(Abbott Hosp.)/INJ, IJ (VAIL FLIPTOP)	150 mg/ml, 6 ml, 10s	00074-7445-01	ASD, BB, MK, OS	$30.00
Clindamycin Phosphate	(Abbott Hosp.)/(Vial, Flipiop)	150 mg/ml, 2 ml, 25s	00074-4050-01	FI	$75.35
Clindamycin Phosphate	(Abbott Hosp.)/(Vial, Flipiop)	150 mg/ml, 4 ml, 25s	00074-4051-01	BB	$174.00
Clindamycin Phosphate	(Pharmacia/Upjohn) Cleocin/INJ, IJ	150 mg/ml, 2 ml, 25s	00009-0870-26	BB, MK	$61.20
Clindamycin Phosphate	(Pharmacia/Upjohn) Cleocin/INJ, IJ	150 mg/ml, 4 ml, 25s	00009-0775-26	BB, MK	$126.00
Clindamycin Phosphate	(Add-Vantage)	150 mg/ml, 4 ml, 25s	00009-3124-03	BB, MK	$126.00
Clindamycin Phosphate	(Add-Vantage)	150 mg/ml, 6 ml, 25s	00009-0902-18	BB, MK	$162.00
Clindamycin Phosphate	(Add-Vantage)	150 mg/ml, 6 ml, 25s	00009-3447-03	BB, MK	$162.00
Clindamycin Phosphate	(Add-Vantage)	150 mg/ml, 4 ml, 25s	00009-0728-09	BB, MK	$259.20
Cromolyn Sodium	(Dey)/SOL, IH	10 mg/ml, 2ml, 60s,	49502-0689-02	BB, MK	$23.01

		UD			
Cromolyn Sodium	(Dey)/SOL, IH	10 mg/ml, 2ml, 120s, UD	49502-0689-12	BB, MK	$45.71
Dexamethasone Acetate	(Schein)/INJ, IJ (M.D.V.)	8 mg/ml, 5 ml	00364-6699-53	R	$11.50
Dexamethasone Sodium Phosphate	(Elkins-Sin)/(M.D.V.)	10 mg/ml, 10 ml	00641-2277-41	R, DS	$2.65
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 1 ml ea	00469-1650-00	BB	$0.66
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 5 ml	00469-1650-20	BB	$1.67
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	30 ml	00469-1650-50	BB	$10.00
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	4 mg/ml, 5 ml	63323-0165-05	OTN	$0.90
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL)	30 ml	63323-0165-30	R	$10.00
Dexamethasone Sodium Phosphate	(Fujisawa/APP)/INJ, IJ (VIAL), (M.D.V.)	30 ml	63323-0165-01	BB	$0.66
Dexamethasone Sodium Phosphate	(Schein)/INJ, IJ (M.D.V)	4 mg/ml, 5 ml ea	00364-6681-32	BB	$1.08
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE LIFECARE)	5%, 50 ml	00074-7100-13	BB, TRI	$3.22
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE)	5%, 250 ml	00074-7100-02	TRI	$4.12
Dextrose	(Abbott Hosp.)/(ADD-VANTAGE LIFECARE)	5%, 100 ml	00074-7100-23	TRI	$3.22
Dextrose	(Abbott Hosp.)/(LIFECARE)	250 ml	00074-1522-02	TRI, R	$3.63
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 150 ml	00074-7922-61	BB, TRI	$1.46
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 50 ml	00074-7923-35	BB, TRI	$1.45
Dextrose	(Abbott Hosp.)/(LIFECARE)	5%, 100 ml	00074-7923-37	ASD	$1.45
Dextrose	(Abbott Hosp.)/(LIFECARE/PLASTIC)	(1000 ml container), 1000 ml	00074-1518-05	BB, R, OTN, TRI, DS	$14.54
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 1000 ml	00074-1519-05	ASD, DS, R, OTN, TRI	$13.71
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	5%, 500 ml	00074-1522-03	ASD, DS, R, OTN, TRI	$3.87
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 500 ml	00074-1536-03	BB	$9.19
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 50%, 500 ml	00074-5645-25	BB, AHT	$3.69
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 70%, 500 ml	00074-5647-25	BB, DS, R	$4.26
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(Bulk Package), 70%, 2000 ml	00074-7120-07	BB	$13.60
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 500 ml	00074-7918-19	BB	$8.81
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	5%, 250 ml	00074-7922-02	BB	$1.54
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	5%, 500 ml	00074-7922-03	BB, TRI	$1.61

Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	5%, 1000 ml	00074-7922-09	BB, TRI	$2.34
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(2000 ml container), 50%, 1000 ml	00074-7936-17	BB, FL OTH, TRI, OS	$11.24
Dextrose	(Abbott Hosp.) /(LIFECARE/PLASTIC)	(1000 ml container), 50%, 500 ml	00074-7936-19	ASD, OTH, FL TRI, OS	$7.09
Dextrose	(Abbott Hosp.)/(INJ, U, (50/150 ML PART FILL)	5%, 50 ml	00074-1523-01	BB, OTH, FL TRI, OS	$3.91
Dextrose	(Baxter)/ (QUAD PACK, MINI-BAG)	5%, 100ml	00338-0017-18	BB, TRI	$1.55
Dextrose	(Baxter)/(BULK PACKAGE)	50%, 2000 ml	00338-0031-06	BB, TRI	$21.60
Dextrose	(Baxter)/(BULK PACKAGE)	70%, 2000 ml	00338-0719-06	ASD, OS	$13.31
Dextrose	(Baxter)/(GLASS FULL FILL)	70%, 1000 ml	00338-0348-04	TRI, FI	$6.20
Dextrose	(Baxter)/(GLASS UNDERFILL)	70%, 500 ml	00338-0032-13	TRI	$8.16
Dextrose	(Baxter)/(MINI-BAG PLUS)	5%, 50 ml	00338-0551-11	TRI	$3.17
Dextrose	(Baxter)/(MULTI-PACK, MINI-BAG)	5%, 50 ml	00338-0017-31	TRI	$1.80
Dextrose	(Baxter)/(MULTI-PACK, MINI-BAG)	5%, 100ml	00338-0017-38	TRI	$1.55
Dextrose	(Baxter)/(QUAD PACK, MINI-BAG)	5%, 25 ml	00338-0017-10	TRI	$1.80
Dextrose	(Baxter)/(QUAD PACK, MINI-BAG)	5%, 50 ml	00338-0017-11	TRI, FI	$1.55
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	250 ml	00338-0016-02	TRI	$3.39
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	150 ml	00338-0017-01	FI, TRI	$1.50
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	250 ml	00338-0017-02	FI, TRI	$1.50
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	500ml	00338-0017-03	BB, TRI	$1.47
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	1000 ml	00338-0017-04	FI, TRI	$2.11
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	5%, 100ml	00338-0017-48	FI, TRI	$1.55
Dextrose	(Baxter)/(SINGLE PACK, MINI-BAG)	10%, 250 ml	00338-0023-02	BB	$1.69
Dextrose	(Baxter)/(SINGLE PACK MINI-BAG)	5%, 50 ml	00338-0017-41	TRI, FI	$2.25
Dextrose	(McGaw)/(1000 ML GLASS W/ STOPPER)	50%, 500 ml	00264-1280-55	TRI	$4.07
Dextrose	(McGaw)/(EXCEL)	5%, 1000 ml	00264-7510-00	TRI, OTH, ASD, OS	$2.20
Dextrose	(McGaw)/(EXCEL)	500 ml	00264-7510-10	TRI, OTH, ASD, /OS	$1.69
Dextrose	(McGaw)/(EXCEL)	5%, 250 ml	00264-7510-20	TRI, OTH, ASD, OS	$1.59
Dextrose	(McGaw)/(EXCEL)	10%, 1000 ml	00264-7520-00	TRI	$1.99
Dextrose	(McGaw)/(GLASS CONTAINER, 1000 ML)	500 ml	00264-1290-50	TRI	$7.15
Dextrose	(McGaw)/(GLASS CONTAINER, 1000 ML)	70%, 500 ml	00264-1292-55	TRI	$5.28

B

Dextrose	(McGaw)/(GLASS W/ AIR TUBE)	70%, 2000 ml	00264-1129-50	TRI	$18.35
Dextrose	(McGaw)/(GLASS W/SOLID STOPPER	70%, 1000 ml	00264-1290-55	TRI	$6.62
Dextrose	(McGaw)/(GLASS W/SOLID STOPPER)	50%, 500 ml	00264-1281-55	TRI	$2.76
Dextrose	(McGaw)/(W/SOLID STOPPER, GLASS)	50%, 2000 ml	00264-1285-55	TRI	$11.32
Dextrose	(McGaw)/INJ, IJ (100 ML PAB)	50 ml	00264-1510-31	TRI, OTH	$1.61
Dextrose	(McGaw)/INJ, IJ (150 ML PAB)	5%, 100 ml	00264-1510-32	TRI, OTH	$1.62
Dextrose with Sodium Chloride	(Abbott Hosp.)	5%-0.45%, 250 ml	00074-7926-02	TRI, R, OS	$1.80
Dextrose with Sodium Chloride	(Abbott Hosp.)	500 ml	00074-7926-03	TRI, OTH, ASD, R, OS	$1.96
Dextrose with Sodium Chloride	(Abbott Hosp.)	1000 ml	00074-7926-09	TRI, OTH, ASD, R, OS	$2.66
Dextrose with Sodium Chloride	(Abbott Hosp.)	5%-0.9%, 250 ml	00074-7941-02	TRI	$1.93
Dextrose with Sodium Chloride	(Abbott Hosp.)	500 ml	00074-7941-03	TRI, OTH, ASD, R, OS	$1.85
Dextrose with Sodium Chloride	(Abbott Hosp.)	1000 ml	00074-7941-09	BB, OTH, ASD, R, OS	$2.24
Dextrose with Sodium Chloride	(Baxter)	5%-0.45%, 250 ml	00338-0085-02	TRI, R	$2.47
Dextrose with Sodium Chloride	(Baxter)	500 ml	00338-0085-03	TRI, R	$1.90
Dextrose with Sodium Chloride	(Baxter)	1000 ml	00338-0085-04	R	$2.25
Dextrose with Sodium Chloride	(Baxter)	5%-0.9%, 250 ml	00338-0089-02	TRI	$2.93
Dextrose with Sodium Chloride	(Baxter)	500 ml	00338-0089-03	R	$2.00
Dextrose with Sodium Chloride	(Baxter)	1000 ml	00338-0089-04	R	$2.25
Dextrose with Sodium Chloride	(McGaw)	1000 ml	00264-7610-00	TRI, R	$2.10
Dextrose with Sodium Chloride	(McGaw)	500 ml	00264-7610-10	TRI, R	$1.81
Dextrose with Sodium Chloride	(McGaw)	5%-0.9%, 250 ml	00264-7610-20	TRI	$1.78
Dextrose with Sodium Chloride	(McGaw)	1000 ml	00264-7612-00	TRI, R, ASD	$1.85
Dextrose with Sodium Chloride	(McGaw)	500 ml	00264-7612-10	TRI, R	$1.85
Dextrose with Sodium Chloride	(McGaw)	5%-0.45%, 250 ml	00264-7612-20	TRI, R	$1.89
Diazepam	(Abbott Hosp.)/(CARPUJECT IJ/EB LOCK)	5 mg/ml,2 ml, ea C-IV	00074-1273-32	BB	$2.03
Diazepam	(Abbott Hosp.)/(CARPUJECT, 22GX1-1/4")	5 mg/ml, 2ml, ea C-IV	00074-1273-02	BB, R	$2.72

Diazepam	(Abbott Hosp.)/(VIAL, FLIPTOP)	5 mg/ml, 10 ml, ea. C-IV	00074-3213-01	OTN, MK	$2.50
Diazepam	(Abbott Hosp.)/INJ, LJ (AMP)	5 mg/ml, 2ml, EA C-IV	00074-3210-32	BB	$1.49
Diazepam	(Schein)/INJ, LJ (S.D.V.) (M.D.V.)	5 mg/ml, 10 ml, ea. C-IV	00364-0825-54	ASD	$2.50
Furosemide	(Abbott Hosp.)/INJ, LJ (VIAL, PF, FLIPTOP)	10 mg/ml, 2 ml 25s	00074-6102-02	ASD, BB, MK	$14.38
Furosemide	(Abbott Hosp.)/INJ, LJ (VIAL, PF, FLIPTOP)	10 mg/ml, 4 ml 25s	00074-6102-04	OS, ASD, OTN, BB, MK	$20.28
Gentamicin Sulfate	(Abbott Hosp.)/(Vial, Flptop)	40 mg/ml, 2 ml	00074-1207-03	OTN, BB, OS, R	$0.51
Gentamicin Sulfate	(Fujisawa)/(Bulk Package)	40 mg/ml, 50 ml	00469-1000-60	MK, BB	$7.00
Gentamicin Sulfate	(Fujisawa)/(Bulk Package)	40 mg/ml, 50 ml	63323-0010-50	MK, BB	$7.00
Gentamicin Sulfate	(Fujisawa)/INJ, LJ (M.D.V.)	40 mg/ml, 20 ml	00469-1000-40	OTN	$5.40
Gentamicin Sulfate	(Fujisawa)/INJ, LJ (M.D.V.)	40 mg/ml, 20 ml	63323-0010-20	BB, MK	$3.50
Gentamicin Sulfate	(Schein)/(M.D.V.)	40 mg/ml, 20 ml	00364-6739-55	BB	$2.63
Gentamicin Sulfate	(Schein)/INJ, LJ (S.D.V.)	40 mg/ml, 2 ml	00364-6739-48	BB	$1.18
Heparin Lock Flush	(Abbott Hosp.)/INJ, LJ (VIAL, FLIPTOP)	10 u/ml, 10 ml 25s	00074-1151-70	OS, OTN	$13.60
Heparin Lock Flush	(Abbott Hosp.)/INJ, LJ (VIAL, FLIPTOP)	100 u/ml, 10 ml 25s	00074-1152-70	ASD, OS, R, OTN	$13.43
Heparin Lock Flush	(Abbott Hosp.)/INJ, LJ (VIAL, FLIPTOP)	30 ml, 25s	00074-1152-78	ASD, OS, OTN	$21.07
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	100 mg, ea	00009-0900-13	BB, MK, ASD, BB, R, OS	$1.55
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	250 mg, ea	00009-0909-08	ASD, R, BB, MK	$2.65
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	500 mg, ea	00009-0912-05	ASD, MK, BB, OS, R	$5.89
Hydrocortisone Sodium Succinate	(Pharmacia/Upjohn) Solu-Cortef/ (ACT-O-VIAL)	1000 mg, ea	0009-0920-03	R, MK	$11.57
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, LJ (10 gm/Vial, w/Admin. Set)	100 mg/ml, 100 ml	49669-1623-01	R	$780.00
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, LJ (20 gm/Vial, w/Admin. Set)	100 mg/ml, 200 ml	49669-1624-01	R	$1,560.00
Immune Globulin	(Alpha Therapeutics) Venoglobulin-S 10%/INJ, LJ (5 gm/Vial, w/Admin. Set)	100 mg/ml, 50 ml	49669-1622-01	R	$390.00
Immune Globulin	(Baxter Hyland/Immuno) Gammagard S/D/PDI, LJ	2.5 gm, ea	00944-2620-02	R	$175.00
Immune Globulin	(Baxter Hyland/Immuno) Gammagard S/D/PDI, LJ	5.0 gm, ea	00944-2620-03	R	$350.00
Immune Globulin	(Baxter Hyland/Immuno) Gammagard S/D/PDI, LJ	10.0 gm, ea	00944-2620-04	R	$700.00
Immune Globulin	(Bayer) Gamimune N10%/INJ, LJ (10 gm/Vial)	100 mg/ml, 100 ml	00026-0648-71	R, ASD, OS, Bayer Wholesale	$727.50
Immune Globulin	(Bayer) Gamimune N10%/INJ, LJ (20 gm/Vial)	100 mg/ml, 200 ml	00026-0648-24	R, OS, Bayer Wholesale	$1,503.33
Immune Globulin	(Bayer) Gamimune N10%/INJ, LJ (5 gm/Vial)	100 mg/ml, 50 ml	00026-0648-20	R, ASD, OS, Bayer Wholesale	$362.50

Immune Globulin	(Cantean) Gamma-P.I.V./PDL LI (w/diluent)	5 gm. ea	00053-7486-05	Health Coalition. ASD. OS	$296.67
Immune Globulin	(Cantean) Gamma-P.I.V./PDL LI (w/diluent)	10 gm. ea	00053-7486-10	Health Coalition. ASD. OS	$593.33
Iron Dextran	(Schein)/INJ, LI (S.D.V.)	50 mg/ml. 2 ml	00364-3012-67	ASD. OS. R. OTN	$24.69
Lorazepam	(Abbott Hosp.)/(HYPAK SYRINGE)	2 mg/ml. 1ml. C-IV	00074-6776-01	BB	$3.80
Lorazepam	(Abbott Hosp.)/(VIAL)	4 mg/ml. 1ml. C-IV	00074-1539-01	MK	$3.80
Lorazepam	(Abbott Hosp.)/(VIAL)	4 mg/ml. 10ml. C-IV	00074-1539-10	MK	$30.00
Lorazepam	(Abbott Hosp.)/(VIAL)	2 mg/ml. 10ml. C-IV	00074-1985-10	BB	$25.83
Lorazepam	(Abbott Hosp.)/ (VIAL FLIPTOP)	2 mg/ml. 1ml. C-IV	00074-6778-01	BB. R	$2.98
Lorazepam	(Abbott Hosp.)/ (VIAL FLIPTOP)	4 mg/ml. 1ml. C-IV	00074-6779-01	BB	$3.80
Lorazepam	(Abbott Hosp.)/ (VIAL FLIPTOP)	2 mg/ml. 10ml. C-IV	00074-6780-01	ASD. OTN. R	$24.42
Lorazepam	(Abbott Hosp.)/ (VIAL FLIPTOP)	4 mg/ml. 10ml. C-IV	00074-6781-01	BB. R	$28.75
Lorazepam	(Abbott Hosp.)/INJ, LI (VIAL)	2 mg/ml. 1ml. C-IV	00074-1985-01	MK	$3.00
Lorazepam	(Wyeth-Ayerst) Ativan/(M.D.V.)	4 mg/ml. 10ml. C-IV	00008-0570-01	R	$48.00
Lorazepam	(Wyeth-Ayerst) Ativan/(M.D.V.)	2 mg/ml. 10ml. C-IV	00008-0581-01	R	$29.50
Lorazepam	(Wyeth-Ayerst) Ativan/(S.D.V.)	2 mg/ml. 1ml. C-IV	00008-0581-04	R	$8.85
Lupron	(Tap) Lupron Depot/(3 Month Formulation)	22.5 mg. ea	00300-3336-01	ASD. R. OTN. OS	$1,447.60
Lupron	(Tap) Lupron Depot/(3 Month Formulation)	11.25 mg. ea	00300-3342-01	R	$1,149.00
Lupron	(Tap) Lupron Depot/(4 Month Formulation)	30 mg. ea	00300-3473-01	R. ASD. OS	$1,902.80
Lupron	(Tap) Lupron Depot/PDL LI (S.D.V.)	7.5 mg. ea	00300-3629-01	ASD. OS. R. OTN	$482.52
Lupron	(Tap) Lupron Depot/PDL LI (S.D.V.)	3.75 mg. ea	00300-3639-01	R. OS	$406.00
Metaproterenol Sulfate	(Dey)/SOL, IN (SULFATE FREE)	0.6%. 2500 ml. 25s. UD	49502-0676-03	BB. MK	$11.29
Metaproterenol Sulfate	(Dey)/SOL, IN (SULFATE FREE)	0.4%. 2500 ml. 25s. UD	49502-0678-03	BB. MK	$11.29
Methylprednisolone Sodium Succinate	(Abbott Hosp.) A-Methapred/PDL LI (UNIVIAL)	1 gm. ea	00074-5631-08	OTN	$16.75
Methylprednisolone Sodium Succinate	(Abbott Hosp.) A-Methapred/PDL LI (UNIVIAL)	40 mg. ea	00074-5684-01	OTN	$2.30
Methylprednisolone Sodium Succinate	(Abbott Hosp.) A-Methapred/PDL LI (UNIVIAL)	125 mg. ea	00074-5685-02	OTN	$3.55
Methylprednisolone Sodium Succinate	(Abbott Hosp.) A-Methapred/PDL LI (ABD-VANTAGE)	500 mg. ea	00074-5601-44	OTN	$9.40
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	125 mg. ea	00009-0190-09	BB. OS	$2.52
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	500 mg. ea	00009-0765-02	BB	$5.51

Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(ACT-O-VIAL)	1 gm, ea	00009-3389-01	BB, ASD, R, OS	$11.39
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(VIAL)	1 gm, ea	00009-0698-01	BB, R, OS	$11.69
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(VIAL)	500 mg, ea	00009-0758-01	BB, R, OS	$6.37
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(W/DILUENT)	2 gm, ea	00009-0796-01	BB, R	$14.41
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/(W/DILUENT)	500 mg, ea	00009-0887-01	ASD	$6.17
Methylprednisolone Sodium Succinate	(Pharmacia/Upjohn) Solu-Medrol/PDL IJ (ACT-O-VIAL)	40 mg, ea	00009-0113-12	ASD, BB, OS	$1.45
Mitomycin	(Bedford)/PDL IJ (S.D.V.)	5 mg, ea	55390-0251-01	R, OS, ASD	$51.83
Mitomycin	(Bedford)/PDL IJ (S.D.V.)	20 mg, ea	55390-0252-01	R, ASD, OS	$146.67
Mitomycin	(Fujisawa)/PDL IJ	20 mg, ea	61703-0306-50	ASD, OS	$134.00
Pentamidine Isethionate	(Fujisawa) Nebupent/PDR, IM (S.D.V., P.F.)	300 mg, ea	57317-0210-06	R	$36.00
Pentamidine Isethionate	(Fujisawa) Nebupent/PDR, IM (S.D.V., P.F.)	300 mg, ea	63323-0877-15	R	$36.00
Pentamidine Isethionate	(Gensia)/PDL IJ (S.D.V.)	300 mg, ea	00053-1000-05	R	$29.00
Sodium Chloride	(Abbott Hosp.)/(ADD-VANT, LIFECARE P.P.)	0.9%, 50 ml	00074-7101-13	TRI, BB	$3.22
Sodium Chloride	(Abbott Hosp.)/(ADD-VANT, LIFECARE P.P.)	0.9%, 100 ml	00074-7101-23	TRI, BB	$3.22
Sodium Chloride	(Abbott Hosp.)/(ADD-VANT, LIFECARE)	0.9%, 250 ml	00074-7101-02	TRI, BB	$4.19
Sodium Chloride	(Abbott Hosp.)/(LIFECARE)	0.9%, 50 ml	00074-7984-36	TRI, ASD, OS, OTN, R	$1.45
Sodium Chloride	(Abbott Hosp.)/(LIFECARE)	0.9%, 100 ml	00074-7984-37	TRI, ASD, OS, OTN, R	$1.45
Sodium Chloride	(Abbott Hosp.)/(LIFECARE, PLASTIC CONT)	0.9%, 500 ml	00074-7983-03	R, ASD, BB, OS	$1.69
Sodium Chloride	(Abbott Hosp.)/(LIFECARE, PLASTIC CONT)	0.9%, 1000 ml	00074-7983-09	R, ASD, BB, OS	$2.17
Sodium Chloride	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 250 ml	00074-1583-02	TRI, OTN, R, OS	$1.94
Sodium Chloride	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 250 ml	00074-7983-02	R, ASD, BB	$1.41
Sodium Chloride	(Abbott Hosp.)/(LIFECARE, PLASTIC)	0.9%, 150 ml	00074-7983-61	R, ASD, OS, OTN	$1.43
Sodium Chloride	(Baxter)/(MINI-BAG PLUS)	0.9%, 50 ml	00338-0553-11	TRI	$3.32
Sodium Chloride	(Baxter)/(MINI-BAG PLUS)	0.9%, 100 ml	00338-0553-18	TRI	$3.17
Sodium Chloride	(Baxter)/(MULTI PACK, MINI-BAG)	0.9%, 50 ml	00338-0049-31	TRI, R	$1.55
Sodium Chloride	(Baxter)/(MULTI PACK, MINI-BAG)	0.9%, 100 ml	00338-0049-38	TRI, R	$1.55
Sodium Chloride	(Baxter)/(QUAD PACK, MINI-PACK)	0.9%, 50 ml	00338-0049-11	TRI	$1.80
Sodium Chloride	(Baxter)/(QUAD PACK, MINI-PACK)	0.9%, 100 ml	00338-0049-18	TRI	$1.80
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 150 ml	00338-0049-01	TRI, R	$1.51

Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 250 ml	00338-0049-02	TRL R	$1.49
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 500 ml	00338-0049-03	TRL R	$1.58
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 1000 ml	00338-0049-04	TRL R	$2.03
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 50 ml	00338-0049-41	TRL	$1.71
Sodium Chloride	(Baxter)/(SINGLE PACK, MINI-BAG)	0.9%, 100 ml	00338-0049-48	TRL R	$1.55
Sodium Chloride	(McGaw)	50 ml	00264-1800-31	TRL R	$1.49
Sodium Chloride	(McGaw)/(150 ML PAB)	0.9%, 100 ml	00264-1800-32	TRL R	$1.49
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 1000 ml	00264-7800-00	TRL OTN, R, ASD	$2.19
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 500 ml	00264-7800-10	TRL OTN, R, ASD	$1.53
Sodium Chloride	(McGaw)/(EXCEL)	0.9%, 250 ml	00264-7800-20	TRL OTN, R, ASD	$1.51
Testosterone Cypionate	(Pharmacia/Upjohn) Depo-Testosterone	200 mg/ml, 1 ml, C-III	00009-0417-01	BB, OTN	$11.79
Testosterone Cypionate	(Pharmacia/Upjohn) Depo-Testosterone	200 mg/ml, 10 ml, C-III	00009-0417-02	BB, OTN	$24.78
Testosterone Enanthate	(Schein)/INJ, U (M.D.V.)	200 mg/ml, 10 ml, C-III	00364-6617-54	ASD, MK, R	$13.39
Tobramycin Sulfate	(Abbott Hosp.)/(SEN)	40 mg/ml, 2 ml	00074-3583-01	BB	$5.89
Tobramycin Sulfate	(Abbott Hosp.)/(Vial, Bulk)	40 mg/ml, 50 ml	00074-3590-02	BB, MK	$103.64
Tobramycin Sulfate	(Abbott Hosp.)/(Vial, Flipjop)	40 mg/ml, 2 ml	00074-3578-01	BB, MK	$4.99
Tobramycin Sulfate	(Abbott Hosp.)/INJ, U (Vial Flipjop)	10 mg/ml, 2 ml	00074-3577-01	BB, MK	$2.94
Tobramycin Sulfate	(Gensia)/INJ, U (M.D.V.)	40 mg/ml, 2ml	00703-9402-04	R, MK	$6.98
Tobramycin Sulfate	(Gensia)/INJ, U (M.D.V.)	40 mg/ml, 30 ml	00703-9416-01	R	$36.90
Vancomycin Hydrochloride	(Abbott Hosp.)/(BULK VIAL)	5 gm, ea	00074-6509-01	R, MK, BB	$41.24
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	500 mg, 10s, ea	00074-4332-01	R, OTN, MK, BB, DS	$4.98
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	1 gm, 10s, ea	00074-6533-01	R, ASD, DS, MK, BB	$9.05
Vancomycin Hydrochloride	(Abbott Hosp.)/(VIAL, FLIPTOP)	1 gm, 10s, ea	00074-6535-01	R, OTN, MK, BB	$12.17
Vancomycin Hydrochloride	(Abbott Hosp.)/PDI, U (ADD-VANTAGE)	500 mg, 10s, ea	00074-6534-01	R, MK, BB	$5.09
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	500 mg, ea	00469-2210-30	BB, MK	$7.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	1 gm, ea	00469-2840-40	BB, MK	$13.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	5 gm, ea	00469-2951-00	BB	$71.50
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	1 gm, ea	63323-0284-20	BB, MK	$13.00
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	5 gm, ea	63323-0295-41	BB	$71.50
Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	10 gm, ea	63323-0314-61	MK	$143.00

Vancomycin Hydrochloride	(Fujisawa) Lyphocin/PDI U (VIAL)	500 mg. ea	63323-2210-30	BB, MK	$7.00
Vancomycin Hydrochloride	(Lederle Std. Prod.) Vancoled/PDI INJ. U	5 gm. ea	00205-3154-05	MK, BB	$45.09
Vancomycin Hydrochloride	(Lederle Std. Prod.) Vancoled/PDI INJ. U	1 gm. 10s. ea	00205-3154-15	MK, BB	$9.02
Vancomycin Hydrochloride	(Lederle Std. Prod.) Vancoled/PDI INJ. U	500 mg. 10s. ea	00205-3154-88	MK, BB	$4.51
Vancomycin Hydrochloride	(Schein)/PDI, U (M.D.V.)	1 gm. 10s. ea	00364-2473-91	OTN	$12.90
Vancomycin Hydrochloride	(Schein)/PDI, U (S.D.V.)	500 mg. 10s. ea	00364-2472-33	MK	$3.84
Winho SDF	(Nabi) rho (d) Immune globulin/ (VIAL).	5000 iu. ea	60492-0024-01	ASD, R, OTN, OS	$505.56
Winho SDF	(Nabi) rho (d) Immune globulin/PDI, U (S.D.V.)	600 iu. ea	60492-0021-01	ASD,R, OS	$64.96
Winho SDF	(Nabi) rho (d) Immune globulin/PDI, U (S.D.V.)	1500 iu. ea	60492-0023-01	ASD, R, OTN, OS	$152.30

Wholesaler Information

ASD = ASD Specialty Healthcare (1-800-786-6273)
BB = Bergen Brunswig (1-800-746-6273)
FI = Florida Infusion (1-800-824-0152)
MK = McKesson (1-888-782-6756)
OS = Oncology Supply (1-800-633-7255)
OTN = Oncology Therapeutics Network (1-800-482-6700)
TRI = Triad Medical (1-800-999-8633)
ANDA = ANDA (1-800-331-2632)
Biomed Plus 3/99 = Biomed Plus, Inc. (1-800-809-2308)
FFF = FFF Enterprises (1-800-843-7477)
Bayer Wholesale = Bayer Wholesale (1-203-812-2000)
Health Coalition = Health Coalition (1-800-456-7283)

Attachment 2 – Do not use these data to update the HCPCS billing codes that correspond to the drugs on this list. Instead, use your usual source for average wholesale prices.

Drug Name	Prod/Mfr	Measurements	NDC	Wholesaler	Average Wholesale (AWP)
Anti-Inhibitor Coagulant Complex	(NABI) AutoPlex T/PDI, LJ (390-1050 FECU)	ea	59730-6059-07	Biomed Plus 3/99	1.06
Anzemet/Dolasetron Mesylate	(Hoechst Marion)/INJ, LJ (VIAL)	20 mg/ml, 5 ml	00088-1206-32	DS	$74.08
Bleomycin Sulfate	(Bristol-Myer Onc/Imm) Blexonane/PDI, LJ (VI)	15 u, ea	00015-3010-20	FI, OS, ASD	$255.39
Bleomycin Sulfate	(Bristol-Myer Onc/Imm) Blexonane/PDI, LJ (VI)	30 u, ea	00015-3063-01	FI, OS	$509.29
Bleomycin Sulfate	(Pharmacia/Upjohn)/PDI, LJ (VIAL)	15 u, ea	00013-1616-78	ASD, FI, OS	$158.67
Bleomycin Sulfate	(Pharmacia/Upjohn)/PDI, LJ (VIAL)	30 u, ea	00013-1636-86	ASD, FI, OS	$322.00
Cisplatin	(APP)/INJ, LJ	1 mg/ml, 50 mg, 50 ml	63323-0103-51	OS, FI	$150.98
Cisplatin	(APP)/INJ, LJ	1 mg/ml, 200 mg, 200 ml	63323-0103-64	OS, FI	$603.50
Cisplatin	(APP)/INJ, LJ	1 mg/ml, 100 mg, 100 ml	63323-0103-65	OS, FI	$301.50
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, LJ (VIAL)	100 mg, ea	00015-0539-41	ASD, OS, OTN	$4.18
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, LJ (VIAL)	200 mg, ea	00015-0546-41	ASD, OS, OTN	$7.03
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, LJ (VIAL)	500 mg, ea	00015-0547-41	ASD, OS, OTN	$11.59
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, LJ (VIAL)	1gm, ea	00015-0548-41	ASD, OS, OTN	$23.19
Cyclophosphamide	(Bristol-Myer Onc/Imm) Cytoxan Lyophilized/PDI, LJ (VIAL)	2 gm, ea	00015-0549-41	ASD, OS, OTN	$45.83
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, LJ, (S.D.V.)	100 mg, ea	00013-5606-93	ASD, OTN, OS, FI	$3.92
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, LJ, (S.D.V.)	200 mg, ea	00013-5616-93	ASD, FI, OS, OTN	$5.06
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, LJ, (S.D.V.)	500 mg, ea	00013-5626-93	ASD, FI, OS, OTN	$7.33

Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, LJ, (S.D.V.)	1 gm. ea	00013-5636-70	ASD, FL OTN, DS	$11.24
Cyclophosphamide	(Pharmacia/Upjohn) Neosar/PDI, LJ, (S.D.V.)	2 gm. ea	00013-5646-70	ASD, FL OTN, DS	$21.60
Cytarabine	(Bedford)/PDI, LJ (VIAL)	100 mg. ea	55390-0131-10	ASD,OS, FL, MK, BB, OTN	$3.55
Cytarabine	(Bedford)/PDI, LJ (VIAL)	500 mg. ea	55390-0132-10	ASD,OS, FL, OTN, MK, BB	$11.46
Cytarabine	(Bedford)/PDI, LJ (VIAL)	1 gm. ea	55390-0133-01	ASD,OS, FL, OTN, MK, BB	$23.64
Cytarabine	(Bedford)/PDI, LJ (VIAL)	2 gm. ea	55390-0134-01	ASD,OS, FL, OTN, BB, MK	$47.94
Cytarabine	(Bedford)/PDI, LJ (VIAL)	100 mg. ea	55390-0806-10	BB	$3.50
Cytarabine	(Bedford)/PDI, LJ (VIAL)	500 mg. ea	55390-0807-10	BB	$10.50
Cytarabine	(Bedford)/PDI, LJ (VIAL)	1 gm. ea	55390-0808-01	BB	$22.00
Cytarabine	(Bedford)/PDI, LJ (VIAL)	2 gm. ea	55390-0809-01	BB	$44.00
Cytarabine	(Foulding)/INJ, LJ (S.D.V.P.F.)	(P.F. BULK PACKAGE) 20 mg/ml. 50 ml	61703-0303-50	BB, MK	$39.00
Cytarabine	(Foulding)/INJ, LJ (S.D.V.P.F.)	20 mg/ml. 25 ml	61703-0304-25	ASD, BB, FL, DS	$12.63
Cytarabine	(Foulding)/INJ, LJ (S.D.V.P.F.)	20 mg/ml. 5 ml (M.D.V.)	61703-0305-09	BB, MK, FL	$4.62
Cytarabine	(Pharmacia/Upjohn) Cytosar-U/PDI, LJ (M.D.V.)	100 mg. ea	00009-0373-01	ASD, OS, OTN, FL MK	$4.06
Cytarabine	(Pharmacia/Upjohn) Cytosar-U/PDI, LJ (M.D.V.)	500 mg. ea	00009-0473-01	ASD, OS, OTN, FL MK	$13.18
Cytarabine	(Pharmacia/Upjohn) Cytosar-U/PDI, LJ (M.D.V.)	30 ml vial, 1 gm. ea	00009-3295-01	ASD, OS, OTN, FL MK	$25.11
Cytarabine	(Pharmacia/Upjohn) Cytosar-U/PDI, LJ (M.D.V.)	2 gm. ea	00009-3296-01	ASD, OS, OTN, FL MK	$49.82
Cytarabine	(Schein)/PDI, LJ (M.D.V.)	100 mg. ea	00364-2467-53	BB, MK	$4.16
Cytarabine	(Schein)/PDI, LJ (M.D.V.)	500 mg. ea	00364-2468-54	BB, MK, OTN	$12.14
Doxorubicin Hydrochloride	(Bedford)/INJ, LJ (M.D.V)	2 mg/ml. 100 ml	55390-0238-01	FL OTN	$139.75
Doxorubicin Hydrochloride	(Bedford)/INJ, LJ (S.D.V)	2 mg/ml. 5 ml	55390-0235-10	FL OTN	$10.35
Doxorubicin Hydrochloride	(Bedford)/INJ, LJ (S.D.V)	10 ml	55390-0236-10	FL OTN	$20.20
Doxorubicin Hydrochloride	(Bedford)/INJ, LJ (S.D.V)	25 ml	55390-0237-01	FL, OTN, OS	$37.97
Doxorubicin Hydrochloride	(Bedford)/PDI, LJ (S.D.V)	10 mg	55390-0231-10	FL OTN	$9.68
Doxorubicin Hydrochloride	(Bedford)/PDI, LJ (S.D.V)	20 mg	55390-0232-10	FL, OTN	$18.48
Doxorubicin Hydrochloride	(Bedford)/PDI, LJ (S.D.V)	50 mg. ea	55390-0233-01	FL, OTN, DS	$35.92
Doxorubicin Hydrochloride	(Fujikawa/APP)/(VIAL)	2 mg/ml. 100 ml	00469-1001-61	ASD	$140.00

Doxorubicin Hydrochloride	(Fujisawa/APP)/(VIAL)	2 mg/ml, 100 ml	63323-0101-61	OS	$117.17
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	2 mg/ml, 5 ml	00469-8830-20	OS	$7.35
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	10 ml	00469-8831-30	OS	$14.70
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	25 ml	00469-8832-50	ASD	$35.00
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	2 mg/ml, 5 ml	63323-0883-05	OS	$7.35
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	10 ml	63323-0883-10	OS	$14.70
Doxorubicin Hydrochloride	(Fujisawa/APP)/INJ, LI (S.D.V., P.F.)	25 ml	63323-0883-30	ASD	$34.00
Doxorubicin Hydrochloride	(Gensia)/(M.D.V. POLYMER)	2 mg/ml, 100 ml	00703-5040-01	ASD, OS	$142.00
Doxorubicin Hydrochloride	(Gensia)/INJ, LI (S.D.V. POLYMER)	2 mg/ml, 5 ml	00703-5043-03	ASD, OS, BB	$12.63
Doxorubicin Hydrochloride	(Gensia)/INJ, LI (S.D.V. POLYMER)	25 ml	00703-5046-01	ASD, OS	$35.50
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/(M.D.V. P.F.)	2 mg/ml, 100 ml	00013-1166-83	ASD, OS, FL OTN	$150.86
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/(M.D.V.)	150 mg, ea	00013-1116-83	ASD, OS, FL OTN	$113.75
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/PFS INJ, LI (VIAL P.F.)	2 mg/ml, 5 ml	00013-1136-91	ASD, OS, FL OTN	$8.49
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/PFS INJ, LI (VIAL P.F.)	10 ml	00013-1146-91	ASD,OS, FL OTN	$16.74
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/PFS INJ, LI (VIAL P.F.)	25 ml	00013-1156-79	ASD, FL OTN	$37.80
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/PFS INJ, LI (VIAL P.F.)	37.500 ml	00013-1176-67	ASD, FL OTN, OS	$59.59
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/RDF PDI, LI	10 mg, ea	00013-1086-91	ASD, FL OTN, OS	$8.24
Doxorubicin Hydrochloride	(Pharmacia/Upjohn) Adriamycin/RDF PDI, LI	50 mg, ea	00013-1106-79	ASD, OS, FL OTN	$37.15
Etoposide	(Bedford)/INJ, LI (M.D.V.)	20 mg/ml, 5 ml	55390-0291-01	FL OS	$8.45
Etoposide	(Bedford)/INJ, LI (M.D.V.)	25 ml	55390-0292-01	FL OS	$45.13
Etoposide	(Bedford)/INJ, LI (M.D.V.)	50 ml	55390-0293-01	OS, FL	$87.43
Etoposide	(Bristol-Myer Onc/Imm) Vepesid/INJ, LI (M.D.V.)	7.5 ml	00015-3084-20	OS	$51.45
Etoposide	(Bristol-Myer Onc/Imm) Vepesid/INJ, LI (M.D.V.)	20 mg/ml, 5 ml	00015-3095-20	OS	$34.30
Etoposide	(Gensia)/(BULK PACKAGE)	20 mg/ml, 50 ml	00703-5668-01	ASD, OS	$78.63
Etoposide	(Gensia)/(M.D.V.)	20 mg/ml, 25 ml	00703-5646-01	ASD, OS	$40.00

Etoposide	(Gensia)/INJ, LJ (M.D.V. POLYMER)	20 mg/ml. 5 ml	00703-5653-01	ASD, OS	$7.00
Etoposide	(Pharmacia/Upjohn) Toposar/INJ, LJ (M.D.V.)	20 mg/ml. 5 ml	00013-7336-91	ASD,OS, R	$9.47
Etoposide	(Pharmacia/Upjohn) Toposar/INJ, LJ (M.D.V.)	10 ml	00013-7346-94	ASD,OS, R	$19.00
Etoposide	(Pharmacia/Upjohn) Toposar/INJ, LJ (M.D.V.)	25 ml	00013-7356-88	ASD,OS,R	$44.00
Factor IX	(Centeon) Mononine/Factor IX Coagulation Factor PDI, LJ	1 iu, ea	00053-7668-01	ASD 3/99	$0.79
Factor IX	(Centeon) Mononine/Factor IX Coagulation Factor PDI, LJ	1 iu, ea	00053-7668-02	ASD 3/99	$0.79
Factor IX	(Centeon) Mononine/Factor IX Coagulation Factor PDI, LJ	1 iu, ea	00053-7668-04	ASD 3/99	$0.79
Factor IX	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, LJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0001-01	ASD 2/00	$0.81
Factor IX	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, LJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0002-01	ASD 2/00	$0.81
Factor IX	(Genetics Inst.) Benefix/Factor IX Coagulation Factor PDI, LJ (S.D.V. w/diluent, 1000 iu)	1 iu, ea	58394-0003-01	ASD 2/00	$0.81
Factor VIII	(Baxter Hyland/Immuno) Recombinate/anti-hemophilic factor, human PDI, LJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-01	Biomed Plus, all sizes, 3/99	$0.92
Factor VIII	(Baxter Hyland/Immuno) Recombinate/anti-hemophilic factor, human PDI, LJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-02	Biomed Plus, all sizes, 3/99	$0.92
Factor VIII	(Baxter Hyland/Immuno) Recombinate/anti-hemophilic factor, human PDI, LJ (approx. 1000 iu/Vial)	1 iu, ea	00944-2938-03	ASD, all sizes 3/99	$0.78
Factor VIII	(Bayer Pharm) Kogate HP/anti-hemophilic factor, human PDI, LJ (approx 1000 u/Vial)	1 iu, ea	00026-0664-50	ASD all sizes 3/99	$0.42

Factor VIII	(Bayer Pharm) Kodate HP/anti-hemophilic factor, human PDL, IJ (approx 1500 u/Vial)	1 iu, ea	00026-0664-60	ASD all sizes 3/99	$0.42
Factor VIII	(Bayer Pharm) Kodate HP/anti-hemophilic factor, human PDL, IJ (approx 250 u/Vial)	1 iu, ea	00026-0664-20	ASD all sizes 3/99	$0.42
Factor VIII	(Bayer Pharm) Kodate HP/anti-hemophilic factor, human PDL, IJ (approx 500 u/Vial)	1 iu, ea	00026-0664-30	ASD all sizes 3/99	$0.42
Factor VIII	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00026-0670-20	Biomed Plus, all sizes, 3/99	$0.92
Factor VIII	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00026-0670-30	Biomed Plus, all sizes, 3/99	$0.92
Factor VIII	(Bayer Pharm) Kogenate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00026-0670-50	Biomed Plus, all sizes, 3/99	$0.92
Factor VIII	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8110-01	Biomed Plus, all sizes 3/99	$0.91
Factor VIII	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8110-02	(unit) FFF, 8/99	$0.86
Factor VIII	(Centeon) Bioclate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8110-04	ASD, all sizes 3/99	$0.78
Factor VIII	(Centeon) Helixate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8120-01	ASD, all sizes 3/99	$0.78
Factor VIII	(Centeon) Helixate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8120-02	(unit) FFF, 8/99	$0.86
Factor VIII	(Centeon) Helixate/anti-hemophilic factor, recombinant PDL, IJ	1 iu, ea	00053-8120-04	Biomed Plus, all sizes 3/99	$0.91
Factor VIII	(Centeon) Monoclate-P/anti-hemophilic factor, human PDL, IJ	1 iu, ea	00053-7656-01	ASD all sizes 2/00	$0.70
Factor VIII	(Centeon) Monoclate-P/anti-hemophilic factor, human PDL, IJ	1 iu, ea	00053-7656-02	ASD all sizes 2/00	$0.70
Factor VIII	(Centeon) Monoclate-P/anti-hemophilic factor, human PDL, IJ	1 iu, ea	00053-7656-04	ASD all sizes 2/00	$0.70
Fluorouracil	(Fujisawa/AFP)/INJ, IJ (VIAL)	50 mg/ml 10 ml	63323-0117-10	OS, FI	$1.20
Fluorouracil	(Fujisawa/AFP)/INJ, IJ (VIAL)	1gm. 20 ml	63323-0117-20	OS, FI	$2.60

Fluorouracil	(Fujisawa/APP)/INJ, IJ (VIAL)	2.5 gm, 50 ml	63323-0117-51	OS, FI	$6.00
Fluorouracil	(Fujisawa/APP)/INJ, IJ (VIAL)	5 gm, 100 ml	63323-0117-61	OS, FI	$11.00
Fluorouracil	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	50 mg/ml, 10 ml	00013-1036-91	ASD,OS, OTN, FI	$1.47
Fluorouracil	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	50 ml	00013-1046-94	ASD, OTN, FI	$8.15
Fluorouracil	(Pharmacia/Upjohn) Adrucil/INJ, IJ (VIAL)	100 ml	00013-1056-94	ASD, OTN, FI, OS	$14.44
Kytril	(SK Beecham Pharm.)/INJ, IJ (S.D.V.)	1 mg/ml, 1 ml	00029-4149-01	FI, OS, OTN, ASD	$139.04
Kytril	(SK Beecham Pharm.)/INJ, IJ (S.D.V.)	1 mg/ml, 4 ml	00029-4152-01	FI, OTN, ASD, OS	$555.67
Leucovorin Calcium	(Abbott Hosp.)/(VIAL, FLIPTOP 50 ML)	10 mg/ml, 25 ml	00074-4541-04	FI, OTN, ASD, OS	$8.56
Leucovorin Calcium	(Abbott Hosp.)/INJ, IJ (VIAL, FLIPTOP)	10mg/ml, 10ml	00074-4541-02	FI, OTN, OS	$3.85
Leucovorin Calcium	(Bedford)/PDI, IJ (VIAL)	50 mg, 10s ea	55390-0051-10	FI, OTN, ASD, OS	$2.76
Leucovorin Calcium	(Bedford)/PDI, IJ (VIAL)	100 mg, 10s ea	55390-0052-10	FI, OTN, ASD, OS	$3.24
Leucovorin Calcium	(Bedford)/PDI, IJ (VIAL)	200 mg, ea	55390-0053-01	FI, OTN, ASD, OS	$8.19
Leucovorin Calcium	(Genzia)/PDI, IJ (P.F. VIAL)	100 mg, ea	00703-5140-01	OTN, ASD, OS	$3.47
Leucovorin Calcium	(Genzia)/PDI, IJ (P.F. VIAL)	350 mg, ea	00703-5145-01	OTN, ASD, OS	$15.83
Leucovorin Calcium	(Immunex)/PDI, IJ (P.F.)	350 mg, ea	58406-0623-07	OTN, FI, OS	$14.58
Methotrexate Sodium	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 2 ml, ea	55390-0031-10	ASD, OTN, FI	$2.63
Methotrexate Sodium	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 4 ml, ea	55390-0032-10	ASD, OTN, FI	$3.65
Methotrexate Sodium	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 8 ml, ea	55390-0033-10	ASD, OTN, FI	$5.03
Methotrexate Sodium	(Bedford)/INJ, IJ (S.D.V.)	25 mg/ml, 10 ml, ea	55390-0034-10	ASD, OTN, FI	$5.70
Methotrexate Sodium	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 8 ml	58406-0683-12	ASD, OS, OTN, FI	$5.84
Methotrexate Sodium	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 2 ml	58406-0683-15	ASD, ASD, OS, FI	$2.91
Methotrexate Sodium	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 10 ml	58406-0683-16	ASD, OTN, FI, OS	$7.10
Methotrexate Sodium	(Immunex) LPF/INJ, IJ (S.D.V., P.F.)	25 mg/ml, 4 ml	58406-0683-18	FI, MK, OTN, OS	$4.32
Methotrexate Sodium	(Immunex)/INJ, IJ (VIAL, LP.F.)	25 mg/ml, 2 ml	58406-0681-14	ASD,OS, OTN, FI	$3.43
Methotrexate Sodium	(Immunex)/PDI, IJ (S.D.V.)	1 gm, ea	58406-0671-05	OS, OTN, MK	$45.97
Vinblastine Sulfate	(Bedford)/PDI, IJ (VIAL)	10 mg, ea	55390-0091-10	ASD, OS, OTN, FI	$8.19
Vinblastine Sulfate	(Faulding)/INJ, IJ (VIAL)	10 mg, ea	61703-0310-18	ASD	$7.95

Vinblastine Sulfate	(Fujisawa/APP)	1 mg/mL 10 ml	00469-2780-30	ASD, OS	$9.00
Vinblastine Sulfate	(Fujisawa/APP)	1 mg/mL 10 ml	63323-0278-10	OTN, R	$10.93
Vincristine Sulfate	(Faulding)/INJ, LJ (S.D.V., P.F.)	1 mg/mL 1 ml	61703-0309-06	ASD, OS, OTN, R	$4.34
Vincristine Sulfate	(Faulding)/INJ, LJ (S.D.V., P.F.)	1 mg/mL 2 ml	61703-0309-16	ASD,OS, OTN, R	$7.60
Vincristine Sulfate	(Pharmacia/Upjohn) Vincasar/INJ, LJ (VIAL)	1 mg/mL 1 ml	00013-7456-86	ASD, OTN, R, OS	$5.10
Vincristine Sulfate	(Pharmacia/Upjohn) Vincasar/INJ, LJ (VIAL)	1 mg/mL 2 ml	00013-7466-86	ASD, OTN, R, OS	$8.35
Zofran	(Cerenex)/INJ, LJ (M.D.V.)	2 mg/mL 20 ml	000173-0442-00	R, OTN, ASD, OS	$169.06
Zofran	(Cerenex)/INJ, LJ (PREMIXED BAG)	30 mg/50ml, 50 ml	000173-0461-00	R, OTN, R, OS	$128.09
Zofran	(Cerenex)/INJ, LJ (S.D.V.)	2 mg/mL 2 ml	000173-0442-02	R, OTN, OS	$22.61

Exhibit “3”

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ABBOTT	AGTIO	00074246324	13.854	13.618			15.000	14.437			15.333	15.172		
	AZMACORT	60598005160												
	BIAXIN	00074258860	3.949	3.948	3.148	25%	4.143	4.142	3.298	25%	4.523	4.361	3.459	26%
	BIAXIN	00074336860	3.949	3.948	3.149	25%	4.143	4.142	3.300	25%	4.523	4.361	3.454	26%
	BIAXIN XL	00074316560	4.458	4.457	3.556	25%	4.588	4.587	3.651	25%	4.764	4.711	3.736	26%
	CALCIJEX	00074120001	13.502	13.502			13.502	13.502			13.502	13.502		
	DEFEROXAMINE MESYLATE	00074233725					2.328	2.328			2.328	2.328		
	DEPAKENE	00074568216	0.379	0.379	0.272	39%	0.409	0.406	0.299	36%	0.460	0.448	0.335	34%
	DEPAKOTE	00074621213	0.474	0.473	0.378	25%	0.511	0.508	0.404	26%	0.575	0.559	0.441	27%
	DEPAKOTE	00074621413	0.930	0.930	0.742	25%	1.003	0.997	0.795	25%	1.129	1.098	0.871	26%
	DEPAKOTE	00074621459	0.930	0.930	0.742	25%	1.004	0.997	0.794	26%	1.128	1.098	0.865	27%
	DEPAKOTE	00074621511	1.733	1.732	1.450	19%	1.967	1.955	1.547	26%	2.209	2.151	1.670	29%
	DEPAKOTE	00074621513	1.715	1.715	1.369	25%	1.851	1.839	1.466	25%	2.001	2.028	1.607	26%
	DEPAKOTE	00074621563	1.715	1.715	1.369	25%	1.851	1.839	1.464	26%	2.081	2.028	1.596	27%
	DEPAKOTE ER	00074382613					1.003	1.003	0.877	14%	1.128	1.098	0.886	24%
	DEPAKOTE ER	00074712613	1.715	1.715	1.369	25%	1.755	1.759	1.402	26%	1.985	1.932	1.533	26%
	DEPAKOTE ER	00074712653									1.985	1.985	1.569	26%
	DEPAKOTE SPRINKLE	00074611413	0.476	0.475	0.380	25%	0.614	0.511	0.407	26%	0.578	0.582	0.440	28%
	DILAUDID-HP	00044101706	3.450	3.401	2.486	36%	3.450	3.450	2.704	28%	3.450	3.450		
	GENGRAF	00074646332	1.376	1.376	1.013	36%	1.376	1.376	0.995	38%	1.376	1.376	0.988	40%
	GENGRAF	00074647932	5.496	5.496	4.041	36%	5.496	5.496	3.977	38%	5.496	5.496	3.926	40%
	HUMIRA	00074379902									685.920	663.118	531.479	25%
	HYTRIN	00074360513	1.962	1.962	1.568	25%	2.078	2.048	1.625	26%	2.183	2.137	1.674	28%
	HYTRIN	00074380613	1.962	1.962	1.568	25%	2.078	2.048	1.631	26%	2.183	2.137	1.688	27%
	HYTRIN	00074380713	1.962	1.962	1.568	25%	2.078	2.048	1.632	25%	2.183	2.137	1.686	27%
	HYTRIN	00074380813	1.962	1.962	1.569	25%	2.078	2.048	1.630	26%	2.183	2.137	1.680	27%
	KALETRA	00074395977	3.762	3.762	3.002	25%	3.908	3.908	3.114	26%	3.908	3.908	3.098	26%
	KALETRA	00074679922												
	LIPOSYN III	00074579103	0.061	0.109	0.026	327%	0.061	0.061	0.029	106%	0.061	0.061	0.030	100%
	MORPHINE SULFATE	00074113403	0.526	1.505	0.372	304%	0.526	0.526	0.377	39%	0.526	0.526	0.380	38%
	NIASPAN	60598000101	0.723	0.698			0.865	0.821			1.096	1.041		
	NIASPAN	60598000301	1.292	1.246			1.545	1.487			1.959	1.860		
	NORVIR	00074194068	1.444	1.444	1.152	25%	1.500	1.500	1.198	26%	7.501	1.961	1.564	26%
	NORVIR	00074663322	2.063	2.062	1.646	25%	2.143	2.143	1.706	26%	10.716	2.801	2.138	31%
	NORVIR	00074663330												
	NORVIR	00074049202	1.855	1.855			1.855	1.855			1.855	1.855		
	OMNICEF	00074376960	4.121	4.120	3.298	25%	4.329	4.301	3.430	25%	4.539	4.501	3.579	26%
	PACLITAXEL	00074433501												
	PACLITAXEL	00074433502												
	PACLITAXEL	00074433504												
	SYNTHROID	00048104003	0.348	0.343	0.272	26%	0.372	0.363	0.283	28%	0.372	0.372	0.302	23%
	SYNTHROID	00048104005	0.292	0.287	0.231	24%	0.315	0.307	0.240	28%	0.340	0.338	0.249	35%
	SYNTHROID	00048105003	0.384	0.379	0.301	26%	0.410	0.401	0.312	28%	0.410	0.410	0.334	23%
	SYNTHROID	00048107003	0.394	0.386	0.311	25%	0.420	0.411	0.322	28%	0.420	0.420	0.345	22%
	SYNTHROID	00048107005	0.336	0.331	0.267	24%	0.353	0.353	0.278	27%	0.392	0.389	0.293	33%
	SYNTHROID	00048109003	0.475	0.468	0.372	26%	0.507	0.495	0.386	28%	0.507	0.507	0.415	22%
	SYNTHROID	00048113003	0.461	0.454	0.360	26%	0.492	0.481	0.374	29%	0.492	0.492	0.398	24%
	TRICOR	00074401390	2.487	2.532	1.975	28%	2.739	2.626	2.090	26%	3.195	3.089	2.437	26%
	TRICOR	00074612390												
	TRICOR	00074641590	2.487	2.487	1.985	25%	2.584	2.584	2.064	25%	2.584	2.584		

Exhibit "3"

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ABBOTT	VANCOMYCIN HCL	00074653301	17.725	33.001	5.157	540%	6.063	10.089	4.681	116%	6.063	6.063	4.302	41%
	ZEMPLAR	00074165601	28.838	28.637	21.581	33%	28.838	28.838	21.601	33%	29.200	29.020	21.912	32%
	ZEMPLAR	00074463701	11.125	11.125	7.913	41%	11.125	11.125	8.636	29%	11.690	11.410	8.998	27%
ALPHARMA	CIMETIDINE HCL	00472051408	0.376	0.376	0.051	643%	0.376	0.378	0.052	623%	0.376	0.376	0.051	634%
	CIMETIDINE HCL	00472051416	0.348	0.348	0.065	435%	0.348	0.348	0.054	546%	0.348	0.348	0.052	571%
	CLOBETASOL PROPIONATE	00472040030	1.070	0.948	0.133	615%	1.070	1.070	0.151	608%	1.070	1.070	0.241	345%
	CONSTULOSE	00472136032	0.064	0.064	0.008	737%	0.068	0.067	0.013	405%	0.068	0.068	0.015	360%
	ENULOSE	00472136016	0.072	0.072	0.007	924%	0.075	0.075	0.011	565%	0.075	0.075	0.011	601%
	GUIATUSS DM	00472103116	0.017	0.016	0.007	145%	0.017	0.017	0.006	155%	0.017	0.017	0.006	189%
	PROMETHAZINE VC W/CODEINE	00472162916	0.048	0.044	0.012	280%	0.100	0.091	0.036	155%	0.105	0.101	0.049	107%
	PROMETHAZINE W/CODEINE	00472162704	0.064	0.061	0.018	243%	0.075	0.073	0.027	176%	0.075	0.075	0.028	166%
	PROMETHAZINE W/CODEINE	00472162716	0.048	0.045	0.011	305%	0.068	0.064	0.022	196%	0.068	0.068	0.023	192%
ASTRAZENECA	ACCOLATE	00310040260	1.126	1.104	0.915	21%	1.260	1.243	0.987	26%	1.335	1.302	1.030	26%
	ARIMIDEX	00310020130	6.794	8.851	5.622	20%	7.574	7.335	5.838	26%	7.813	7.670	6.094	26%
	ATACAND	00186001631	1.342	1.319	1.097	20%	1.447	1.408	1.138	24%	1.543	1.502	1.190	26%
	ATACAND	00186001654	1.342	1.319	1.103	20%	1.447	1.408	1.143	23%	1.544	1.503	1.194	26%
	ATACAND	00186003231	1.815	1.784	1.486	20%	1.957	1.905	1.540	24%	2.088	2.033	1.612	26%
	ATACAND	00186003254	1.815	1.785	1.484	19%	1.957	1.905	1.547	23%	2.088	2.033	1.618	26%
	ATACAND HCT	00186016254	1.815	1.785	1.496	19%	1.957	1.905	1.547	23%	2.088	2.033	1.618	26%
	ATACAND HCT	00186032254	1.852	1.820	1.528	19%	1.996	1.943	1.576	23%	2.130	2.073	1.650	26%
	CASODEX	00310070510	12.408	12.359	10.310	20%	14.034	13.588	10.819	26%	14.476	14.212	11.248	26%
	CASODEX	00310070530	12.408	12.359	10.255	21%	14.034	13.588	10.799	26%	14.476	14.212	11.260	26%
	CRESTOR	00310076190									2.625	2.626	2.069	27%
	EMLA	00186151601	1.562	1.560	1.199	30%	1.773	1.717	1.329	29%	1.749	1.754	1.368	28%
	IRESSA	00310048230									65.000	65.000	51.766	26%
	LEXXEL	00186000168	1.371	1.365	1.140	20%	1.556	1.507	1.205	25%	1.605	1.576	1.257	25%
	NEBBEM	00310032130	51.840	51.840	42.921	21%	51.840	51.840	42.764	21%	57.240	55.264	42.227	31%
	NEXIUM	00186504031	3.997	3.997	3.319	20%	4.421	4.354	3.479	25%	4.685	4.568	3.627	26%
	NEXIUM	00186504054	3.997	3.997	3.315	21%	4.421	4.354	3.482	25%	4.685	4.568	3.629	26%
	NEXIUM	00186504082	3.997	3.997	3.324	20%	4.421	4.354	3.488	25%	4.685	4.568	3.639	26%
	PLENDIL	00186045031	1.073	1.069	0.886	21%	1.218	1.180	0.943	25%	1.218	1.218	0.982	24%
	PLENDIL	00186045058	1.073	1.069	0.892	20%	1.219	1.180	0.942	25%	1.291	1.259	1.000	26%
	PLENDIL	00186045131	1.073	1.069	0.888	20%	1.218	1.180	0.935	26%	1.218	1.218	0.971	25%
	PLENDIL	00186045158	1.073	1.069	0.891	20%	1.219	1.180	0.942	26%	1.291	1.259	1.000	26%
	PLENDIL	00186045231	1.928	1.926	1.600	20%	2.189	2.119	1.701	25%	2.188	2.188	1.738	25%
	PLENDIL	00186045258	1.929	1.921	1.599	20%	2.189	2.120	1.695	25%	2.321	2.262	1.796	26%
	PLENDIL	61113045058	1.073	1.069			1.219	1.180			1.291	1.259		
	PLENDIL	61113045158	1.073	1.069			1.219	1.180			1.291	1.259		
	PLENDIL	61113045258	1.929	1.921			2.189	2.120			2.321	2.262		
	PRILOSEC	00186074231	4.301	4.228	3.512	20%	4.615	4.612	3.678	25%	4.615	4.615	3.668	26%
	PRILOSEC	00186074282	4.301	4.228	3.492	21%	4.614	4.612	3.672	26%	4.614	4.614	3.668	26%
	PRILOSEC	00186074331	6.172	6.067	5.044	20%	6.622	6.618	5.278	25%	6.622	6.622	5.269	26%
	PRILOSEC	61113074231	4.301	4.228			4.615	4.612			4.615	4.615		
	PRILOSEC	61113074282	4.301	4.228			4.614	4.612			4.614	4.614		

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ASTRAZENECA	PULMICORT	00186091542	129.480	125.912	105.328	20%	146.390	137.601	111.113	24%	151.000	148.247	117.567	26%
	PULMICORT	00186198804	2.100	2.100	1.754	20%	2.375	2.234	1.809	24%	2.375	2.375	1.890	26%
	PULMICORT	00186198904	2.100	2.100	1.752	20%	2.375	2.234	1.813	23%	2.375	2.375	1.888	26%
	RHINOCORT	00186107509	5.897	5.782	4.790	21%	6.593	6.534	5.185	26%	6.593	6.593	5.211	27%
	RHINOCORT AQUA	00186107008	6.857	6.857	5.573	23%	7.824	7.479	5.954	26%	8.292	8.084	6.416	26%
	SEROQUEL	00310027110	2.680	2.535	2.160	21%	2.806	2.823	2.277	24%	3.101	3.016	2.387	26%
	SEROQUEL	00310027210	5.056	4.970	4.120	21%	5.483	5.325	4.305	24%	5.850	5.894	4.511	26%
	SEROQUEL	00310027239	5.056	4.970	4.063	23%	5.483	5.325	4.261	25%	5.850	5.894	4.442	25%
	SEROQUEL	00310027460	7.219	7.096	5.952	19%	7.219	7.219	6.004	20%	7.219	7.219	5.981	21%
	SEROQUEL	00310027510	1.473	1.448	1.196	21%	1.597	1.551	1.251	24%	1.704	1.658	1.308	27%
	SULAR	00310089110	1.002	1.002	0.834	20%	1.157	1.145	0.933	23%	1.328	1.266	1.002	26%
	SULAR	00310089210	1.002	1.002	0.834	20%	1.157	1.145	0.935	22%	1.320	1.266	1.006	25%
	SULAR	00310089410	1.002	1.002	0.835	20%	1.157	1.145	0.936	22%	1.441	1.323	1.031	28%
	TOPROL XL	00186108805	0.652	0.636	0.535	19%	0.736	0.704	0.573	23%	0.783	0.768	0.610	26%
	TOPROL XL	00186109005	0.652	0.639	0.526	20%	0.736	0.704	0.568	24%	0.783	0.768	0.610	26%
	TOPROL XL	00186109205	0.980	0.951	0.790	20%	1.106	1.057	0.855	24%	1.176	1.154	0.916	26%
	TOPROL XL	00186109405	1.959	1.902	1.572	21%	1.959	1.959	1.630	20%	1.959	1.959	1.620	21%
	ZESTORETIC	00310014210	1.222	1.196	0.983	22%	1.387	1.343	1.081	27%	1.431	1.406	1.114	26%
	ZESTRIL	00310013010	0.980	0.959	0.790	21%	1.112	1.077	0.851	27%	1.147	1.126	0.890	27%
	ZESTRIL	00310013034	0.959	0.949	0.775	22%	1.140	1.085	0.837	27%	1.135	1.114	0.813	37%
	ZESTRIL	00310013110	1.011	0.990	0.817	21%	1.148	1.112	0.881	26%	1.186	1.163	0.914	27%
	ZESTRIL	00310013134	1.002	0.981	0.810	21%	1.095	1.094	0.867	26%	1.095	1.095	0.872	26%
	ZESTRIL	00310013210	1.083	1.060	0.875	21%	1.229	1.190	0.943	26%	1.268	1.245	0.974	28%
	ZESTRIL	00310013234	1.072	1.050	0.867	21%	1.172	1.171	0.922	27%	1.172	1.172		
	ZESTRIL	00310013410	1.584	1.550	1.275	22%	1.798	1.741	1.375	27%	1.855	1.821	1.434	27%
	ZOLADEX	00310095036									469.990	469.990	369.426	27%
	ZOLADEX	00310095130									1409.980	1409.980	868.671	46%
	ZOLADEX	00310096036	469.990	469.990	381.848	23%	469.990	469.990	382.461	23%	469.990	469.990	374.144	25%
	ZOLADEX	00310096130	1409.980	1409.980	1147.824	23%	1409.980	1409.980	1137.214	24%	1409.980	1409.980	1138.056	24%
	ZOMIG	00310021125	16.716	16.432	13.660	20%	18.127	17.605	14.184	24%	19.337	18.822	14.842	27%
AVENTIS	ALLEGRA	00088110947	2.162	2.165	1.804	20%	2.352	2.332	1.868	25%	2.446	2.444	1.937	26%
	ALLEGRA-D	00088109047	1.226	1.211	1.006	20%	1.379	1.366	1.095	25%	1.434	1.433	1.137	26%
	AMARYL	00039022210	0.446	0.432	0.356	21%	0.502	0.485	0.392	24%	0.592	0.560	0.443	25%
	AMARYL	00039022310	0.841	0.816	0.675	21%	0.946	0.914	0.740	24%	1.116	1.056	0.838	26%
	ANZEMET	00088120305	76.241	74.528	49.568	50%	76.241	76.241	47.544	60%	76.241	76.241	54.455	40%
	ANZEMET	00088120632	34.632	34.347	22.202	55%	34.632	34.632	14.889	132%	34.632	34.832	19.424	78%
	ARAVA	00088216130	8.650	8.545	7.112	20%	10.123	9.372	7.669	22%	11.806	10.832	8.585	26%
	AZMACORT	00075006037	3.105	3.082	2.473	26%	3.429	3.422	2.710	26%	3.760	3.667	2.890	27%
	CARAFATE	00088170015	0.095	0.094	0.078	20%	0.095	0.095	0.079	21%	0.102	0.102	0.081	26%
	CARDIZEM CD	00088179642	1.331	1.327	1.103	20%	1.442	1.393	1.126	24%	1.442	1.442	1.143	26%
	CARDIZEM CD	00088179642	1.606	1.601	1.331	20%	1.740	1.681	1.360	24%	1.740	1.740	1.382	26%
	CARDIZEM CD	00088176742	2.279	2.272	1.888	20%	2.469	2.385	1.928	24%	2.469	2.469	1.958	26%
	CARDIZEM CD	00088179842	2.954	2.944	2.447	20%	3.200	3.090	2.495	24%	3.200	3.200	2.544	26%
	COPAXONE	00088115003	33.231	32.038	26.589	20%	33.231	33.231	27.589	20%	33.231	33.231		
	COPAXONE	00088115330					1107.690	1107.690	864.090	25%	1211.810	1179.861	935.642	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
AVENTIS	ADAVP	00075002600	2.819	2.819	2.250	25%	3.257	3.091	2.461	25%	3.657	3.551	2.819	26%
	ADAVP	00075295201	32.213	31.823	25.388	25%	32.213	32.213	25.698	25%	33.180	33.161	26.342	26%
	HIPREX	00058027761	1.390	1.373	1.143	20%	1.390	1.390	1.156	20%	1.491	1.489	1.185	26%
	INTAL	00085067501	5.764	5.706	4.733	21%	6.545	5.835	4.774	22%	6.545	6.545	5.178	26%
	LANTUS	00088222033	4.351	4.351	3.474	25%	4.699	4.691	3.742	25%	5.583	5.283	4.200	26%
	LOVENOX	00075062040	61.156	61.156	45.780	34%	64.225	61.921	46.438	36%	68.075	66.746	49.788	34%
	LOVENOX	00075062160	61.229	61.229	46.645	31%	64.300	61.995	46.517	33%	68.150	65.821	50.917	31%
	LOVENOX	00075062280	61.230	61.230	47.226	30%	64.300	61.995	47.038	32%	68.183	66.829	51.359	30%
	LOVENOX	00075062300	61.230	61.230	47.635	29%	64.290	61.993	47.288	31%	68.150	65.818	51.833	29%
	LOVENOX	00075062430	61.156	61.156	45.037	36%	64.200	61.917	45.072	37%	68.100	66.754	49.792	34%
	LOVENOX	00075291501	91.875	91.875	72.194	27%	95.480	93.023	71.148	31%	102.260	100.265	79.042	27%
	NASACORT	00075150543	4.848	4.777	3.824	25%	5.568	5.405	4.295	26%	5.986	5.877	4.730	26%
	NASACORT AQ	00075150616	3.100	2.957	2.410	23%	3.733	3.608	2.871	26%	4.261	4.070	3.232	26%
	PENLAC	00066800802	18.220	18.220	14.631	25%	18.220	18.220	14.498	26%	20.651	19.489	15.489	26%
	RILUTEK	00075770060	14.995	14.992	11.927	25%	14.995	14.995	11.995	25%	15.445	15.437	12.302	25%
	TAXOTERE	00075608120	658.350	637.049	508.673	25%	691.280	676.664	539.340	25%	753.500	752.307	587.563	28%
	TAXOTERE	00075800100	658.350	637.049	508.479	25%	691.270	676.659	537.501	26%	753.480	752.287	586.732	28%
BARR	BENZONATATE	50111085101	0.772	0.772			1.013	0.956			1.013	1.013		
	BETHANECHOL CHLORIDE	50111032501	0.620	0.620			0.620	0.620			1.784	0.913		
	CIMETIDINE	50111055103	1.400	1.400			1.400	1.400			1.400	1.400		
	CIPROFLOXACIN HCL	00555081402									4.956	4.956	3.634	36%
	CIPROFLOXACIN HCL	00555081502									5.801	5.801	4.258	36%
	DANAZOL	00555063602	3.331	3.327	2.112	58%	3.741	3.674	2.474	48%	3.865	3.856	2.734	45%
	DIAZEPAM	00555016405	0.303	0.288	0.027	982%	0.303	0.303	0.039	676%	0.303	0.303	0.039	681%
	FLUOXETINE HCL	00555087702	2.668	2.668	1.832	45%	2.668	2.668	1.194	123%	2.868	2.868	0.110	2327%
	HYDROXYZINE HCL	50111030701	0.127	0.084			0.824	0.410			0.824	0.824		
	HYDROXYZINE HCL	50111030703	0.098	0.070			0.581	0.369			0.561	0.561		
	HYDROXYZINE HCL	50111030801	0.176	0.127			0.915	0.597			0.915	0.915		
	HYDROXYZINE HCL	50111030802	0.154	0.104			0.851	0.551			0.851	0.851		
	HYDROXYZINE HCL	50111030803	0.136	0.101			0.823	0.528			0.823	0.823		
	MEDROXYPROGESTERONE ACETA	00555087202	0.298	0.296	0.053	464%	0.298	0.298	0.063	376%	0.313	0.313	0.140	124%
	MEGESTROL ACETATE	00555060702	1.102	1.102	0.272	306%	1.102	1.102	0.279	295%	1.102	1.102	0.416	165%
	MEPERIDINE HCL	00555038102	0.681	0.681	0.265	157%	0.681	0.681	0.331	106%	0.681	0.681	0.381	79%
	MEPERIDINE HCL	00555038202	1.296	1.296	0.509	155%	1.296	1.296	0.640	102%	1.296	1.296	0.736	76%
	METFORMIN HCL	00555038502					0.704	0.704			0.704	0.704		
	METFORMIN HCL	00555038602					1.197	1.197			1.197	1.197		
	METFORMIN HCL	00555038702					1.451	1.451			1.451	1.451		
	METHOTREXATE	00555057202	4.050	3.921	0.278	1308%	3.564	3.917	0.288	1351%	3.564	3.564	0.263	1257%
	METOCLOPRAMIDE HCL	50111043001	0.275	0.275			0.275	0.275			0.275	0.275		
	MIRTAZAPINE	00555024171									2.961	2.961	1.697	39%
	NALTREXONE HYDROCHLORIDE	00555090201	4.275	4.275	2.128	101%	4.275	4.275	1.905	124%	4.275	4.275	1.884	127%
	NALTREXONE HYDROCHLORIDE	00555090202	4.275	4.275	2.091	104%	4.275	4.275	1.820	135%	4.275	4.275	1.849	131%
	OXYBUTYNIN CHLORIDE	50111045601	0.386	0.356			0.544	0.533			0.544	0.544		
	TAMOXIFEN CITRATE	00555044603	1.764	1.764			1.764	1.764			1.764	1.764		
	TAMOXIFEN CITRATE	00555044609	1.899	1.892	1.474	28%	2.037	1.998	1.568	27%	1.894	1.912	1.272	50%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
BARR	TAMOXIFEN CITRATE	00555044663	1.899	1.882	1.486	27%	2.027	1.899	1.573	27%	1.894	1.912	0.694	175%
	TAMOXIFEN CITRATE	00555090401	3.798	3.783	2.965	28%	4.053	3.998	3.137	27%	3.788	3.824	0.998	283%
	TAMOXIFEN CITRATE	00555090414	3.798	3.783	2.890	27%	4.053	3.998	3.151	27%	3.788	3.824	0.868	341%
	TRAZODONE HCL	50111043301	0.565	0.565			0.565	0.565			0.565	0.565		
	TRAZODONE HCL	50111043302	0.441	0.441			0.441	0.441			0.441	0.441		
	TRAZODONE HCL	50111043303	0.414	0.414			0.414	0.414			0.414	0.414		
	TRAZODONE HCL	50111043401	0.733	0.733			0.733	0.733			0.733	0.733		
	TRAZODONE HCL	50111044101	1.469	1.469			1.469	1.469			1.469	1.469		
	WARFARIN SODIUM	00555083102	0.583	0.583	0.256	128%	0.583	0.583	0.215	172%	0.583	0.583	0.199	194%
	WARFARIN SODIUM	00555083202	0.628	0.628	0.260	141%	0.628	0.628	0.215	193%	0.628	0.628	0.190	230%
	WARFARIN SODIUM	00555083302	0.637	0.637	0.275	132%	0.637	0.637	0.214	198%	0.637	0.637	0.195	226%
	WARFARIN SODIUM	00555088902	0.609	0.609	0.257	137%	0.609	0.609	0.218	179%	0.609	0.609	0.201	203%
	WARFARIN SODIUM	00555087402	0.633	0.633	0.277	128%	0.633	0.633	0.227	178%	0.633	0.633	0.201	215%
	WARFARIN SODIUM	00555092502	0.631	0.631	0.345	83%	0.631	0.631	0.237	166%	0.631	0.631	0.200	215%
BAXTER	ADVATE	00944294001									1.880	1.880		
	ADVATE	00944294002									1.880	1.880		
	ADVATE	00944294003									1.880	1.880		
	GAMMAGARD S/D	00944262003	598.250	523.799	348.258	50%	596.250	596.250	248.027	140%	596.250	598.250	192.461	210%
	HEMOFIL-M	00944293501	1.225	1.101			1.225	1.225			1.225	1.225		
	RECOMBINATE	00944293801	1.625	1.470			1.625	1.625			1.625	1.625		
	RECOMBINATE	00944293802	1.625	1.470			1.625	1.625			1.625	1.625		
	RECOMBINATE	00944293803	1.625	1.470			1.625	1.625			1.625	1.625	1.120	45%
BAYER	ADALAT CC	00026884151	1.352	1.306	1.027	27%	1.434	1.394	1.100	27%	1.491	1.477	1.168	26%
	ADALAT CC	00026884154	1.351	1.306	1.016	29%	1.434	1.394	1.057	31%	1.491	1.477	1.151	28%
	ADALAT CC	00026885151	2.407	2.327	1.797	29%	2.554	2.483	1.955	27%	2.656	2.631	2.077	27%
	ADALAT CC	00026885154	2.407	2.327	1.789	30%	2.554	2.483	1.950	27%	2.656	2.631	2.057	28%
	ADALAT CC	00026885151	2.741	2.662	2.048	30%	2.993	2.845	2.232	27%	3.113	3.083	2.428	27%
	AVELOX	00026858169	9.061	8.917	7.103	26%	9.423	9.393	7.470	26%	9.800	9.768	7.707	27%
	CIPRO	00026851251	3.991	3.958	3.280	21%	4.671	4.460	3.538	26%	4.956	4.909	3.857	27%
	CIPRO	00026851351	4.672	4.633	3.842	21%	5.468	5.209	4.142	26%	5.801	5.747	4.518	27%
	CIPRO	00026851450	4.672	4.633	3.850	20%	5.672	5.240	4.174	26%	6.054	6.007	4.738	27%
	GANITHONE N	00026064812	9.000	9.000	7.472	20%	10.125	9.416	7.070	33%	10.125	10.125	6.212	63%
	GANITHONE N	00026064824	9.000	9.000	7.484	20%	10.125	9.416	6.491	45%	10.125	10.125	5.645	79%
	GANITHONE N	00026064871	9.000	9.000	7.414	21%	10.125	9.416	6.197	52%	10.125	10.125	6.055	67%
	KOGENATE	00026067030	1.180	1.180			1.180	1.180			1.180	1.180		
	NIMOTOP	00026286548	7.000	6.925	5.747	21%	7.547	7.367	5.940	24%	7.999	7.982	6.383	25%
	NIMOTOP	00026285570	7.328	7.248	6.034	20%	7.898	7.710	6.237	24%	8.372	8.354	6.647	25%
	PRECOSE	00026286151	0.576	0.567	0.471	20%	0.659	0.649	0.510	25%	0.725	0.723	0.574	26%
	PRECOSE	00026286251	0.742	0.732	0.393	86%	0.820	0.810	0.651	24%	0.869	0.867	0.691	25%
	PRECOSE	00026286351	0.576	0.567	0.473	20%	0.636	0.628	0.504	25%	0.674	0.672	0.534	26%
BEN VENUE	CARBOPLATIN	55390015301												
	CARBOPLATIN	55390015401												
	CARBOPLATIN	55390015501												

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
BEN VENUE	CARBOPLATIN	55390022001												
	CARBOPLATIN	55390022101												
	CARBOPLATIN	55390022201												
	FLUPHENAZINE DECANOATE	55390046505	5.000	5.000	1.756	185%	5.000	5.000	1.394	259%	5.000	5.000	1.293	287%
	PACLITAXEL	55390011405												
	PACLITAXEL	55390011420												
	PACLITAXEL	55390011450												
	PACLITAXEL	55390031405												
	PACLITAXEL	55390031420												
	PACLITAXEL	55390031450												
	PAMIDRONATE DISODIUM	55390012701	291.525	291.525			291.525	291.525	119.281	144%	291.525	291.525	104.295	180%
	PAMIDRONATE DISODIUM	55390012801	874.588	874.588	698.620	25%	874.588	874.586	402.987	117%	874.588	874.588	327.025	167%
	PAMIDRONATE DISODIUM	55390015701												
	PAMIDRONATE DISODIUM	55390015901												
	PAMIDRONATE DISODIUM	55390020401												
	PAMIDRONATE DISODIUM	55390050401												
BUS	AVALIDE	00087277531	1.731	1.665	1.382	21%	1.904	1.841	1.484	24%	2.000	1.976	1.569	26%
	AVALIDE	00087277532	1.731	1.665	1.385	20%	1.904	1.841	1.491	23%	1.899	1.976	1.573	28%
	AVALIDE	00087277631	1.801	1.731	1.438	20%	2.036	1.950	1.576	24%	2.138	2.113	1.680	26%
	AVALIDE	00087277632	1.800	1.731	1.443	20%	2.036	1.949	1.582	23%	2.138	2.113	1.682	26%
	AVAPRO	00087277231	1.440	1.385	1.148	21%	1.584	1.531	1.238	24%	1.663	1.643	1.305	26%
	AVAPRO	00087277232	1.440	1.385	1.147	21%	1.584	1.531	1.238	24%	1.663	1.644	1.302	26%
	AVAPRO	00087277331	1.731	1.665	1.384	20%	1.904	1.841	1.480	24%	2.000	1.976	1.573	26%
	AVAPRO	00087277332	1.731	1.665	1.381	21%	1.904	1.841	1.487	24%	1.899	1.976	1.566	26%
	BUSPAR	00087081841	0.907	0.879	0.716	23%	0.907	0.907	0.750	21%	0.907	0.907	0.744	22%
	BUSPAR	00087081844	0.882	0.854	0.698	22%	0.882	0.882	0.732	20%	0.882	0.882	0.728	21%
	BUSPAR	00087081941	1.582	1.532	1.249	23%	1.582	1.582	1.305	21%	1.582	1.582	1.295	22%
	BUSPAR	00087081944	1.536	1.489	1.217	22%	1.536	1.536	1.274	21%	1.536	1.536	1.257	21%
	BUSPAR	00087082232	2.363	2.289	1.877	22%	2.363	2.363	1.982	20%	2.363	2.363	1.954	21%
	BUSPAR	00087082233	2.329	2.256	1.846	22%	2.329	2.329	1.933	21%	2.329	2.329	1.918	21%
	CARBOPLATIN	00015323011												
	CARBOPLATIN	00015323111												
	CARBOPLATIN	00015323211												
	CARBOPLATIN	00015323311												
	CEFZIL	00087772060	3.756	3.640	3.011	21%	4.209	4.097	3.250	25%	4.481	4.399	3.471	27%
	CEFZIL	00087772160	7.551	7.414	6.112	21%	8.572	8.345	6.621	26%	9.087	8.960	7.061	27%
	COUMADIN	00056016970	0.654	0.646	0.537	20%	0.716	0.693	0.558	24%	0.751	0.751	0.595	26%
	COUMADIN	00056017070	0.682	0.674	0.560	20%	0.746	0.723	0.582	24%	0.784	0.784	0.621	26%
	COUMADIN	00056017270	0.714	0.705	0.586	20%	0.803	0.770	0.620	24%	0.843	0.843	0.669	26%
	COUMADIN	00056017670	0.704	0.696	0.577	20%	0.770	0.746	0.601	24%	0.809	0.809	0.641	26%
	COUMADIN	00056018870	0.707	0.698	0.579	21%	0.773	0.749	0.603	24%	0.812	0.812	0.643	26%
	DOVONEX	00072254005	1.783	1.715	1.403	22%	1.988	1.988	1.581	26%	2.127	2.127	1.685	26%
	DOVONEX	00072254010	1.621	1.620	1.299	25%	1.621	1.621	1.304	24%	1.621	1.621		
	DOVONEX	00072254012	1.621	1.621	1.349	20%	1.807	1.807	1.440	25%	1.933	1.933	1.533	26%
	FLORINEF ACETATE	00003042950	0.833	0.787	0.706	9%	0.883	0.848	0.686	24%	0.883	0.880	0.701	25%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
BMS	GLUCOPHAGE	00087606005	0.812	0.781	0.637	23%	0.812	0.812	0.647	25%	0.812	0.812	0.643	26%
	GLUCOPHAGE	00087606010	0.812	0.781	0.635	23%	0.812	0.812	0.646	26%	0.812	0.812	0.645	26%
	GLUCOPHAGE	00087607005	1.380	1.328	1.083	23%	1.380	1.380	1.102	25%	1.380	1.380	1.098	26%
	GLUCOPHAGE	00087607010	1.174	1.174	0.862	22%	1.174	1.174			1.174	1.174		
	GLUCOPHAGE	00087607111	1.672	1.609	1.314	22%	1.672	1.672	1.335	25%	1.672	1.672	1.331	25%
	GLUCOPHAGE	00087607112	1.423	1.423			1.423	1.423	.		1.423	1.423		
	GLUCOPHAGE XR	00087606310	0.601	0.670	0.569	20%	0.767	0.720	0.586	23%	0.829	0.814	0.644	26%
	GLUCOVANCE	00087607211	0.725	0.692	0.579	20%	0.821	0.794	0.596	25%	0.895	0.859	0.681	26%
	GLUCOVANCE	00087607311	0.865	0.825	0.696	20%	0.980	0.947	0.759	25%	1.068	1.024	0.812	25%
	GLUCOVANCE	00087607411	0.865	0.825	0.691	19%	0.980	0.947	0.760	25%	1.068	1.024	0.814	26%
	MEGACE	00015050842	0.666	0.659	0.544	21%	0.666	0.666	0.554	20%	0.666	0.666	0.538	24%
	MONOPRIL	00087015846	1.030	0.998	0.826	21%	1.235	1.174	0.933	25%	1.322	1.301	1.029	26%
	MONOPRIL	00087050942	1.030	0.998	0.826	21%	1.235	1.174	0.934	25%	1.322	1.301	1.030	26%
	MONOPRIL	00087120213	1.030	0.998	0.827	21%	1.235	1.174	0.934	25%	1.322	1.301	1.031	25%
	PARAPLATIN	00015321030									34.192	34.192	25.564	28%
	PARAPLATIN	00015321078												
	PARAPLATIN	00015321130												
	PARAPLATIN	00015321176												
	PARAPLATIN	00015321230												
	PARAPLATIN	00015321276												
	PARAPLATIN	00015321030	115.675	114.260	84.089	21%	143.130	137.673	110.008	25%	170.650	164.681	128.295	28%
	PARAPLATIN	00015321429	346.990	342.568			346.990	346.990			346.990	346.990		
	PARAPLATIN	00015321430	346.990	342.568	262.740	21%	429.330	412.869	328.444	25%	511.980	494.010	383.259	28%
	PARAPLATIN	00015321530	1040.993	1027.727	838.369	23%	1288.010	1238.931	979.595	26%	1535.900	1482.049	1154.050	28%
	PARAPLATIN	00015321630												
	PRAVACHOL	00003515405	2.607	2.603	2.076	25%	2.781	2.774	2.210	25%	3.031	3.031	2.405	26%
	PRAVACHOL	00003517805	2.552	2.550	2.035	25%	2.892	2.828	2.246	26%	3.080	3.080	2.443	26%
	PRAVACHOL	00003517875	2.552	2.551	2.045	25%	2.893	2.829	2.259	25%	3.081	3.081	2.471	25%
	PRAVACHOL	00003519410	4.140	4.137	3.302	25%	4.347	4.339	3.457	26%	4.620	4.620	3.566	26%
	PRAVACHOL	00003519510					4.347	4.347	3.468	25%	4.620	4.620	3.593	26%
	REYATAZ	00003362412									13.800	13.800	10.929	26%
	REYATAZ	00003363112									13.800	13.800	10.940	26%
	SERZONE	00087003231	1.384	1.340	1.108	21%	1.622	1.622	1.213	25%	1.710	1.670	1.317	27%
	SERZONE	00087003331	1.410	1.365	1.130	21%	1.680	1.680	1.257	26%	1.775	1.733	1.360	27%
	SERZONE	00087003931	1.397	1.353	1.118	21%	1.651	1.651	1.235	26%	1.742	1.701	1.341	27%
	SINEMET CR	00056052160	2.012	1.971	1.561	26%	2.012	2.012	1.593	26%	2.012	2.012	1.582	28%
	SINEMET CR	00056050160	1.046	1.025	0.813	26%	1.046	1.046	0.832	26%	1.046	1.046	0.826	27%
	STADOL NS	00087565041	35.225	34.120	28.147	21%	39.105	39.105	31.200	25%	41.060	41.060	32.661	26%
	SUSTIVA	00058047492	4.380	4.360	3.634	21%	4.795	4.798	3.975	21%	5.146	5.017	4.028	25%
	SUSTIVA	00056031030					14.988	14.988	11.906	26%	15.438	15.273	12.120	26%
	TAXOL	00015347527												
	TAXOL	00015347530	35.070	35.070	29.331	20%	35.070	35.070	22.092	59%	35.070	35.070	13.687	156%
	TAXOL	00015347630	35.001	35.001	29.036	21%	35.001	35.001	16.156	93%	35.001	35.001	10.315	239%
	TAXOL	00015347911	35.070	35.070	29.011	21%	35.070	35.070	16.473	113%	35.070	35.070	11.236	212%
	TEQUIN	00015117760	8.188	7.863	6.524	21%	8.955	8.786	7.003	25%	9.403	9.362	7.423	26%
	TRIMOX	00003010160	0.237	0.237	0.028	747%	0.237	0.237	0.040	496%	0.237	0.237	0.041	484%
	TRIMOX	00003010960	0.381	0.381	0.047	702%	0.381	0.381	0.061	526%	0.381	0.381	0.061	528%
	ULTRAVATE	00072140050	1.377	1.376	1.114	24%	1.535	1.535	1.216	26%	1.612	1.612	1.281	26%
	ULTRAVATE	00072145050	1.377	1.376	1.136	21%	1.535	1.635	1.215	26%	1.612	1.612	1.279	26%
	VIDEX	00087665201	2.186	2.035	1.664	22%	2.302	2.273	1.801	26%	2.371	2.345	1.858	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
BMS	VIDEX EC	00087657417	9.552	9.552	7.913	21%	10.435	10.215	8.194	25%	10.696	10.601	8.396	26%
	ZERIT	00003196501	5.083	4.874	3.877	26%	5.352	5.288	4.268	26%	5.513	5.454	4.317	26%
	ZERIT	00003196601	5.399	5.177	4.121	26%	5.685	5.615	4.468	26%	5.855	5.793	4.594	26%
	ZERIT	00003196701	5.490	5.273	4.194	26%	5.780	5.718	4.537	26%	5.884	5.900	4.671	26%
BMS-SANOFI	PLAVIX	63653117101	3.553	3.442	2.857	20%	3.944	3.944	3.146	25%	4.217	4.217	3.348	26%
	PLAVIX	63653117103	3.553	3.442	2.834	21%	3.944	3.944	3.125	26%	4.217	4.217	3.287	28%
	PLAVIX	63653117104	2.892	2.892			2.892	2.892			2.892	2.892		
	PLAVIX	63653117105	3.553	3.442	2.855	21%	3.944	3.944	3.138	26%	4.217	4.217	3.342	26%
	PLAVIX	63653117106	3.553	3.442	2.839	21%	3.944	3.944	3.126	26%	4.216	4.216	3.331	27%
BOEHRINGER	AGGRENOX	00597000160	1.595	1.568	1.301	20%	1.823	1.787	1.426	24%	2.087	2.054	1.618	27%
	ATROVENT	00597008214	3.060	2.997	2.358	27%	3.654	3.370	2.585	30%	3.891	3.807	2.987	27%
	CATAPRES-TTS 1	00597003112	10.525	10.514	8.678	21%	12.163	11.647	9.369	24%	14.050	13.714	10.771	27%
	CATAPRES-TTS 2	00597003212	17.888	17.700	14.614	21%	20.476	19.809	15.777	24%	23.653	23.085	18.150	27%
	CATAPRES-TTS 3	00597003334	24.015	24.555	20.278	21%	28.410	27.203	21.892	24%	32.813	32.026	25.199	27%
	COMBIVENT	00597001014	3.052	2.990	2.474	21%	3.722	3.393	2.736	24%	4.076	3.987	3.145	27%
	FLOMAX	00597005601	1.772	1.712	1.388	23%	1.898	1.854	1.482	26%	2.079	2.042	1.614	27%
	MICARDIS	00597004028	1.421	1.382	1.122	23%	1.507	1.474	1.185	24%	1.845	1.578	1.250	26%
	MICARDIS	00597004128	1.490	1.454	1.180	23%	1.638	1.591	1.279	24%	1.764	1.719	1.353	26%
	MICARDIS HCT	00597004428	1.562	1.524	1.246	22%	1.717	1.675	1.354	24%	1.934	1.859	1.486	25%
	MOBIC	00597002901	2.145	2.079	1.695	23%	2.570	2.395	1.870	25%	2.874	2.724	2.161	25%
	SPIRIVA	00597007537												
	VIRAMUNE	00597004601	5.314	5.314	4.397	21%	6.010	5.836	4.694	24%	6.010	6.010	4.687	28%
	VIRAMUNE	00597004680	5.314	5.314	4.336	23%	6.010	5.836	4.726	24%	6.753	6.561	5.197	26%
DEY	ALBUTEROL	49502050317	1.276	1.276			1.276	1.276			1.276	1.276		
	ALBUTEROL	49502033317	1.276	1.276	0.443	188%	1.276	1.276	0.580	120%	1.276	1.276	0.271	371%
	ALBUTEROL SULFATE	49502089703	0.403	0.403	0.058	595%	0.403	0.403	0.049	728%	0.403	0.403	0.043	838%
	ALBUTEROL SULFATE	49502069724			0.062				0.049				0.044	
	ALBUTEROL SULFATE	49502069760	0.403	0.403	0.058	589%	0.403	0.403	0.050	710%	0.403	0.403	0.043	829%
	DUONEB	49502067230	0.667	0.667	0.527	26%	0.667	0.667	0.524	27%	0.693	0.688	0.489	35%
	DUONEB	49502067260	0.667	0.667	0.529	26%	0.667	0.667	0.529	26%	0.693	0.688	0.503	33%
	IPRATROPIUM BROMIDE	49502068503	0.706	0.706	0.162	334%	0.706	0.706	0.119	495%	0.706	0.706	0.099	611%
ELKINS-SINN	FENTANYL CITRATE	00641240341	0.500	0.500	0.129	288%	0.500	0.500	0.144	247%	0.494	0.406	0.151	168%
FOREST	AEROBID	00456067299	9.573	9.573	7.716	24%	10.147	10.045	8.172	23%	10.993	10.847	8.466	28%
	AEROBID-M	00456067099	9.573	9.573	7.825	22%	10.147	10.045	8.253	22%	10.993	10.847	8.524	27%
	BENZONATATE	00258367001	1.977	1.977			1.977	1.977			1.977	1.977		
	CELEXA	00456401001	2.158	2.097	1.743	20%	2.313	2.239	1.817	23%	2.502	2.410	1.886	28%
	CELEXA	00456402001	2.247	2.179	1.801	21%	2.411	2.334	1.903	23%	2.609	2.512	1.979	27%
	CELEXA	00456404001	2.345	2.273	1.878	21%	2.516	2.435	1.986	22%	2.721	2.621	2.060	27%
	ISOSORBIDE DINITRATE	00258361301	0.565	0.565			0.566	0.565			0.623	0.609		
	LEVOTHROID	00456032101	0.233	0.217	0.090	142%	0.242	0.238	0.115	110%	0.242	0.242	0.118	106%
	LEXAPRO	00456201001					2.224	2.224	1.762	26%	2.313	2.273	1.800	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
FOREST	LEXAPRO	00456202001					2.320	2.320	1.851	25%	2.413	2.372	1.895	25%
	LORCET 10/650	00785635001	1.343	1.330			1.343	1.343			1.455	1.435		
	NAMENDA	00456320550									2.325	2.325	1.846	26%
	NAMENDA	00456321060									2.325	2.325	1.792	30%
	TIAZAC	00456261290	1.055	1.055	0.771	38%	1.108	1.100	0.865	27%	1.152	1.144	0.881	28%
	TIAZAC	00456261390	1.285	1.285	0.949	35%	1.337	1.328	1.043	27%	1.390	1.381	1.074	29%
	TIAZAC	00456261490	1.824	1.824	1.342	36%	1.897	1.884	1.480	27%	1.973	1.960	1.525	29%
	TIAZAC	00456261590	2.363	2.363	1.691	40%	2.457	2.441	1.919	27%	2.556	2.539	1.976	29%
	TIAZAC	00456261690	2.409	2.409	1.747	38%	2.505	2.488	1.956	27%	2.605	2.588	2.015	28%
GSK	ADVAIR DISKUS	00173069500	1.784	1.742	1.451	20%	1.952	1.883	1.503	25%	2.049	2.020	1.602	26%
	ADVAIR DISKUS	00173069600	2.259	2.187	1.825	20%	2.471	2.383	1.902	25%	2.594	2.556	2.028	26%
	ADVAIR DISKUS	00173069700	3.105	2.983	2.403	20%	3.396	3.276	2.611	25%	3.566	3.514	2.787	26%
	AGENERASE	00173067200	1.388	1.387	1.152	20%	1.532	1.529	1.218	26%	1.632	1.632	1.215	26%
	AUGMENTIN	00029608012	4.043	3.982	3.166	26%	4.205	4.201	3.345	26%	4.373	4.270	3.350	27%
	AUGMENTIN	00029608612	5.398	5.316	4.227	26%	5.613	5.608	4.461	26%	5.838	5.700	4.489	27%
	AVANDAMET	00007316818					2.750	2.750	2.163	27%	2.860	2.785	2.227	25%
	AVANDIA	00029315810	1.998	1.920	1.535	25%	1.998	1.998	1.593	25%	2.118	2.006	1.590	26%
	AVANDIA	00029315813	2.668	2.621	2.099	25%	2.774	2.725	2.181	25%	3.024	2.866	2.278	26%
	AVANDIA	00029315818	2.668	2.621	2.095	25%	2.774	2.725	2.174	25%	3.024	2.866	2.270	26%
	AVANDIA	00029315920	2.668	2.621	2.093	25%	2.774	2.725	2.171	26%	3.024	2.866	2.268	26%
	AVANDIA	00029316013	4.937	4.805	3.836	25%	5.134	5.043	4.014	26%	5.601	5.204	4.204	26%
	AVANDIA	00029316020	4.936	4.804	3.847	25%	5.133	5.042	4.029	25%	5.600	5.303	4.205	26%
	BACTROBAN	00029152522	1.457	1.457			1.457	1.457			1.457	1.457		
	BACTROBAN	00029152525	1.315	1.315	1.052	25%	1.315	1.315			1.315	1.315		
	BACTROBAN	00029152544	1.883	1.808	1.437	26%	2.075	1.991	1.586	26%	2.159	2.109	1.666	27%
	BACTROBAN	00029152722	1.979	1.952	1.560	25%	2.099	2.014	1.600	26%	2.183	2.131	1.694	26%
	BACTROBAN	00029152725	1.670	1.655	1.322	25%	1.779	1.707	1.355	26%	1.850	1.806	1.432	26%
	BECLOVENT	00173031288	2.676	2.675	2.198	22%	2.675	2.675			2.675	2.675		
	BECONASE	00173033602	2.994	2.897	2.343	24%	3.399	3.390	2.652	28%	3.399	3.399	2.709	25%
	BECONASE AQ	00173039879	2.063	1.998	1.654	21%	2.582	2.400	1.903	26%	2.866	2.695	2.078	27%
	CEFTIN	00173038742	4.410	4.283	3.486	22%	4.984	4.788	3.747	28%	5.652	5.367	4.212	27%
	CEFTIN	00173039442	8.036	7.879	6.475	22%	9.085	8.726	6.842	28%	10.300	9.781	7.675	27%
	COMBIVIR	00173058500	10.344	10.341	8.578	21%	11.421	11.398	9.066	26%	11.421	11.421	9.053	26%
	COREG	00007410520	1.672	1.653	1.322	25%	1.722	1.721	1.372	25%	1.854	1.797	1.421	26%
	COREG	00007414020	1.672	1.653	1.322	25%	1.722	1.721	1.371	25%	1.854	1.797	1.423	26%
	COREG	00007414120	1.672	1.653	1.322	25%	1.722	1.721	1.371	25%	1.854	1.797	1.425	26%
	COREG	00007414220	1.672	1.653	1.321	25%	1.722	1.721	1.372	25%	1.854	1.797	1.426	26%
	EPIVIR	00173047001	4.770	4.769	3.857	21%	5.267	5.256	4.183	26%	5.267	5.267	4.174	26%
	EPIVIR	00173071400					10.535	10.535	8.396	25%	10.535	10.535	8.362	26%
	EPIVIR HBV	00173068200	4.770	4.769	3.987	20%	5.267	5.256	4.204	25%	5.358	5.865	4.651	26%
	EPZICOM	00173074200												
	ESKALITH CR	00007401020	0.475	0.466	0.372	25%	0.568	0.532	0.423	26%	0.597	0.579	0.458	27%
	FAMVIR	00007411713	7.377	7.377	5.911	25%	7.377	7.377	5.852	26%	7.377	7.377		
	FLOLAN	00173051900	38.016	37.442			41.580	39.520			43.850	42.305		
	FLONASE	00173045301	3.607	3.566	2.954	21%	4.063	3.919	3.114	26%	4.266	4.142	3.282	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
GSK	FLOVENT	00173049100	3.906	3.826	3.171	21%	4.272	4.115	3.311	24%	4.989	4.446	3.497	27%
	FLOVENT	00173049400	5.430	5.284	4.369	21%	5.938	5.721	4.603	24%	6.547	6.165	4.852	27%
	FLOVENT	00173049500	8.433	8.153	6.725	21%	9.224	8.886	7.139	24%	10.169	9.576	7.524	27%
	FLOVENT	00173071900												
	FLOVENT	00173072000												
	HYCAMTIN	00007420105	762.073	715.268	569.381	26%	800.180	778.151	619.432	26%	919.500	872.261	684.343	27%
	IMITREX	00173044002	107.170	103.642	86.088	20%	116.180	110.943	90.718	22%	120.760	120.377	95.146	27%
	IMITREX	00173045003	16.007	16.007	13.320	20%	17.174	17.148	13.658	25%	17.938	17.471	13.883	26%
	IMITREX	00173045000	16.007	16.007	13.295	20%	17.174	17.148	13.650	25%	17.861	17.805	14.114	25%
	IMITREX	00173046002	17.647	17.064	14.167	20%	18.117	18.267	14.857	23%	20.072	19.894	15.842	26%
	IMITREX	00173047800	108.604	105.211	87.588	20%	117.880	112.633	91.672	23%	122.590	122.203	96.901	26%
	IMITREX	00173047900	114.878	111.083	92.141	21%	124.450	118.915	96.714	23%	129.430	129.021	102.228	26%
	IMITREX	00173052300	22.940	22.183	18.421	20%	24.852	23.747	19.330	23%	25.847	25.765	20.438	26%
	IMITREX	00173073701												
	KYTRIL	00029414901	195.200	195.200	148.780	31%	195.200	195.200	163.470	19%	195.200	195.200		
	KYTRIL	00029415105	47.043	47.043	37.571	25%	47.043	47.043	37.468	26%	47.043	47.043		
	KYTRIL	00029415201	187.392	194.216			195.200	195.681			195.200	195.200		
	LAMICTAL	00173052600	2.184	2.101	1.769	19%	2.703	2.537	2.031	25%	2.956	2.822	2.256	25%
	LAMICTAL	00173053302	2.311	2.223	1.847	20%	2.860	2.685	2.135	26%	3.128	2.986	2.360	27%
	LAMICTAL	00173054255	2.453	2.360	1.861	20%	3.038	2.850	2.269	25%	3.321	3.170	2.509	26%
	LAMICTAL	00173054360	2.578	2.480	2.065	20%	3.190	2.995	2.387	25%	3.489	3.331	2.632	27%
	LAMICTAL	00173054460	2.702	2.599	2.165	20%	3.344	3.139	2.501	25%	3.658	3.491	2.760	27%
	LANOXIN	00173024275	0.170	0.168	0.137	21%	0.185	0.178	0.145	23%	0.190	0.187	0.147	27%
	LANOXIN	00173024975	0.170	0.166	0.136	22%	0.185	0.176	0.142	24%	0.190	0.187	0.148	26%
	LANOXIN	00173026427	0.561	0.546	0.451	21%	0.607	0.580	0.471	23%	0.625	0.614	0.487	26%
	LEXIVA	00173072100									10.000	10.000	7.904	27%
	NEPRON	00173066518	3.185	3.185	2.648	20%	3.517	3.510	2.799	25%	3.517	3.517	2.790	26%
	NAVELBINE	00173055501	91.680	88.764	73.429	21%	114.380	107.070	82.622	30%	119.530	119.107	89.342	33%
	PAXIL	00029321013	2.602	2.533	2.052	23%	2.706	2.704	2.153	26%	2.913	2.812	2.213	27%
	PAXIL	00029321113	2.715	2.643	2.156	23%	2.824	2.821	2.253	25%	3.040	2.934	2.322	26%
	PAXIL	00029321120	2.715	2.643	2.140	24%	2.824	2.822	2.245	26%	3.040	2.935	2.313	27%
	PAXIL	00029321213	2.797	2.722	2.207	23%	2.909	2.907	2.313	26%	3.131	3.022	2.378	27%
	PAXIL	00029321313	2.955	2.876	2.330	23%	3.073	3.070	2.444	26%	3.308	3.193	2.514	27%
	PAXIL	00029321548	0.520	0.506	0.410	23%	0.540	0.540	0.430	26%	0.607	0.563	0.443	27%
	PAXIL CR	00029320813					2.706	2.706	2.153	26%	2.913	2.812	2.229	26%
	PAXIL CR	00029320713					2.824	2.824	2.245	26%	3.040	2.934	2.327	26%
	PURINETHOL	00173080725	3.646	3.460	2.874	20%	3.988	3.830	3.099	24%	4.547	4.280	3.388	26%
	RETROVIR	00173010855	1.858	1.857	1.544	20%	2.052	2.047	1.633	25%	2.052	2.052	1.628	26%
	RETROVIR	00173050100	5.574	5.573	4.625	20%	6.155	6.142	4.888	25%	6.155	6.155	4.878	26%
	SEREVENT	00173046400	5.896	5.700	4.723	21%	6.732	6.250	5.043	24%	7.058	6.956	5.379	29%
	SEREVENT	00173046500	5.682	5.502	4.546	21%	6.489	6.034	4.888	24%	6.824	6.728	5.180	30%
	SEREVENT DISKUS	00173052100	1.334	1.289	1.066	21%	1.458	1.405	1.133	24%	1.608	1.514	1.210	25%
	TRIZIVIR	00173059100	16.754	16.750	13.923	20%	18.499	18.461	14.729	25%	18.498	18.498	14.587	26%
	VALTREX	00173055502	5.652	5.652	4.589	21%	6.756	6.562	5.225	26%	8.319	7.590	5.966	26%
	VALTREX	00173093305	3.816	3.551	2.859	20%	4.030	4.021	3.197	26%	4.030	4.030	3.205	26%
	VALTREX	00173093306									4.568	4.565	3.463	26%
	WELLBUTRIN SR	00173013555	1.684	1.653	1.370	21%	1.916	1.877	1.489	26%	2.162	2.012	1.590	27%
	WELLBUTRIN SR	00173072200					3.575	3.575	2.846	26%	3.897	3.739	2.975	26%
	WELLBUTRIN SR	00173094755	1.571	1.542	1.279	21%	1.787	1.751	1.387	26%	2.008	1.878	1.478	27%
	WELLBUTRIN XL	00173073001									3.055	2.940	2.341	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
GSK	WELLBUTRIN XL	00173073101									4.034	3.880	3.085	26%
	ZANTAC	00173038354	0.451	0.443	0.363	22%	0.451	0.451	0.372	21%	0.533	0.492	0.387	27%
	ZIAGEN	00173066101	6.410	6.409	5.316	21%	7.078	7.063	5.621	26%	7.078	7.078	5.609	26%
	ZOFRAN	00173044200	12.820	12.820	9.337	37%	12.820	12.820	8.705	47%	13.355	13.311	9.117	46%
	ZOFRAN	00173044202	12.824	12.824	9.056	42%	12.824	12.824	8.956	43%	12.824	12.824	9.671	33%
	ZOFRAN	00173044600	17.358	16.895	13.994	21%	18.985	18.044	14.640	23%	21.031	20.007	15.770	27%
	ZOFRAN	00173044700	28.912	28.141	23.331	21%	31.623	30.056	24.425	23%	35.030	33.324	26.337	27%
	ZOVIRAX	00173099394	3.982	3.540	2.930	21%	5.243	5.324	4.242	26%	5.714	5.714	4.703	21%
	ZYBAN	00173055601	1.684	1.653	1.367	21%	1.916	1.877	1.491	26%	2.152	2.012	1.588	27%
IVAX	ACYCLOVIR	00172438760	2.169	2.169	0.108	1905%	2.169	2.160	0.092	2259%	2.169	2.169	0.098	2150%
	ALBUTEROL	00172439018	1.752	1.730	0.547	216%	1.752	1.752	0.368	376%	1.752	1.752	0.247	610%
	ASPIRIN	00182108105	0.016	0.016	0.009	81%	0.016	0.016	0.008	92%	0.016	0.016	0.008	93%
	ASPIRIN	00182106107	0.027	0.027	0.018	51%	0.027	0.027	0.017	61%	0.027	0.027	0.018	84%
	BACLOFEN	00172409660	0.371	0.371	0.028	1216%	0.610	0.441	0.057	661%	0.610	0.610	0.175	249%
	BACLOFEN	00172409680	0.331	0.331	0.027	1119%	0.559	0.398	0.063	536%	0.559	0.559	0.167	234%
	BACLOFEN	00172409760	0.646	0.646	0.058	1012%	1.095	0.779	0.124	530%	1.095	1.095	0.327	235%
	CEFADROXIL	00172405860	3.280	3.280	0.591	454%	4.147	3.301	0.393	739%	4.147	4.147	0.789	426%
	CEPHALEXIN	00172407470	1.114	1.087	0.098	1011%	1.348	1.298	0.151	752%	1.348	1.348	0.170	692%
	CIMETIDINE	00172717160	1.676	1.676	0.071	2271%	1.676	1.676	0.064	2534%	1.429	1.636	0.060	2650%
	CIMETIDINE	00172717170	1.808	1.608	0.062	2477%	1.608	1.608	0.055	2802%	1.421	1.579	0.051	3008%
	CIMETIDINE	00172771160	2.648	2.793	0.124	2161%	2.648	2.648	0.129	1952%	2.648	2.648	0.116	2192%
	CLOZAPINE	00172435970	1.249	1.242	0.502	147%	1.249	1.249	0.457	174%	1.249	1.249	0.422	196%
	CLOZAPINE	00172436060	3.328	3.309	1.394	137%	3.328	3.328	1.217	173%	3.328	3.328	1.088	206%
	CLOZAPINE	00172436070	3.236	3.217	1.318	144%	3.236	3.236	1.160	179%	3.236	3.236	1.080	200%
	DIPHENHYDRAMINE HCL	00182049210	0.027	0.027	0.013	101%	0.027	0.027	0.012	115%	0.032	0.031	0.016	93%
	GABAPENTIN	00172444160												
	GLYBURIDE-METFORMIN HCL	00172571160												
	GLYBURIDE-METFORMIN HCL	00172571260												
	HYDROCHLOROTHIAZIDE	00172208380	0.077	0.077	0.010	685%	0.079	0.079	0.026	202%	0.079	0.079	0.027	194%
	INDOMETHACIN	00172403070	0.633	0.633	0.047	1238%	0.633	0.633	0.044	1348%	0.642	0.640	0.048	1195%
	LABETALOL HCL	00172435560	0.691	0.691	0.128	441%	0.691	0.691	0.113	512%	0.780	0.758	0.181	320%
	NITROFURANTOIN MACROCRYST	00172213060	0.678	0.578	0.180	276%	1.094	0.884	0.461	92%	1.094	1.094	0.692	58%
	NITROFURANTOIN MACROCRYST	00172213160	1.198	1.198	0.308	289%	1.859	1.510	0.730	107%	1.859	1.859	1.181	57%
	ONXOL	00172375377	34.544	34.544	25.036	38%	34.544	34.544	23.782	45%	34.544	34.544	6.834	405%
	ONXOL	00172375396												
	ONXOL	00172375473	34.544	34.544	24.763	39%	34.544	34.544	23.058	50%	34.544	34.544	9.268	273%
	ONXOL	00172375494												
	ONXOL	00172375531												
	ONXOL	00172375575	34.544	34.544			34.544	34.544	10.772	221%	34.544	34.544	15.578	122%
	ONXOL	00172375695												
	OXYCODONE	00172635560												
	OXYCODONE	00172635660												
	OYST-CAL-500	00182157807	0.035	0.035	0.018	102%	0.035	0.035	0.018	100%	0.035	0.035	0.017	108%
	OYST-CAL-500	00182157610	0.029	0.029	0.015	92%	0.029	0.029	0.014	108%	0.029	0.029	0.013	126%
	OYST-CAL-500	00182157626	0.054	0.054	0.029	89%	0.054	0.054	0.027	103%	0.054	0.054	0.022	147%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
TVAX	PROPOXYPHENE NAPSYLATE W/	00172498070	0.572	0.572	0.081	605%	0.572	0.572	0.073	687%	0.572	0.572	0.065	780%
	QUININE SULFATE	00172300160	0.145	0.141	0.062	128%	0.701	0.284	0.152	87%	0.701	0.701	0.468	53%
	OVAR	59310017780			5.920		8.579	8.249	6.477	27%	9.095	8.897	7.103	25%
	SENNA-GEN	00182109310	0.025	0.025	0.013	88%	0.025	0.025	0.013	84%	0.025	0.025	0.012	117%
	TRAMADOL	00172635960												
	VERAPAMIL HCL	00172428060	1.556	1.446	0.156	824%	1.636	1.557	0.187	734%	1.635	1.635	0.276	492%
	VERAPAMIL HCL	00172428070	1.541	1.416	0.135	924%	1.689	1.646	0.179	765%	1.689	1.689	0.265	537%
	VERAPAMIL HCL	00172428560	1.073	0.992	0.425	133%	1.073	1.073	0.451	198%	1.073	1.073	0.412	160%
	VERAPAMIL HCL	00172428660	1.360	1.264	0.152	732%	1.440	1.362	0.186	637%	1.440	1.440	0.277	420%
J&J	DITROPAN XL	17314050001	2.563	2.523	2.013	25%	2.932	2.671	2.122	26%	3.119	3.022	2.399	26%
	DITROPAN XL	17314050101	2.788	2.756	2.210	25%	3.047	2.894	2.303	26%	3.196	3.119	2.475	26%
	DITROPAN XL	17314050201	3.088	3.040	2.497	22%	3.375	3.206	2.588	23%	3.540	3.454	2.751	26%
	ELMIRON	17314930001	1.953	1.923	1.601	20%	2.273	2.112	1.697	24%	2.407	2.337	1.870	25%
	HYCELEX	17314940001	1.377	1.372	1.144	20%	1.593	1.488	1.200	24%	1.587	1.698	1.293	27%
	NEUTRA-PHOS	17314931102	0.397	0.387	0.331	17%	0.460	0.429	0.356	21%	0.487	0.473	0.389	21%
	REMICADE	57894003001	691.610	680.017			691.610	691.610			691.610	691.610		
JANSSEN	DURAGESIC	50458003305	12.814	12.698	10.465	20%	14.548	13.829	11.093	25%	15.146	14.835	11.774	26%
	DURAGESIC	50458003405	21.365	20.916	17.380	20%	24.722	23.093	18.544	25%	26.875	25.659	20.386	26%
	DURAGESIC	50458003505	33.905	33.333	27.694	20%	38.862	38.618	29.426	24%	40.590	39.738	31.619	26%
	DURAGESIC	50458003605	42.646	41.751	34.641	21%	50.262	46.167	37.110	24%	54.002	52.056	41.406	26%
	NIZORAL	50458022304	0.195	0.194	0.161	20%	0.229	0.214	0.171	25%	0.243	0.236	0.186	26%
	PROPULSID	50458043010	0.748	0.748			0.748	0.748			0.748	0.748		
	PROPULSID	50458043012	0.808	0.808	0.667	21%	0.808	0.808	0.667	21%	0.808	0.808		
	PROPULSID	50458044010	1.450	1.450			1.450	1.450			1.450	1.450		
	PROPULSID	50458045045	0.131	0.131			0.131	0.131			0.131	0.131		
	REMINYL	50458039060	2.160	2.160	1.794	20%	2.499	2.335	1.872	25%	2.622	2.558	2.023	26%
	REMINYL	50458039160	2.160	2.160	1.790	21%	2.499	2.395	1.876	24%	2.622	2.558	2.027	26%
	RISPERDAL	50458030005	2.788	2.729	2.266	20%	3.303	3.030	2.427	25%	3.564	3.428	2.715	26%
	RISPERDAL	50458030050	2.788	2.729	2.251	21%	3.302	3.030	2.406	26%	3.563	3.427	2.677	28%
	RISPERDAL	50458030104	2.788	2.729	2.269	20%	3.087	2.961	2.372	25%	3.173	3.125	2.477	26%
	RISPERDAL	50458030206	2.788	2.729	2.268	20%	3.196	3.011	2.413	25%	3.352	3.271	2.592	26%
	RISPERDAL	50458030250	2.788	2.729	2.244	22%	3.195	3.011	2.390	26%	3.352	3.270	2.556	28%
	RISPERDAL	50458030505	3.440	3.368	2.789	21%	3.943	3.715	2.964	25%	4.136	4.036	3.175	27%
	RISPERDAL	50458031528									4.293	4.293	3.405	26%
	RISPERDAL	50458031530									4.293	4.283	3.407	26%
	RISPERDAL	50458032006	4.640	4.543	3.773	20%	5.319	5.011	4.017	25%	5.579	5.444	4.316	26%
	RISPERDAL	50458032050	4.640	4.543	3.752	21%	5.319	5.012	3.991	26%	5.579	5.444	4.291	27%
	RISPERDAL	50458032528									6.914	6.914	5.497	26%
	RISPERDAL	50458033008	5.480	5.365	4.454	20%	6.431	5.951	4.770	25%	6.875	6.844	5.265	26%
	RISPERDAL	50458033050	5.479	5.364	4.432	21%	6.431	5.951	4.730	26%	6.875	6.844	5.210	28%
	RISPERDAL	50458035006	7.221	7.069	5.856	21%	8.475	7.842	6.259	25%	9.145	8.796	6.935	27%
	RISPERDAL CONSTA	50458030611									138.800	138.800		
	RISPERDAL CONSTA	50458030711									208.205	208.205		
	RISPERDAL CONSTA	50458030811									277.605	277.605		

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt.Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
JANSSEN	SPORANOX	50458020004	7.770	7.615	5.318	21%	8.942	8.403	6.700	25%	9.362	9.143	7.252	26%
	SPORANOX	50458029515	0.815	0.769	0.659	20%	0.885	0.818	0.681	20%	0.935	0.893	0.726	23%
MERCK	CANCIDAS	00006982210	360.000	360.000	285.702	26%	376.910	360.046	283.553	27%	388.210	380.037	295.197	28%
	COSOPT	00006362835	8.770	8.770	7.011	25%	9.380	9.198	7.330	25%	10.076	9.552	7.575	26%
	COSOPT	00006362835	8.771	8.771	7.004	25%	9.384	9.201	7.329	26%	10.080	9.556	7.587	26%
	COZAAR	00006095154	1.430	1.386	1.108	25%	1.515	1.501	1.197	25%	1.662	1.580	1.258	26%
	COZAAR	00006095158	1.430	1.386	1.107	25%	1.515	1.501	1.196	26%	1.662	1.580	1.245	27%
	COZAAR	00006095231	1.430	1.385	1.112	25%	1.515	1.501	1.198	25%	1.662	1.581	1.250	26%
	COZAAR	00006095254	1.430	1.385	1.110	25%	1.515	1.501	1.199	25%	1.662	1.580	1.253	26%
	COZAAR	00006095258	1.430	1.386	1.105	25%	1.515	1.501	1.194	26%	1.662	1.580	1.250	26%
	COZAAR	00006095282	1.430	1.386	1.116	24%	1.515	1.501	1.206	24%	1.662	1.580	1.242	27%
	COZAAR	00006096031	1.948	1.948	1.557	25%	2.063	2.044	1.630	25%	2.263	2.163	1.711	26%
	COZAAR	00006096054									2.264	2.211	1.770	24%
	COZAAR	00006096058	1.948	1.946	1.555	25%	2.063	2.044	1.539	25%	2.264	2.163	1.700	27%
	CRIXIVAN	00006057382	2.008	2.826	2.244	26%	3.035	3.005	2.382	26%	3.035	3.035	2.404	26%
	FOSAMAX	00006003144	16.191	15.680	12.752	25%	17.144	16.914	13.472	26%	18.328	17.865	14.160	26%
	FOSAMAX	00006007744	16.191	15.889	12.781	24%	17.144	16.914	13.457	26%	18.328	17.885	14.150	26%
	FOSAMAX	00006071044												
	FOSAMAX	00006092531	2.313	2.269	1.608	26%	2.449	2.416	1.824	26%	2.618	2.562	2.030	25%
	FOSAMAX	00006092558	2.313	2.269	1.798	26%	2.449	2.416	1.816	26%	2.618	2.552	2.019	26%
	FOSAMAX	00006093631	2.313	2.269	1.811	25%	2.449	2.416	1.829	25%	2.618	2.552	2.029	25%
	FOSAMAX	00006093658	2.313	2.269	1.797	26%	2.449	2.416	1.816	26%	2.618	2.552	2.020	26%
	FOSAMAX	00006093682	2.313	2.269	1.816	25%	2.449	2.416	1.829	25%	2.618	2.552	2.034	25%
	HYZAAR	00006071731	1.430	1.385	1.104	26%	1.515	1.501	1.193	26%	1.662	1.581	1.248	27%
	HYZAAR	00006071754	1.430	1.386	1.109	25%	1.515	1.501	1.197	25%	1.662	1.580	1.255	26%
	HYZAAR	00006071756	1.430	1.388	1.109	25%	1.515	1.501	1.197	25%	1.662	1.560	1.253	26%
	HYZAAR	00006071782	1.430	1.366	1.150	21%	1.515	1.501	1.229	22%	1.662	1.580	1.283	23%
	HYZAAR	00006074731	1.948	1.948	1.555	25%	2.063	2.044	1.628	26%	2.263	2.163	1.708	26%
	HYZAAR	00006074754									2.264	2.211	1.769	25%
	HYZAAR	00006074758	1.948	1.948	1.558	25%	2.063	2.044	1.633	25%	2.264	2.163	1.703	26%
	MAXALT	00006026706	16.165	15.685	12.681	25%	17.117	16.963	13.497	26%	18.708	17.876	14.169	26%
	MAXALT MLT	00006380105	16.165	15.685	12.683	25%	17.117	16.963	13.500	26%	18.800	17.875	14.180	26%
	NEVACOR	00006073061	1.495	1.456	1.171	25%	1.495	1.495	1.183	26%	1.495	1.495	1.058	41%
	NEVACOR	00006073161	2.636	2.588	2.060	28%	2.636	2.636	2.100	25%	2.636	2.636	2.083	27%
	NEVACOR	00006073182	2.636	2.586	2.058	26%	2.636	2.636	2.121	24%	2.636	2.636	2.144	23%
	NEVACOR	00006073261	4.746	4.655	3.714	25%	4.746	4.746	3.787	25%	4.746	4.748	3.769	26%
	PRIMAXIN I.V.	00006851659	30.727	30.727	23.586	30%	31.434	31.434	23.472	34%	32.690	31.647	23.397	35%
	PRINIVIL	00006001958	0.980	0.961	0.779	23%	1.081	1.064	0.835	27%	1.081	1.081	0.856	26%
	PRINIVIL	00006010631	1.012	0.992	0.827	20%	1.116	1.099	0.879	25%	1.116	1.116	0.885	26%
	PRINIVIL	00006010658	1.011	0.992	0.810	22%	1.116	1.099	0.866	27%	1.116	1.116	0.887	26%
	PRINIVIL	00006020758	1.083	1.062	0.869	22%	1.195	1.176	0.928	27%	1.195	1.195	0.948	26%
	PRINIVIL	00006023758	1.584	1.553	1.257	24%	1.747	1.720	1.350	27%	1.747	1.747	1.377	27%
	PROSCAR	00006007231	2.514	2.499	2.005	25%	2.715	2.683	2.126	25%	2.875	2.762	2.199	25%
	PROSCAR	00006007258	2.514	2.499	1.991	25%	2.715	2.663	2.117	26%	2.875	2.762	2.183	26%
	PROSCAR	00006007282									2.875	2.772	2.148	29%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
MERCK	SINGULAIR	00006011731	2.752	2.731	2.176	25%	2.914	2.888	2.296	26%	3.130	3.053	2.422	26%
	SINGULAIR	00006011754	2.752	2.731	2.185	25%	2.914	2.888	2.303	25%	3.130	3.053	2.426	26%
	SINGULAIR	00006027531	2.752	2.731	2.177	25%	2.914	2.888	2.298	26%	3.130	3.053	2.424	26%
	SINGULAIR	00006027554	2.752	2.731	2.187	25%	2.914	2.888	2.303	25%	3.130	3.053	2.427	26%
	TIMOPTIC-XE	00006355803	8.545	8.477	5.158	26%	7.000	6.865	5.469	26%	7.000	7.000	5.556	26%
	TRUSOPT	00006361910	5.140	5.140	4.113	25%	5.140	5.140	4.093	26%	5.140	5.140		
	TRUSOPT	00006361936	5.140	5.140	4.105	25%	5.499	5.392	4.296	26%	5.821	5.593	4.427	26%
	VASOTEC	00006001466	0.893	0.893	0.718	24%	0.937	0.937	0.756	24%	0.937	0.937	0.760	23%
	VASOTEC	00006071269	1.135	1.135	0.906	25%	1.190	1.190	0.957	24%	1.190	1.190	0.968	24%
	VASOTEC	00006071358	1.191	1.191	0.954	25%	1.250	1.250	1.006	24%	1.250	1.250	0.992	26%
	VASOTEC	00006071382	1.191	1.191	0.944	26%	1.250	1.250			1.250	1.250	1.028	23%
	VASOTEC	00006071468	1.695	1.695	1.355	25%	1.778	1.778	1.453	22%	1.778	1.778	1.432	24%
	VIOXX	00006007431	2.752	2.666	2.137	25%	2.876	2.784	2.217	26%	3.014	2.948	2.334	26%
	VIOXX	00006007468	2.752	2.666	2.119	26%	2.876	2.784	2.211	26%	3.014	2.948	2.331	26%
	VIOXX	00006011031	2.752	2.666	2.144	24%	2.876	2.784	2.220	25%	3.014	2.948	2.342	25%
	VIOXX	00006011058	2.752	2.666	2.124	25%	2.876	2.784	2.214	26%	3.014	2.948	2.336	26%
	VIOXX	00006011082	2.752	2.666	2.125	25%	2.876	2.784	2.209	26%	3.014	2.948	2.336	26%
	VIOXX	00006011468	4.019	3.894	3.111	25%	4.200	4.066	3.235	26%	4.401	4.305	3.411	26%
	VYTORIN	66582031231												
	VYTORIN	66582031254												
	VYTORIN	66582031331												
	ZETIA	66582041431					2.413	2.413			2.550	2.480		
	ZETIA	66582041454					2.413	2.413			2.550	2.480		
	ZOCOR	00006054331	4.163	4.163	3.319	25%	4.585	4.400	3.509	26%	4.787	4.620	3.671	26%
	ZOCOR	00006054354	4.163	4.163	3.319	25%	4.585	4.408	3.506	26%	4.787	4.619	3.643	27%
	ZOCOR	00006054361	4.163	4.163	3.323	25%	4.585	4.164	3.321	25%	4.787	4.619		
	ZOCOR	00006054382	4.163	4.163	3.302	26%	4.585	4.409	3.496	26%	4.787	4.619	3.247	42%
	ZOCOR	00006072654	1.781	1.781	1.423	25%	1.981	1.886	1.499	26%	2.047	1.978	1.547	28%
	ZOCOR	00006073531	2.387	2.387	1.805	25%	2.628	2.627	2.012	26%	2.744	2.648	2.105	26%
	ZOCOR	00006073554	2.387	2.387	1.903	25%	2.628	2.527	2.009	26%	2.744	2.648	2.093	27%
	ZOCOR	00006073561	2.387	2.387	1.900	26%	2.628	2.528	2.000	26%	2.744	2.648	2.119	25%
	ZOCOR	00006073582	2.387	2.387	1.904	25%	2.628	2.527	1.978	26%	2.744	2.648	1.840	44%
	ZOCOR	00006074031	4.163	4.163	3.325	25%	4.585	4.409	3.515	25%	4.787	4.620	3.678	26%
	ZOCOR	00006074054	4.163	4.163	3.305	26%	4.585	4.409	3.503	26%	4.787	4.619	3.656	27%
	ZOCOR	00006074061	4.163	4.163	3.316	26%	4.586	4.164	3.313	26%	4.787	4.619	3.674	26%
	ZOCOR	00006074082	4.163	4.163	3.308	26%	4.585	4.409	3.478	27%	4.787	4.619	3.509	32%
	ZOCOR	00006074931	4.163	4.163	3.326	25%	4.585	4.409	3.516	25%	4.787	4.620	3.682	25%
	ZOCOR	00006074954	4.163	4.163	3.309	26%	4.585	4.409	3.499	25%	4.787	4.619	3.647	27%
	ZOCOR	00006074961	4.163	4.163	3.318	25%	4.585	4.164	3.319	25%	4.787	4.619	3.681	25%
	ZOCOR	00006074982	4.163	4.163	3.305	26%	4.585	4.409	3.504	26%	4.787	4.619	3.577	29%
MYLAN	ACTICIN	62794010106	0.467	0.448	0.316	45%	0.467	0.467	0.344	36%	0.486	0.481	0.246	95%
	ALLOPURINOL	00378010105	0.578	0.578	0.077	648%	0.578	0.578	0.094	514%	0.578	0.578	0.112	414%
	ATENOLOL	00378023110	0.805	0.805	0.018	4457%	0.805	0.805	0.048	1577%	0.805	0.805	0.052	1442%
	BUSPIRONE HCL	00378116580	1.991	1.991	1.476	35%	1.991	1.991	0.385	418%	1.991	1.991	0.154	1195%
	BUSPIRONE HCL	00378116591	2.019	2.019	1.512	34%	2.019	2.019	0.443	355%	2.019	2.019	0.166	1118%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
MYLAN	BUSPIRONE HCL	00378117591	3.635	3.635	2.709	34%	3.635	3.635	1.082	236%	3.635	3.635	0.642	466%
	CARBIDOPA/LEVODOPA	00378008601	0.696	0.696	0.552	62%	0.940	0.929	0.554	66%	0.940	0.940	0.551	71%
	CARBIDOPA/LEVODOPA	00378009401	1.707	1.707	1.159	47%	1.809	1.768	1.204	47%	1.809	1.809	1.230	47%
	CIMETIDINE	00378037205	1.612	1.612	0.068	2267%	1.470	1.475	0.084	1648%	1.470	1.470	0.095	1451%
	CLORAZEPATE DIPOTASSIUM	00378003001	1.284	1.284	0.174	637%	1.284	1.284	0.175	629%	1.284	1.284	0.180	613%
	CLORAZEPATE DIPOTASSIUM	00378003005	1.258	1.258	0.161	682%	1.258	1.258	0.207	509%	1.258	1.258	0.144	772%
	CLORAZEPATE DIPOTASSIUM	00378004001	1.597	1.597	0.232	587%	1.597	1.597	0.220	625%	1.597	1.597	0.208	663%
	CLORAZEPATE DIPOTASSIUM	00378004005	1.566	1.566	0.219	615%	1.566	1.566	0.209	648%	1.566	1.566	0.172	808%
	DIGITEK	62794014501	0.188	0.188	0.104	74%	0.189	0.187	0.107	75%	0.215	0.204	0.109	87%
	DIGITEK	62794014510	0.150	0.148	0.096	52%	0.157	0.156	0.095	64%	0.166	0.162	0.105	54%
	DIGITEK	62794014610	0.150	0.146	0.099	48%	0.157	0.156	0.094	65%	0.166	0.162	0.107	52%
	DILTIAZEM HCL	00378528001	1.072	1.072	0.427	151%	1.072	1.072	0.402	167%	1.072	1.072	0.400	168%
	DILTIAZEM HCL	00378534001	1.146	1.146	0.443	159%	1.146	1.146	0.446	157%	1.146	1.146	0.448	156%
	DIPHENOXYLATE W/ATROPINE	00378041510	0.445	0.445	0.120	272%	0.445	0.445	0.044	922%	0.445	0.445	0.035	1159%
	DOCUSATE SODIUM	51079001960	0.021	0.021	0.014	49%	0.021	0.021	0.015	36%	0.021	0.021	0.016	30%
	DOXEPIN HCL	00378425001	0.552	0.552	0.054	930%	0.552	0.552	0.081	584%	0.552	0.552	0.078	610%
	FENTANYL	00378912498												
	FUROSEMIDE	00378020810	0.140	0.140	0.014	882%	0.140	0.140	0.028	398%	0.140	0.140	0.037	276%
	FUROSEMIDE	00378021610	0.160	0.160	0.018	778%	0.160	0.160	0.029	442%	0.160	0.160	0.039	308%
	FUROSEMIDE	00378023205	0.428	0.428	0.035	1121%	0.428	0.428	0.052	727%	0.428	0.428	0.061	607%
	HALOPERIDOL	00378032701	0.709	0.709	0.026	2600%	0.708	0.708	0.043	1567%	0.780	0.770	0.099	679%
	HYDROCHLOROTHIAZIDE	00378061001	0.425	0.425	0.232	83%	0.425	0.425	0.239	78%	0.425	0.425	0.228	85%
	LOPERAMIDE HCL	00378210001	0.682	0.682	0.048	1326%	0.682	0.682	0.055	1117%	0.682	0.682	0.053	1191%
	LOPERAMIDE HCL	00378210005	0.627	0.627	0.045	1299%	0.627	0.627	0.049	1170%	0.627	0.627	0.050	1155%
	LORAZEPAM	00378032105	0.662	0.662	0.119	457%	0.662	0.662	0.069	862%	0.662	0.662	0.065	918%
	LORAZEPAM	00378045701	0.883	0.883	0.277	219%	0.883	0.883	0.151	485%	0.883	0.883	0.169	423%
	LORAZEPAM	00378045705	0.862	0.862	0.214	303%	0.862	0.862	0.115	651%	0.862	0.862	0.113	668%
	LORAZEPAM	00378045710	0.843	0.843	0.130	548%	0.843	0.843	0.080	951%	0.843	0.843	0.071	1090%
	LORAZEPAM	00378077701	1.285	1.285	0.389	230%	1.285	1.285	0.260	395%	1.285	1.285	0.216	495%
	LOVASTATIN	00378654091	4.268	4.268	1.585	169%	4.268	4.268	1.428	199%	4.268	4.268	1.675	155%
	METFORMIN HCL	00378023401					0.704	0.704	0.323	118%	0.704	0.704	0.109	542%
	MIRTAZAPINE	00378351593									2.715	2.715	0.248	1002%
	MIRTAZAPINE	00378353093									2.797	2.797	0.350	699%
	NIFEDIPINE ER	00378347501	1.325	1.324	0.874	49%	1.325	1.325	0.779	70%	1.325	1.325	0.737	80%
	NIFEDIPINE ER	00378347530	1.298	1.278	0.846	51%	1.298	1.298	0.765	70%	1.298	1.298	0.725	79%
	NIFEDIPINE ER	00378348201	2.292	2.256	1.461	54%	2.292	2.292	1.284	81%	2.292	2.292	1.198	81%
	NIFEDIPINE ER	00378349501	2.562	2.562	1.762	45%	2.562	2.562	1.750	46%	2.562	2.562	1.776	44%
	NITROGLYCERIN	00378910293	1.580	1.580	0.518	205%	1.580	1.580	0.525	201%	1.580	1.580	0.525	201%
	NITROGLYCERIN	00378910493	1.817	1.817	0.553	193%	1.817	1.817	0.547	196%	1.817	1.817	0.640	190%
	NITROGLYCERIN	00378811293	1.847	1.847	0.655	182%	1.847	1.847	0.550	184%	1.847	1.847	0.842	188%
	ORPHENADRINE CITRATE	00378335801	2.175	2.175	0.228	855%	2.175	2.175	0.154	1314%	2.175	2.175	0.152	1327%
	PACLITAXEL	51079098101												
	PACLITAXEL	51079098201	34.228	34.228			34.228	34.228			34.228	34.228		
	PACLITAXEL	51079095301	34.502	34.502			34.502	34.502			34.502	34.502	4.538	660%
	PHENYTOIN SODIUM, EXTENDE	00378156001	0.262	0.257	0.160	61%	0.266	0.266	0.166	60%	0.286	0.279	0.177	58%
	PROBENECID	00378015601	0.983	1.846	0.422	338%	0.983	0.983	0.313	214%	0.983	0.983	0.308	219%
	PROPOXYPHENE NAPSYLATE W/	00378015505	0.572	0.554	0.081	581%	0.572	0.572	0.083	588%	0.572	0.572	0.073	685%
	SPIRONOLACTONE	00378214601	0.459	0.435	0.175	149%	0.459	0.459	0.199	130%	0.459	0.459	0.197	133%
	SPIRONOLACTONE	00378214805	0.436	0.420	0.163	158%	0.436	0.436	0.184	138%	0.436	0.436	0.182	140%
	TEMAZEPAM	00378401001	0.696	0.696	0.049	1314%	0.696	0.696	0.063	1000%	0.735	0.729	0.075	888%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
DYLAN	TEMAZEPAM	00378505001	0.812	0.812	0.064	1174%	0.812	0.812	0.090	804%	0.885	0.875	0.107	716%
	THIORIDAZINE HCL	00378061401	0.467	0.467	0.060	677%	0.467	0.467	0.129	263%	0.467	0.467	0.184	154%
	THIORIDAZINE HCL	00378061601	0.665	0.665	0.122	446%	0.665	0.665	0.218	205%	0.665	0.665	0.305	118%
NOVARTIS	ACTIGALL	00078031505	3.149	3.029	2.494	21%	3.498	3.195	2.638	21%	3.887	3.611	2.891	25%
	AREDIA	00083280104	279.860	274.719	224.550	22%	279.860	279.860	231.053	21%	279.860	279.880	230.113	22%
	AREDIA	00083280901	839.600	824.158	683.193	21%	839.600	839.600	693.733	21%	839.600	839.600	690.510	22%
	CLOZARIL	00078012605	1.413	1.412	1.144	23%	1.529	1.523	1.175	30%	1.605	1.604	1.242	29%
	CLOZARIL	00078012705	3.660	3.658	2.981	23%	3.961	3.947	3.080	28%	4.169	4.156	3.239	28%
	COMTAN	00078032705	1.680	1.680	1.401	20%	1.815	1.776	1.434	24%	1.976	1.940	1.536	26%
	DESFERAL	00078034751	57.678	55.410	46.157	20%	62.840	60.815	48.831	25%	72.540	67.346	53.241	26%
	DESFERAL MESYLATE	00083380104	14.905	14.316	11.914	20%	16.240	15.717	12.887	24%	18.660	17.325	13.796	26%
	DIOVAN	00078035805	1.398	1.398	1.117	25%	1.554	1.458	1.170	25%	1.663	1.617	1.282	26%
	DIOVAN	00078035834												
	DIOVAN	00078035905	1.517	1.517	1.213	25%	1.671	1.595	1.274	25%	1.788	1.738	1.380	26%
	DIOVAN	00078035934												
	DIOVAN	00078036005	1.940	1.940	1.555	25%	2.114	2.025	1.635	24%	2.282	2.198	1.760	25%
	DIOVAN	00078036034												
	DIOVAN	00083400001	1.398	1.374	1.094	26%	1.398	1.398	1.137	23%	1.388	1.398	1.182	17%
	DIOVAN	00083400101	1.517	1.492	1.189	26%	1.517	1.517	1.231	23%	1.517	1.517	1.246	22%
	DIOVAN HCT	00078031405	1.532	1.492	1.194	25%	1.671	1.601	1.277	25%	1.788	1.768	1.404	26%
	DIOVAN HCT	00078031434												
	DIOVAN HCT	00078031505	1.650	1.607	1.286	25%	1.819	1.737	1.387	25%	1.946	1.923	1.528	26%
	DIOVAN HCT	00078031534												
	DIOVAN HCT	00078038334												
	DYNACIRC	00078022605	1.072	0.947	0.787	20%	1.321	1.219	0.901	35%	1.429	1.373	1.068	29%
	DYNACIRC	00078022705	1.560	1.382	1.124	23%	1.923	1.775	1.309	36%	2.079	1.999	1.551	29%
	ELIDEL	00078037546					1.584	1.584	1.318	20%	1.788	1.795	1.427	26%
	EXELON	00078032944	2.236	2.204	1.807	22%	2.420	2.366	1.886	25%	2.629	2.584	2.037	27%
	EXELON	00078032444	2.236	2.204	1.809	22%	2.420	2.366	1.885	25%	2.629	2.584	2.037	27%
	EXELON	00078032944	2.236	2.204	1.814	22%	2.420	2.366	1.888	25%	2.629	2.564	2.041	27%
	EXELON	00078032644	2.236	2.204	1.816	21%	2.420	2.366	1.885	25%	2.629	2.584	2.038	27%
	FAMVIR	00078036715	3.675	3.675	2.938	25%	3.675	3.675	2.929	25%	4.048	3.920	3.110	26%
	FAMVIR	00078036815	7.377	7.377	5.900	25%	7.377	7.377	5.883	25%	8.130	8.021	6.356	26%
	FEMARA	00078024915	6.928	6.835	5.711	20%	7.467	7.256	5.870	24%	8.223	7.822	6.216	26%
	GLEEVEC	00078037366	19.683	19.683	15.428	20%	21.300	18.688	16.397	20%	21.300	21.300	16.996	25%
	GLEEVEC	00078040105									22.088	21.493	17.314	24%
	GLEEVEC	00078040215									88.350	85.974	68.960	25%
	GLEEVEC	00078043815												
	LAMISIL	00078017905	8.348	8.289	6.870	21%	9.043	9.011	7.167	25%	9.828	9.608	7.804	26%
	LAMISIL	00078017915	8.350	8.291	6.809	20%	9.040	9.013	7.209	25%	9.830	9.611	7.653	26%
	LESCOL	00078017605	1.477	1.464	1.215	21%	1.685	1.647	1.314	25%	1.852	1.826	1.441	27%
	LESCOL	00078017615	1.480	1.467	1.222	20%	1.688	1.650	1.323	25%	1.855	1.829	1.439	27%
	LESCOL	00078023405	1.477	1.464	1.214	21%	1.685	1.647	1.314	25%	1.852	1.826	1.445	26%
	LESCOL	00078023415	1.480	1.467	1.223	20%	1.688	1.650	1.325	25%	1.855	1.829	1.446	26%
	LESCOL XL	00078035405	1.922	1.905	1.596	19%	2.162	2.077	1.687	23%	2.376	2.342	1.868	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
NOVARTIS	LESCOL XL	00078035415	1.922	1.822	1.509	19%	2.162	2.077	1.694	23%	2.376	2.343	1.850	27%
	LOTENSIN	00083006330	0.935	0.911	0.753	21%	1.022	0.991	0.799	24%	1.168	1.127	0.890	27%
	LOTENSIN	00083007930	0.935	0.911	0.754	21%	1.022	0.991	0.800	24%	1.168	1.127	0.893	26%
	LOTENSIN	00083009430	0.935	0.911	0.756	20%	1.022	0.991	0.802	24%	1.168	1.127	0.893	26%
	LOTREL	00078036405					2.488	2.488	1.987	25%	2.752	2.691	2.151	25%
	LOTREL	00078040505												
	LOTREL	00078040605												
	LOTREL	00083225530	1.916	1.870	1.556	20%	2.026	1.987	1.807	24%	2.200	2.152	1.709	26%
	LOTREL	00083226030	1.898	1.853	1.543	20%	2.065	2.007	1.823	24%	2.243	2.195	1.743	26%
	LOTREL	00083226530	2.034	2.007	1.672	20%	2.162	2.129	1.723	24%	2.369	2.317	1.841	26%
	MIACALCIN	00078014923	19.440	19.402	16.198	20%	21.055	20.060	16.510	23%	21.055	21.055	16.716	26%
	MIACALCIN	00078031154									22.835	22.635		
	MIACALCIN	00078031190	18.555	18.125	13.406	20%	18.283	17.539	14.168	24%	19.540	19.519	15.442	26%
	NEORAL	00078024615	1.528	1.528	1.269	20%	1.528	1.528	1.257	22%	1.528	1.528	1.250	22%
	NEORAL	00078024815	6.107	6.107	6.078	20%	6.107	6.107	5.018	22%	6.107	6.107	4.881	23%
	NEORAL	00078027422	6.657	6.657	5.550	20%	6.657	6.657	5.535	20%	6.657	6.657	5.516	21%
	PARLODEL	00078001705	2.452	2.389	1.991	20%	2.731	2.649	2.122	25%	3.121	2.989	2.348	27%
	SANDIMMUNE	00078024115	6.933	6.931	5.763	20%	6.933	6.933	5.747	21%	6.933	6.933	5.715	21%
	SANDOGLOBULIN	00078012094	91.380	91.380			91.380	91.380			91.380	91.380		
	SANDOGLOBULIN	00078012496	348.630	348.414			348.630	348.630			348.630	348.630		
	SANDOSTATIN	00078018425	152.868	147.549	121.773	21%	196.262	181.690	145.301	25%	209.806	201.160	159.905	26%
	SANDOSTATIN LAR	00078034184	1653.560	1603.293	1282.668	25%	1867.200	1795.783	1425.676	26%	1951.230	1916.546	1515.700	26%
	STARLIX	00078035105	0.924	0.924	0.769	20%	1.001	0.997	0.797	25%	1.091	1.090	0.866	26%
	STARLIX	00078035205	0.960	0.960	0.799	20%	1.040	1.035	0.828	25%	1.134	1.132	0.899	26%
	TEGRETOL	00083001978	0.073	0.073	0.061	21%	0.081	0.080	0.064	25%	0.086	0.086	0.068	26%
	TEGRETOL	00083002730	0.512	0.512	0.425	20%	0.565	0.560	0.448	25%	0.598	0.598	0.474	26%
	TEGRETOL	00083002740	0.506	0.506	0.419	21%	0.559	0.553	0.440	26%	0.592	0.581	0.461	26%
	TEGRETOL	00083005230	0.269	0.269	0.223	21%	0.297	0.294	0.235	25%	0.314	0.314	0.249	26%
	TEGRETOL XR	00083006030	1.024	1.023	0.852	20%	1.130	1.119	0.895	25%	1.195	1.195	0.952	26%
	TEGRETOL XR	00083006230	0.512	0.512	0.426	20%	0.565	0.560	0.447	25%	0.599	0.598	0.475	26%
	TRILEPTAL	00078033605	0.926	0.920	0.768	20%	1.002	0.999	0.797	25%	1.089	1.070	0.849	26%
	TRILEPTAL	00078033705	1.691	1.679	1.402	20%	1.830	1.824	1.457	25%	1.989	1.955	1.553	26%
	TRILEPTAL	00078033805	3.108	3.087	2.578	20%	3.364	3.352	2.677	25%	3.655	3.593	2.855	26%
	VOLTAREN	58768010005	9.962	9.498	8.118	55%	10.350	10.005	7.247	28%	11.392	10.783	8.174	32%
	ZADITOR	58768010205	9.302	8.629	6.967	27%	10.232	9.564	7.508	27%	11.256	10.653	8.302	28%
	ZELNORM	00078035680					2.563	2.563	2.034	26%	2.691	2.636	2.114	25%
	ZOMETA	00078035084	856.380	856.380	699.920	22%	953.610	891.543	709.479	26%	953.610	953.610	752.176	27%
	ZOMETA	00078038725									199.878	196.838	154.318	28%
ORTHO-MCNEIL	HALDOL DECANOATE 100	00045025446	68.182	64.794	53.690	21%	76.686	71.636	57.318	25%	81.102	78.751	62.510	26%
	HALDOL DECANOATE 50	00045025346	38.080	35.322	29.289	21%	41.750	38.989	31.281	25%	44.212	42.930	34.075	26%
	LEVAQUIN	00045152050	7.599	7.468	6.194	21%	8.627	8.142	6.496	25%	9.223	8.913	7.034	27%
	LEVAQUIN	00045152550	8.875	8.722	7.228	21%	10.075	9.510	7.603	25%	10.570	10.913	8.168	26%
	PANCREASE	00045009560	0.452	0.452	0.370	22%	0.534	0.499	0.394	26%	0.565	0.549	0.430	28%
	PROCRIT	59676030201	26.712	26.100	21.295	23%	26.712	26.712	21.744	23%	26.712	26.712	21.621	24%
	PROCRIT	59676030202	26.712	26.100	21.136	23%	26.712	26.712	21.561	24%	26.712	26.712	21.020	27%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ORTHO-MCNEIL	PROCRIT	59676030301	40.068	39.147	31.983	22%	40.068	40.068	32.655	23%	40.068	40.068	32.335	24%
	PROCRIT	59676030302	40.068	39.147	31.220	25%	40.068	40.068	31.975	25%	40.068	40.068	31.937	25%
	PROCRIT	59676030401	53.423	52.200	43.072	21%	53.423	53.423	43.920	22%	53.423	53.423	43.525	23%
	PROCRIT	59676030402	53.424	52.201	41.564	26%	53.424	53.424	42.766	25%	53.424	53.424	42.608	25%
	PROCRIT	59676031001	133.560	130.495	106.692	22%	133.560	133.560	109.077	22%	133.560	133.560	109.471	23%
	PROCRIT	59676031002	133.560	130.494	104.079	25%	133.560	133.560	106.298	26%	133.560	133.560	104.766	27%
	PROCRIT	59676031200	133.560	130.490			133.560	133.560			133.560	133.560		
	PROCRIT	59676031201	133.560	130.490	105.827	23%	133.560	133.560	107.076	24%	133.560	133.560	107.804	24%
	PROCRIT	59676032001	267.120	260.980	212.862	23%	267.120	267.120	217.014	23%	267.120	267.120	215.741	24%
	PROCRIT	59676034001	534.240	521,969	429,791	21%	534.240	534.240	438.823	22%	534.240	534.240	435.147	23%
	REGRANEX	00045081015	30.543	29.902	24.859	20%	35.543	39.039	26.491	25%	35.543	35.543	26.259	26%
	SPECTAZOLE	00062546001	0.957	0.937	0.779	20%	1.182	1.057	0.845	25%	1.232	1.190	0.933	28%
	SPECTAZOLE	00062546003	0.689	0.674	0.563	20%	0.829	0.761	0.610	25%	0.887	0.857	0.673	27%
	TERAZOL 7	00062535001	0.751	0.736	0.612	20%	0.870	0.812	0.652	25%	0.921	0.894	0.710	26%
	TOPAMAX	00045063965	1.386	1.357	1.129	20%	1.812	1.504	1.206	25%	1.700	1.654	1.312	26%
	TOPAMAX	00045064085												
	TOPAMAX	00045064165	3.250	3.182	2.646	20%	3.778	3.527	2.826	25%	4.141	3.952	3.135	26%
	TOPAMAX	00045064285	3.805	3.725	3.098	20%	4.424	4.129	3.308	25%	4.848	4.627	3.669	26%
	TOPAMAX	00045064585	1.586	1.551	1.293	20%	1.843	1.720	1.381	24%	1.843	1.891	1.505	26%
	ULTRACET	00045065060	0.853	0.853	0.711	20%	0.977	0.921	0.742	24%	1.025	1.000	0.796	26%
	ULTRAM	00045065960	0.853	0.835	0.695	20%	1.065	0.927	0.735	26%	1.128	1.095	0.867	26%
	ULTRAM	00045065970	0.853	0.835	0.693	20%	1.065	0.927	0.731	27%	1.128	1.095	0.663	27%
PAR	BENZTROPINE MESYLATE	49884016501	0.217	0.199	0.095	466%	0.217	0.217	0.109	99%	0.217	0.217	0.104	108%
	BENZTROPINE MESYLATE	49884016510	0.212	0.191	0.034	467%	0.212	0.212	0.083	156%	0.212	0.212	0.101	110%
	CIPROFLOXACIN HCL	49884063801												
	FLUOXETINE HCL	49884074301					5.336	5.336	1.319	305%	5.336	5.336	1.257	324%
	FLUOXETINE HCL	49884074311	5.336	5.336	3.623	47%	5.336	5.336	2.155	148%	5.336	5.336	1.700	214%
	IBUPROFEN	49884046705	0.170	0.170	0.019	774%	0.170	0.170	0.019	787%	0.170	0.170	0.019	809%
	IBUPROFEN	49884046905	0.240	0.240	0.024	901%	0.240	0.240	0.024	886%	0.240	0.240	0.037	547%
	IBUPROFEN	49884046905	0.305	0.305	0.037	720%	0.305	0.305	0.037	733%	0.305	0.305	0.037	727%
	IBUPROFEN	49884077705			0.019		0.170	0.170	0.018	797%	0.170	0.170	0.019	808%
	IBUPROFEN	49884077905			0.025		0.240	0.240	0.025	862%	0.240	0.240	0.024	897%
	IBUPROFEN	49884077905			0.037		0.305	0.305	0.037	714%	0.305	0.305	0.036	742%
	LOVASTATIN	49884075501	2.415	2.415			2.415	2.415			2.415	2.415	0.597	305%
	LOVASTATIN	49884075601	4.271	4.271			4.271	4.271			4.271	4.271	1.099	288%
	LOVASTATIN	49884075610	4.196	4.196			4.196	4.196			4.196	4.196	2.691	55%
	MECLIZINE HCL	49884003410	0.190	0.214	0.021	918%	0.190	0.190	0.025	661%	0.190	0.190	0.024	697%
	MEGESTROL ACETATE	49884029001	1.230	1.230	0.241	411%	1.230	1.230	0.241	410%	1.230	1.230	0.236	421%
	MEGESTROL ACETATE	49884090736	0.600	0.600	0.409	46%	0.600	0.600	0.399	50%	0.600	0.600	0.395	52%
	MEGESTROL ACETATE	49884090781												
	METFORMIN HCL ER	49884092101									0.746	0.746	0.502	49%
	PAROXETINE HCL	49884087611									2.533	2.533	1.724	47%
	PAROXETINE HCL	49884087701									2.644	2.844	1.780	49%
	PAROXETINE HCL	49884087705												
	PAROXETINE HCL	49884087811									2.722	2.722	1.845	46%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
PAR	PAROXETINE HCL	49884087911									2.076	2.076	1.963	46%
	RANITIDINE HCL	49884054402	1.588	1.588	0.042	3651%	1.588	1.588	0.057	2701%	1.588	1.588	0.058	2625%
	RANITIDINE HCL	49884054405	1.560	1.560	0.038	4010%	1.560	1.560	0.054	2783%	1.560	1.560	0.053	2853%
	RANITIDINE HCL	49884054410	1.528	1.528	0.040	3759%	1.528	1.528	0.053	2809%	1.528	1.528	0.051	2905%
	RIBASPHERE	49884085693												
	RIBASPHERE	49884085694												
	TRAMADOL	49884094601												
PFIZER	ACCUPRIL	00071053023	1.049	1.048	0.831	26%	1.148	1.137	0.885	28%	1.258	1.221	0.963	27%
	ACCUPRIL	00071053223	1.049	1.048	0.843	24%	1.148	1.137	0.891	28%	1.258	1.221	0.964	27%
	ACCUPRIL	00071053523	1.049	1.048	0.839	25%	1.148	1.137	0.890	28%	1.258	1.221	0.985	26%
	CARDURA	00049276066	1.060	1.059	0.845	25%	1.114	1.103	0.878	26%	1.190	1.171	0.929	26%
	CARDURA	00049277066	1.113	1.112	0.887	25%	1.169	1.157	0.921	26%	1.249	1.229	0.975	26%
	DIFLUCAN	00049342030	7.708	7.703	6.129	26%	8.255	8.174	6.472	26%	9.056	8.767	6.929	27%
	DIFLUCAN	00049343030	12.613	12.605	10.030	26%	13.908	13.375	10.613	26%	14.820	14.380	11.330	27%
	DIFLUCAN	00049350078	12.275	12.268	9.777	25%	13.140	13.011	10.341	25%	14.410	13.985	11.059	26%
	DILANTIN	00071000724	0.249	0.249	0.205	21%	0.267	0.267	0.212	26%	0.285	0.280	0.218	28%
	DILANTIN	00071036224	0.278	0.278	0.232	20%	0.299	0.299	0.238	25%	0.318	0.314	0.249	26%
	DILANTIN	00071036232	0.278	0.278	0.230	21%	0.299	0.299	0.237	26%	0.318	0.314	0.246	27%
	DILANTIN	00071036524	0.240	0.240	0.199	20%	0.258	0.258	0.205	25%	0.275	0.270	0.213	27%
	DILANTIN-125	00071221420	0.152	0.152	0.125	22%	0.164	0.163	0.128	27%	0.174	0.172	0.133	29%
	GEODON	00049396060	4.063	4.063	3.245	25%	4.286	4.175	3.322	26%	4.470	4.470	3.514	27%
	GEODON	00049397060	4.063	4.063	3.241	25%	4.286	4.175	3.327	26%	4.470	4.470	3.520	27%
	GEODON	00049398060	4.063	4.063	3.253	25%	4.286	4.175	3.333	25%	4.868	4.659	3.653	28%
	GEODON	00049399060	4.063	4.063	3.253	25%	4.286	4.175	3.334	25%	4.868	4.659	3.647	28%
	GLUCOTROL XL	00049155066	0.367	0.366	0.292	25%	0.403	0.391	0.310	26%	0.452	0.439	0.345	27%
	GLUCOTROL XL	00049155073	0.367	0.366	0.292	25%	0.403	0.391	0.310	26%	0.452	0.439	0.345	27%
	GLUCOTROL XL	00049156066	0.725	0.725	0.578	25%	0.797	0.774	0.614	26%	0.898	0.869	0.684	27%
	GLUCOTROL XL	00049156073	0.725	0.725	0.576	26%	0.797	0.774	0.612	26%	0.898	0.869	0.684	27%
	LIPITOR	00071015523	2.034	2.033	1.666	20%	2.309	2.309	1.830	26%	2.471	2.426	1.917	27%
	LIPITOR	00071015534	2.034	2.033	1.690	20%	2.309	2.308	1.832	26%	2.471	2.426	1.929	26%
	LIPITOR	00071015540	2.136	2.134	1.741	23%	2.425	2.424	1.807	34%	2.595	2.548	1.889	35%
	LIPITOR	00071015623	3.144	3.143	2.610	20%	3.441	3.407	2.706	26%	3.644	3.643	2.880	27%
	LIPITOR	00071015723	3.498	3.498	2.908	20%	3.644	3.643	2.899	26%	3.644	3.644	2.888	26%
	LIPITOR	00071015773									3.644	3.644		
	LIPITOR	00071015823	3.498	3.498	2.911	20%	3.644	3.643	2.901	26%	3.644	3.644	2.890	26%
	NAVANE	00049577066	1.653	1.652	1.489	24%	1.909	1.908	1.532	25%	2.037	2.006	1.601	25%
	NEURONTIN	00071040124												
	NEURONTIN	00071041624	2.036	2.035	1.691	20%	2.185	2.184	1.736	26%	2.390	2.283	1.804	27%
	NEURONTIN	00071042624	2.444	2.442	2.031	20%	2.622	2.621	2.085	26%	2.868	2.739	2.164	27%
	NEURONTIN	00071051324												
	NEURONTIN	00071080324	0.479	0.479	0.397	21%	0.530	0.522	0.413	26%	0.555	0.565	0.437	27%
	NEURONTIN	00071080524	1.198	1.197	0.993	21%	1.324	1.304	1.035	26%	1.390	1.390	1.097	27%
	NEURONTIN	00071080540	1.310	1.309	1.088	20%	1.448	1.427	1.104	29%	1.520	1.520	1.140	33%
	NEURONTIN	00071080624	1.437	1.437	1.192	21%	1.588	1.565	1.241	26%	1.668	1.668	1.314	27%
	NEURONTIN	00071080640	1.521	1.520	1.243	22%	1.681	1.657	1.283	29%	1.765	1.765	1.321	34%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
PFIZER	NEURONTIN	00071201223	0.208	0.208	0.165	23%	0.214	0.214	0.170	26%	0.221	0.221	0.174	27%
	NITROSTAT	00071057013	0.195	0.195			0.209	0.209			0.225	0.221		
	NORVASC	00069152068	1.408	1.408	1.118	26%	1.451	1.451	1.147	26%	1.564	1.542	1.212	27%
	NORVASC	00069153068	1.409	1.408	1.121	26%	1.451	1.451	1.154	25%	1.564	1.542	1.219	26%
	NORVASC	00069153072	1.381	1.380	1.097	26%	1.422	1.422	1.127	26%	1.553	1.511	1.190	27%
	NORVASC	00069154068	2.174	2.174	1.734	25%	2.174	2.174	1.728	26%	2.174	2.174	1.723	25%
	RESCRIPTOR	63010002118					1.758	1.758	1.456	21%	1.758	1.758	1.437	22%
	REZULIN	00071035215	2.976	2.976			2.976	2.976			2.976	2.976		
	REZULIN	00071035223	2.976	2.976			2.976	2.976			2.976	2.976		
	REZULIN	00071035315	4.740	4.740			4.740	4.740			4.740	4.740		
	REZULIN	00071035323	4.740	4.740			4.740	4.740			4.740	4.740		
	REZULIN	00071035720	2.976	2.976			2.976	2.976			2.976	2.976		
	VIRACEPT	63010001027	2.328	2.327	1.880	24%	2.328	2.328			2.328	2.328		
	VIRACEPT	63010001050	2.328	2.327	1.934	20%	2.522	2.522	2.012	25%	2.522	2.522	2.000	26%
	VIRACEPT	63010002770												
	ZANTAC 75	00501520020	0.361	0.361			0.361	0.361			0.361	0.361		
	ZANTAC 75	00501520060	0.270	0.270			0.270	0.270			0.270	0.270		
	ZITHROMAX	00069306030	6.972	6.968	5.647	26%	7.325	7.253	5.753	26%	7.845	7.705	6.079	27%
	ZITHROMAX	00069306075	6.973	6.969	5.554	25%	7.325	7.253	5.760	26%	7.947	7.706	6.105	26%
	ZITHROMAX	00069308030	16.730	16.720	13.208	27%	17.576	17.404	13.720	27%	18.828	18.493	14.461	28%
	ZOLOFT	00049490041	2.417	2.415	1.829	32%	2.521	2.520	1.872	35%	2.726	2.684	1.850	38%
	ZOLOFT	00049490066	2.417	2.415	1.825	25%	2.521	2.520	2.002	25%	2.726	2.684	2.124	26%
	ZOLOFT	00049490073	2.416	2.415	1.891	28%	2.521	2.520	1.866	28%	2.726	2.684	2.090	28%
	ZOLOFT	00049491066	2.487	2.485	1.861	25%	2.521	2.521	2.004	26%	2.726	2.684	2.124	26%
	ZOLOFT	00049491073	2.487	2.485	1.847	28%	2.521	2.521	1.873	28%	2.726	2.684	2.093	28%
	ZOLOFT	00049496050	2.340	2.339	1.823	28%	2.521	2.520	1.846	28%	2.725	2.684	2.078	29%
	ZYRTEC	00069561066	1.979	1.978	1.576	26%	2.038	2.038	1.621	26%	2.110	2.109	1.571	26%
PHARMACIA	AMBIEN	00025540131	1.913	1.897	1.575	20%	2.076	2.062	1.717	20%	2.076	2.076	1.779	17%
	AMBIEN	00025542131	2.353	2.334	1.838	20%	2.653	2.536	2.104	21%	2.653	2.653		
	AROMASIN	00009766304	7.688	7.274	5.438	25%	8.180	7.850	6.346	25%	8.180	8.180	6.634	25%
	ARTHROTEC 50	00025141160	1.635	1.599	1.329	20%	1.821	1.749	1.412	24%	1.912	1.864	1.477	26%
	ARTHROTEC 50	00025141190	1.635	1.599	1.328	20%	1.821	1.749	1.410	24%	1.912	1.864	1.476	26%
	ARTHROTEC 75	00025142160	1.635	1.599	1.330	20%	1.821	1.749	1.413	24%	1.912	1.864	1.479	26%
	BEXTRA	00025197531					3.049	2.934	2.336	25%	3.141	3.093	2.459	26%
	BEXTRA	00025198031					3.049	2.934	2.345	25%	3.141	3.093	2.460	26%
	CAMPTOSAR	00009752901	148.705	139.852	109.374	26%	159.808	153.693	121.780	26%	167.838	163.539	127.874	24%
	CAMPTOSAR	00009752902												
	CELEBREX	00025152031	1.642	1.508	1.244	21%	1.766	1.657	1.317	26%	1.808	1.781	1.411	26%
	CELEBREX	00025152051	1.642	1.508	1.238	22%	1.786	1.657	1.313	26%	1.808	1.781	1.406	27%
	CELEBREX	00025152531	2.753	2.549	2.106	21%	2.880	2.770	2.206	26%	2.966	2.921	2.320	26%
	CELEBREX	00025152551	2.753	2.549	2.101	21%	2.878	2.770	2.200	26%	2.966	2.921	2.311	26%
	CLINDAMYCIN HCL	59762332801	1.191	1.191	0.220	441%	1.191	1.191	0.200	495%	1.191	1.191	0.179	564%
	COVERA-HS	00025201131	1.394	1.361	1.124	21%	1.538	1.482	1.180	25%	1.629	1.581	1.252	28%
	COVERA-HS	00025202131	1.911	1.866	1.545	21%	2.150	2.053	1.654	25%	2.288	2.221	1.734	28%
	CYTOTEC	00025145120	0.804	0.773	0.644	20%	0.921	0.875	0.705	24%	0.921	0.921	0.732	26%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
PHARMACIA	CYTOTEC	00025146131	1.171	1.126	0.937	20%	1.341	1.275	1.021	25%	1.341	1.341	1.066	26%
	DEPO-PROVERA	00009074630	53.538	52.455	41.835	25%	56.110	55.109	43.982	25%	57.600	56.916	44.870	27%
	DETROL	00009454102	1.478	1.400	1.106	27%	1.683	1.602	1.260	27%	1.804	1.783	1.408	27%
	DETROL	00009454402	1.517	1.436	1.137	25%	1.727	1.644	1.297	27%	1.852	1.830	1.448	27%
	DETROL	00009454403	1.517	1.436	1.123	28%	1.727	1.643	1.279	29%	1.851	1.830	1.436	27%
	DETROL LA	00009519001	2.725	2.725	2.181	25%	2.858	2.835	2.263	26%	2.999	2.974	2.357	26%
	DETROL LA	00009519101	2.797	2.797	2.233	25%	2.834	2.809	2.318	25%	3.078	3.052	2.421	26%
	DETROL LA	00009519102	2.797	2.797	2.238	25%	2.834	2.809	2.318	25%	3.078	3.052	2.418	26%
	DETROL LA	00009519103	2.797	2.797	2.238	25%	2.934	2.909	2.325	25%	3.077	3.052	2.415	26%
	DOSTINEX	00013700112	32.869	32.204	25.740	25%	35.138	34.265	27.338	25%	35.138	35.138	27.928	26%
	GABAPENTIN	59762502301												
	GENOTROPIN	00013264681	591.250	604.757	427.361	42%	675.600	671.162	452.478	25%	604.280	599.234	478.601	25%
	GLYBURIDE	59762372603	0.459	0.459	0.076	505%	0.459	0.459	0.073	528%	0.459	0.459	0.066	595%
	GLYBURIDE	59762372704	0.777	0.777	0.105	639%	0.777	0.777	0.095	705%	0.777	0.777	0.097	799%
	GLYBURIDE	59762372705	0.683	0.683	0.107	540%	0.683	0.683	0.096	613%	0.683	0.683	0.086	695%
	GLYBURIDE	59762372707	0.661	0.661	0.103	540%	0.661	0.661	0.090	631%	0.661	0.661	0.084	689%
	GLYBURIDE MICRONIZED	59762378301	1.073	1.073	0.166	470%	1.073	1.073	0.164	554%	1.073	1.073	0.137	683%
	GLYBURIDE MICRONIZED	59762378302	0.951	0.951	0.178	435%	0.951	0.951	0.191	398%	0.951	0.951	0.109	781%
	MEDROXYPROGESTERONE ACETA	59762374801	0.298	0.298	0.069	334%	0.298	0.298	0.052	478%	0.298	0.298	0.051	488%
	MIRAPEX	00009000402	1.137	1.081	0.661	26%	1.251	1.175	0.935	26%	1.314	1.281	1.016	26%
	NYCOBUTIN	00013530117	5.722	5.503	4.404	25%	6.288	6.068	4.770	27%	6.540	6.408	4.720	36%
	VANTIN	00009381802	4.536	4.394	3.401	29%	4.845	4.672	3.793	28%	5.395	5.307	4.119	29%
	XALATAN	00013830304	20.020	18.905	15.875	25%	21.200	20.890	16.714	26%	22.240	22.058	17.472	26%
	ZYVOX	00008513502	56.313	54.959	43.987	25%	59.635	58.342	40.626	25%	63.154	61.313	46.860	26%
PUREPAC	DILTIAZEM HCL	00228257709	1.446	1.434	0.788	82%	1.446	1.446	0.764	85%	1.446	1.446	0.756	91%
	DILTIAZEM HCL	00228257809	2.051	2.035	1.114	83%	2.051	2.051	1.074	91%	2.051	2.051	1.051	95%
	DILTIAZEM HCL	00228257909	2.658	2.637	1.446	82%	2.658	2.658	1.378	93%	2.658	2.658	1.358	96%
	DILTIAZEM HCL	00228258809	1.198	1.188	0.653	82%	1.198	1.198	0.631	90%	1.198	1.198	0.628	91%
	GABAPENTIN	00228263611												
	GABAPENTIN	00228263650												
	GABAPENTIN	00228263711												
	GABAPENTIN	00228266511												
	GABAPENTIN	00228266611												
	GABAPENTIN	00228266650												
	GABAPENTIN	00228266711												
	ISOSORBIDE MONONITRATE	00228271311	1.291	1.291	0.285	352%	1.448	1.360	0.202	573%	1.448	1.448	0.274	429%
	ISOSORBIDE MONONITRATE	00228271360	1.083	1.083	0.213	413%	1.448	1.248	0.141	704%	1.448	1.448	0.096	1389%
	LOVASTATIN	00228253506	4.268	4.268	1.359	214%	4.268	4.268	1.688	153%	4.268	4.268	2.969	66%
ROCHE	ACCUTANE	00004015649	10.347	9.770	8.076	21%	10.778	10.694	8.572	25%	13.015	11.345	8.938	27%
	CELLCEPT	00004025901	2.658	2.626	2.101	20%	2.836	2.811	2.256	25%	3.082	3.053	2.424	26%
	CELLCEPT	00004025943	2.658	2.626	2.081	21%	2.835	2.810	2.240	25%	3.082	3.053	2.409	27%
	CELLCEPT	00004026001	5.316	5.052	4.205	20%	5.870	5.621	4.510	25%	6.164	6.106	4.841	26%
	CELLCEPT	00004026043	5.316	5.052	4.206	20%	5.870	5.621	4.515	25%	6.180	6.105	4.774	28%
	COPEGUS	00004008694					6.330	6.330			6.646	6.365	5.002	27%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ROCHE	CYTOVENE	00004028848	4.625	4.281	3.565	20%	4.618	4.780	3.842	24%	5.010	4.872	3.923	27%
	CYTOVENE	00004027848	9.250	8.563	7.118	20%	9.635	9.560	7.652	25%	10.020	9.944	7.899	26%
	FORTOVASE	00004024648	1.335	1.236	1.025	21%	1.391	1.380	1.107	25%	1.391	1.391	1.102	26%
	FUZEON	00004098059									2082.290	2082.290		
	HIVID	00004022101	2.730	2.597	2.160	20%	2.844	2.822	2.275	24%	2.844	2.844	2.268	25%
	INVIRASE	00004024515	2.356	2.388	1.979	21%	2.496	2.477	1.985	25%	2.496	2.496	1.976	26%
	KLONOPIN	00004005801	0.957	0.960	0.783	23%	1.098	1.072	0.859	25%	1.255	1.173	0.924	27%
	KLONOPIN	00004006801	0.848	0.842	0.700	20%	0.963	0.940	0.753	25%	1.101	1.028	0.810	27%
	KLONOPIN	00004009801	1.340	1.330	1.108	20%	1.521	1.486	1.192	25%	1.739	1.625	1.294	26%
	KYTRIL	00004029909			139.807		195.200	193.716	114.979	68%	195.200	195.200	114.595	70%
	KYTRIL	00004024009	187.392	187.392	138.559	35%	195.200	193.681	92.775	108%	195.200	195.200	111.144	76%
	KYTRIL	00004024126			37.198		47.043	47.043	37.242	26%	47.043	47.043	37.159	27%
	KYTRIL	00004024208												
	PEGASYS	00004035009					363.750	363.750	289.287	26%	381.940	369.195	290.214	26%
	PEGASYS	00004035039									1527.750	1480.926	1152.365	27%
	PEGASYS	00004035239												
	ROCALTROL	00004014301	1.344	1.334	1.107	21%	1.400	1.389	1.121	24%	1.400	1.400	1.114	26%
	ROCEPHIN	00004196401	49.067	48.631	40.032	22%	51.111	50.714	40.430	25%	51.111	51.111	39.981	28%
	ROCEPHIN	00004196501	97.502	97.034	78.657	23%	101.565	100.776	79.948	26%	101.565	101.565	80.024	27%
	ROCEPHIN	00004197101	478.320	476.020	387.373	23%	498.250	494.373	385.550	28%	498.250	498.250	392.381	27%
	ROCEPHIN/ISO-OSMOTIC DEXT	00004200278	0.804	0.804	0.445	81%	0.804	0.804			0.804	0.804		
	SORIATANE	00004021457	11.708	11.686	9.572	21%	11.708	11.708	9.716	21%	11.708	11.708	10.550	11%
	SORIATANE	00004028957	12.294	11.747	9.773	20%	13.446	13.222	10.587	25%	15.531	14.663	11.557	27%
	TAMIFLU	00004080085	6.312	6.041	5.034	20%	6.970	6.674	5.317	26%	6.970	6.970	5.542	26%
	TASMAR	00004592001	2.429	2.220	1.846	20%	2.530	2.510	2.026	24%	2.630	2.530	2.018	25%
	TICLID	00004001814	2.372	2.355	1.894	24%	2.471	2.452	1.957	25%	2.471	2.471	1.946	27%
	TICLID	00004001822	2.379	2.357	1.955	21%	2.472	2.453	1.974	24%	2.472	2.472	1.962	26%
	VALCYTE	00004003822	28.776	28.776	23.941	20%	29.975	29.742	23.913	24%	31.474	30.094	23.931	26%
	VESANOID	00004025001	15.132	13.955	11.645	20%	17.874	16.772	13.501	24%	18.768	18.692	14.607	28%
	XELODA	00004110116	9.393	8.478	7.058	20%	12.378	10.718	8.507	25%	13.121	12.734	10.089	26%
	XELODA	00004110150									13.121	13.121		
	XENICAL	00004025652	1.320	1.320	1.100	20%	1.375	1.364	1.096	24%	1.513	1.386	1.100	26%
ROXANE	AZATHIOPRINE	00054408425	1.311	1.311	0.383	242%	1.311	1.311	0.334	292%	1.311	1.311	0.314	317%
	CALCIUM CARBONATE	00054311763	0.019	0.019	0.014	33%	0.019	0.019	0.014	32%	0.025	0.022	0.017	31%
	IPRATROPIUM BROMIDE	00054840211	0.705	0.705	0.159	345%	0.705	0.705	0.132	433%	0.705	0.705	0.143	393%
	LITHIUM CARBONATE	00054252725	0.175	0.175	0.141	24%	0.175	0.175	0.118	47%	0.175	0.175	0.082	112%
	LITHIUM CARBONATE	00054252751	0.162	0.162	0.129	25%	0.162	0.162	0.104	55%	0.162	0.162	0.075	117%
	MARINOL	00054260125	3.352	3.352			3.352	3.352			3.352	3.352		
	MARINOL	00054260225	6.631	6.631	5.140	29%	6.631	6.631			6.631	6.631		
	MARINOL	00054260311	14.936	14.936	11.766	27%	14.936	14.936			14.936	14.936		
	MEGESTROL ACETATE	00054354258					0.600	0.600	0.356	69%	0.600	0.600	0.347	73%
	METHADONE HCL	00054457125	0.147	0.147	0.108	37%	0.147	0.147	0.102	44%	0.147	0.147	0.089	65%
	MORPHINE SULFATE	00054458325	0.312	0.312	0.114	175%	0.312	0.312	0.114	175%	0.312	0.312	0.114	174%
	ORAMORPH SR	00054470325	5.112	5.111	3.145	63%	5.112	5.112	3.177	61%	5.112	5.112	3.502	46%
	ORAMORPH SR	00054480525	1.711	1.711	1.023	67%	1.711	1.711	1.057	62%	1.711	1.711	1.132	51%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
ROXANE	OXYCODONE W/ACETAMINOPHEN	00054279525	0.577	0.577	0.138	320%	0.577	0.577	0.138	318%	0.577	0.577	0.123	370%
	ROXICODONE	00054465726	0.310	0.310	0.187	66%	0.310	0.310	0.207	50%	0.310	0.310	0.244	27%
	ROXICODONE	00054465825	1.100	1.100	0.577	91%	0.749	0.912	0.595	53%	0.749	0.749	0.595	26%
	ROXICODONE	00054465525	2.120	2.120	1.116	90%	1.444	1.757	1.144	54%	1.444	1.444	1.148	26%
	SODIUM POLYSTYRENE SULFON	00054380563	0.096	0.095	0.036	166%	0.096	0.096	0.042	128%	0.096	0.096	0.043	125%
	VIBAMUNE	00054454725	5.314	5.217	4.316	21%	5.314	5.314	4.491	18%	5.314	5.314		
SANDOZ	ALPRAZOLAM	00781107705	0.781	0.701	0.015	4480%	0.761	0.761	0.020	3744%	0.844	0.840	0.047	1704%
	ALPRAZOLAM	00781107905	0.964	0.923	0.018	5099%	0.964	0.964	0.024	3942%	1.127	1.116	0.051	2110%
	ALPRAZOLAM	00781108901	1.696	1.672	0.061	2632%	1.696	1.696	0.109	1456%	1.965	1.950	0.123	1490%
	AMIODARONE HCL	00185014460	3.382	3.354			3.382	3.382			3.382	3.382		
	AMIODARONE HCL	00781120360	3.299	3.299	0.469	604%	3.299	3.299	0.472	586%	3.299	3.299	0.492	670%
	AUGX TB/POTASSIUM CLAVULA	66685100100									5.052	5.052		
	ATENOLOL	00781107801	0.703	0.703	0.018	3823%	0.815	0.725	0.023	2996%	0.818	0.816	0.046	1678%
	ATENOLOL	00781107810	0.665	0.665	0.016	3944%	0.777	0.667	0.021	3180%	0.777	0.777	0.045	1812%
	ATENOLOL	00781150610	0.685	0.685	0.016	4367%	0.792	0.706	0.023	2991%	0.792	0.792	0.046	1626%
	ATENOLOL	00781150701	1.039	1.039	0.032	3160%	1.252	1.080	0.050	2070%	1.252	1.252	0.094	1228%
	BROMOCRIPTINE MESYLATE	68818590500					2.333	2.257			2.333	2.333		
	BUPROPION HCL	00185041580												
	CHOLESTYRAMINE	00185094097	0.116	0.116			0.147	0.125			0.147	0.147		
	CIMETIDINE	00781144905	1.434	1.434			1.434	1.434			1.434	1.434		
	CITALOPRAM	00185037201												
	CLINDAMYCIN HCL	00781211301												
	CLONAZEPAM	00185006301	0.714	0.714			0.714	0.714			0.714	0.714		
	CLONAZEPAM	00185006401	0.814	0.814			0.814	0.814			0.814	0.814		
	CLONAZEPAM	00185006405	0.733	0.733			0.733	0.733			0.733	0.733		
	CLONAZEPAM	00185006501	1.128	1.128			1.128	1.128			1.128	1.128		
	DICLOFENAC SODIUM	00781178701	0.907	0.907	0.089	920%	0.907	0.907	0.078	1058%	1.154	0.872	0.098	890%
	DICLOFENAC SODIUM	00781178801	1.065	1.065	0.096	1005%	1.065	1.065	0.086	1142%	1.410	1.162	0.125	825%
	FENTANYL	00781711455												
	FLUOXETINE HCL	00781282201					2.665	2.665	0.413	646%	2.685	2.685	0.276	858%
	FLUOXETINE HCL	00781282301	2.598	2.598	1.724	51%	2.598	2.598	1.003	159%	2.598	2.598	0.217	1100%
	FLUOXETINE HCL	00781282401					5.331	5.331			5.331	5.331	1.799	186%
	FLUVOXAMINE MALEATE	00781504201	2.639	2.639	1.134	133%	2.639	2.639	0.683	287%	2.639	2.639	0.568	365%
	FUROSEMIDE	00781181810	0.123	0.123	0.017	616%	0.123	0.123	0.025	381%	0.123	0.123	0.031	290%
	FUROSEMIDE	00781198610	0.140	0.140	0.021	558%	0.140	0.140	0.029	392%	0.140	0.140	0.033	390%
	GLYBURIDE	00781119110					0.738	0.738			0.738	0.738	0.063	1063%
	GLYBURIDE	00781145710	0.440	0.440			0.440	0.440			0.440	0.440		
	HALOPERIDOL	00781139701	0.715	0.715	0.074	870%	1.310	0.749	0.089	747%	1.310	1.310	0.979	34%
	HYDROXYCHLOROQUINE SULFAT	00781140701	1.096	1.096	0.215	410%	1.096	1.096	0.218	402%	1.096	1.096	0.232	372%
	LISINOPRIL	00185010101					1.004	1.004			1.004	1.004		
	LISINOPRIL	00185010110					1.004	1.004			1.004	1.004		
	LISINOPRIL	00185010201					1.075	1.075			1.075	1.075		
	LISINOPRIL	00185010210					1.075	1.075			1.075	1.075		
	LISINOPRIL	00185010401					1.572	1.572			1.572	1.572		
	LISINOPRIL	00185010410					1.572	1.572			1.572	1.572		

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
SANDOZ	LISINOPRIL	00185540001					0.973	0.973			0.973	0.973		
	LISINOPRIL	00185540010					0.973	0.973			0.973	0.973		
	LORAZEPAM	00781140305	0.625	0.625	0.073	762%	0.625	0.625	0.060	943%	0.625	0.625	0.055	1024%
	LORAZEPAM	00781140401	0.838	0.838	0.094	788%	0.838	0.838	0.079	964%	0.838	0.838	0.074	1039%
	LORAZEPAM	00781140405	0.810	0.810	0.081	902%	0.810	0.810	0.055	1720%	0.810	0.810	0.063	1180%
	LORAZEPAM	00781140501	1.221	1.221	0.146	737%	1.221	1.221	0.118	933%	1.221	1.221	0.107	1046%
	LOVASTATIN	00185007201	2.373	2.373			2.373	2.373			2.373	2.373		
	LOVASTATIN	00185007210	2.373	2.373			2.373	2.373			2.373	2.373		
	LOVASTATIN	00185007401	4.721	4.721			4.721	4.721			4.721	4.721		
	LOVASTATIN	00185007410	4.271	4.271			4.271	4.271			4.271	4.271		
	LOVASTATIN	00185007460	4.271	4.271			4.271	4.271			4.271	4.271		
	LOVASTATIN	00781121060	2.370	2.370	0.841	182%	2.370	2.370	0.613	287%	2.370	2.370	0.550	331%
	LOVASTATIN	00781121360	4.267	4.267	1.510	183%	4.267	4.267	1.132	277%	4.267	4.267	0.977	337%
	LOVASTATIN	00781132360	1.344	1.344	0.485	177%	1.344	1.344	0.364	269%	1.344	1.344	0.321	318%
	METOPROLOL TARTRATE	00781122310	0.487	0.487	0.032	1422%	0.527	0.494	0.025	2058%	0.527	0.527	0.030	1653%
	MIDODRINE HCL	00185004301									2.421	2.421		
	NAPROXEN	00781116505	1.126	1.126	0.076	1375%	1.126	1.126	0.155	627%	1.126	1.126	0.131	760%
	PENICILLIN V POTASSIUM	00781165510	0.085	0.085			0.379	0.148	0.103	43%	0.379	0.379	0.175	116%
	PERPHENAZINE	00781104601	0.779	0.779	0.149	423%	0.779	0.779	0.099	684%	1.142	1.081	0.391	176%
	PROMETHAZINE HCL	00781183001	0.170	0.140	0.073	92%	0.506	0.384	0.210	73%	0.506	0.506	0.362	40%
	PROMETHAZINE HCL	00781183010	0.086	0.073	0.054	34%	0.481	0.331	0.169	96%	0.481	0.481	0.336	43%
	PROMETHAZINE HCL	00781183201	0.272	0.223	0.155	44%	0.776	0.549	0.357	54%	0.776	0.776	0.584	33%
	RANITIDINE HCL	00781188310	1.480	1.480	0.042	3469%	1.480	1.480	0.071	1974%	1.480	1.480	0.076	1848%
	SOTALOL	00185017101	2.563	2.487			2.563	2.563			2.563	2.563		
	TERAZOSIN HCL	00781205101	1.604	1.604	0.178	800%	1.604	1.604	0.145	1006%	1.604	1.604	0.129	1145%
	TERAZOSIN HCL	00781205201	1.604	1.604	0.177	805%	1.604	1.604	0.144	1011%	1.604	1.604	0.129	1142%
	TERAZOSIN HCL	00781205301	1.604	1.604	0.177	805%	1.604	1.604	0.144	1011%	1.604	1.604	0.128	1150%
	TERAZOSIN HCL	00781205401	1.604	1.604	0.177	805%	1.604	1.604	0.157	925%	1.604	1.604	0.128	1148%
	TIZANIDINE HCL	00185440051					1.465	1.465			1.465	1.465		
	TRIAMTERENE W/HCTZ	00781207410	0.361	0.361	0.054	574%	0.361	0.361	0.049	640%	0.361	0.361	0.045	692%
	TRIFLUOPERAZINE HCL	00781103601	1.522	1.522	0.169	801%	1.522	1.522	0.143	965%	1.585	1.574	0.584	170%
SCHERING	AVELOX	00085173301			7.131				7.486				7.759	
	DIPROLENE AF	00085051704	1.566	1.532	1.264	21%	1.729	1.675	1.301	21%	1.897	1.834	1.448	27%
	ELOCON	00085052506	2.394	2.313	1.872	24%	2.569	2.541	2.014	26%	2.569	2.569	2.040	26%
	INDUR	00085330603	1.627	1.560	1.267	23%	1.834	1.759	1.405	25%	1.926	1.812	1.515	26%
	INDUR	00085411003	1.713	1.640	1.340	22%	1.931	1.851	1.448	28%	2.027	2.012	1.586	31%
	INTRON A	00085125401	568.392	552.797	457.239	21%	622.039	580.583	475.488	22%	652.507	646.579	510.465	27%
	K-DUR	00085078701	0.585	0.563	0.462	22%	0.585	0.585	0.485	21%	0.640	0.631	0.602	26%
	K-DUR	00085078705	0.580	0.559	0.461	21%	0.580	0.580	0.479	21%	0.634	0.625	0.494	27%
	MASONEX	00085119701	3.520	3.361	2.785	21%	4.043	3.829	3.056	25%	4.246	4.213	3.338	28%
	MASONEX	00085128801												
	PEG-INTRON	00085127901	286.932	279.447	232.806	20%	372.860	321.021	262.847	22%	406.930	396.874	311.441	27%
	PEG-INTRON	00085129101	260.266	253.472	211.031	20%	338.190	291.180	236.965	23%	369.090	360.081	284.041	27%
	PEG-INTRON	00085130401	273.276	266.146	221.556	20%	355.100	305.738	250.909	22%	387.560	378.077	298.744	27%
	PEG-INTRON REDIPEN	00085129701												

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
SCHERING	PEG-INTRON REDIPEN	00085137001												
	PROVENTIL	00085043102	0.878	0.044	0.696	21%	0.878	0.878	0.725	21%	0.878	0.878		
	REBETOL	00085119403	9.840	9.840	8.179	20%	11.038	10.622	8.467	24%	11.038	11.038	8.692	27%
	REBETOL	00085195105	9.840	9.840	8.199	20%	11.038	10.622	8.507	24%	11.038	11.038	8.698	27%
	REBETOL	00085138507	9.840	9.840	8.193	20%	11.038	10.622	8.480	24%	11.038	11.038	8.666	27%
	REBETRON 1000	00085125802	804.324	749.631	616.114	22%	804.324	804.324	671.000	20%	804.324	804.324	666.837	21%
	REBETRON 1200	00085124101	888.756	828.328	681.406	22%	888.756	888.756	733.148	21%	888.756	888.756		
	REBETRON 1200	00085125801	888.756	828.328	682.450	21%	888.756	888.756	741.105	20%	888.756	888.756	737.229	21%
	TEUDAR	00085125901	133.788	127.720	105.637	20%	153.670	145.535	117.220	24%	161.352	160.152	127.417	26%
	TEUDAR	00085125902	133.789	127.721	107.253	19%	153.673	145.536	117.850	23%	161.357	160.157	127.252	26%
	VANCENASE AQ	00085104901	3.038	3.038	2.525	20%	3.038	3.038	.		3.038	3.038		
	VANCERIL	00085073604	2.769	2.640	2.167	21%	2.971	2.936	2.356	25%	2.971	2.971	2.344	27%
SICOR	CARBOPLATIN	00703324411												
	CARBOPLATIN	00703324511												
	CARBOPLATIN	00703324811												
	CARBOPLATIN	00703326401												
	CARBOPLATIN	00703326501												
	CARBOPLATIN	00703326601												
	HALOPERIDOL DECANOATE	00703702301	28.800	33.416	17.676	89%	28.800	28.800	10.849	165%	28.800	28.800	9.442	205%
	PAMIDRONATE DISODIUM	00703407519												
	PAMIDRONATE DISODIUM	00703408511												
	PAMIDRONATE DISODIUM	00703408591												
TAP	PREVACID	00300154130	4.067	3.999	3.289	22%	4.543	4.384	3.446	27%	4.679	4.619	3.616	28%
	PREVACID	00300304613	4.144	4.076	3.364	21%	4.629	4.467	3.526	27%	4.768	4.707	3.695	27%
	PREVACID	00300304619	4.144	4.076	3.187	28%	4.629	4.467	3.334	34%	4.768	4.707	3.464	36%
	PREVPAC	00300370201	19.254	18.934	15.440	23%	21.066	20.332	16.220	25%	21.699	21.420	17.022	26%
TEVA	ACETAMINOPHEN W/CODEINE	00093015010	0.284	0.280	0.073	285%	0.284	0.284	0.122	132%	0.284	0.284	0.114	149%
	ACETAMINOPHEN W/CODEINE	00093035001	0.639	0.623	0.168	271%	0.639	0.639	0.250	155%	0.639	0.639	0.233	174%
	ACETAMINOPHEN W/CODEINE	00093035005	0.552	0.542	0.155	251%	0.552	0.552	0.235	135%	0.552	0.552	0.231	139%
	AMIODARONE HCL	00093913306	3.303	3.303	0.494	568%	3.303	3.303	0.437	655%	3.303	3.303	0.470	603%
	AMOX TR/POTASSIUM CLAVULA	00093227434					3.785	3.785	2.612	45%	3.785	3.785	2.548	49%
	AMOX TR/POTASSIUM CLAVULA	00093227534					5.052	5.052	3.478	45%	5.052	5.052	3.349	51%
	AMOXICILLIN	00093310905	0.369	0.369	0.045	727%	0.369	0.369	0.050	630%	0.369	0.369	0.055	675%
	BUDEPRION SR	00093550201												
	CALCITRIOL	00093065701	1.210	1.210	0.908	33%	1.210	1.210	0.889	36%	1.210	1.210	0.869	39%
	CALCITRIOL	00093065801	1.934	1.934	1.441	34%	1.934	1.934	1.427	35%	1.934	1.934	1.392	38%
	CARBIDOPA/LEVODOPA	00093029301	0.800	0.787	0.181	311%	0.800	0.800	0.297	170%	0.800	0.800	0.297	175%
	CARBIDOPA/LEVODOPA	00093029310	0.760	0.746	0.208	258%	0.760	0.760	0.255	198%	0.760	0.760	0.269	194%
	CEPHALEXIN	00093314701	1.260	1.260	0.087	1351%	1.378	1.357	0.210	546%	1.376	1.378	0.246	458%
	CEPHALEXIN	00093314705	1.114	1.114	0.076	1353%	1.226	1.206	0.186	549%	1.226	1.226	0.246	398%
	CLONAZEPAM	00093083201	0.749	0.749	0.050	1407%	0.749	0.749	0.053	1303%	0.749	0.749	0.051	1372%
	CLONAZEPAM	00093083301	0.855	0.855	0.063	1265%	0.855	0.855	0.064	1232%	0.855	0.855	0.062	1280%
	CLONAZEPAM	00093083401	1.184	1.184	0.104	1033%	1.184	1.184	0.118	900%	1.184	1.184	0.094	1162%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
TEVA	DILTIAZEM HCL	00093511298	1.198	1.170	0.656	78%	1.198	1.198	0.622	93%	1.198	1.198	0.614	95%
	DILTIAZEM HCL	00093511708	1.446	1.411	0.793	78%	1.446	1.446	0.752	92%	1.446	1.446	0.742	95%
	DILTIAZEM HCL	00093511898	2.051	2.002	1.126	78%	2.051	2.051	1.094	88%	2.051	2.051	1.058	94%
	DILTIAZEM HCL	00093511998	2.658	2.595	1.459	78%	2.658	2.658	1.389	91%	2.658	2.658	1.364	95%
	FLUCONAZOLE	00093720556												
	GABAPENTIN	00093103301												
	GABAPENTIN	00093103905												
	GABAPENTIN	00093104001												
	GABAPENTIN	00093717301												
	GABAPENTIN	00093717401												
	GEMFIBROZIL	00093067005	1.187	1.187	0.133	790%	1.187	1.187	0.166	616%	1.187	1.187	0.226	425%
	GEMFIBROZIL	00093067005	1.247	1.247	0.146	754%	1.247	1.247	0.176	607%	1.247	1.247	0.242	416%
	GLYBURIDE	00093934410	0.661	0.661	0.102	549%	0.661	0.661	0.101	552%	0.661	0.661	0.097	627%
	GLYBURIDE	00093936410	0.661	0.661	0.106	526%	0.661	0.661	0.109	507%	0.661	0.661	0.108	514%
	GLYBURIDE	38245036420	0.661	0.661			0.661	0.661			0.661	0.661		
	GLYBURIDE	55953034480	0.661	0.661	0.095	595%	0.661	0.661	0.088	651%	0.661	0.661		
	KETOCONAZOLE	00093084030	0.923	0.923	0.624	48%	0.923	0.923	0.600	54%	0.923	0.923	0.593	56%
	KETOCONAZOLE	00093084092	0.701	0.701	0.473	48%	0.701	0.701	0.454	55%	0.701	0.701	0.448	57%
	LISINOPRIL	00093111201					0.962	0.962	0.428	125%	0.962	0.962	0.428	125%
	LISINOPRIL	00093111301					0.993	0.993	0.442	125%	0.993	0.993	0.442	125%
	LISINOPRIL	00093111401					1.063	1.063	0.468	127%	1.063	1.063	0.423	151%
	LISINOPRIL	00093111410					1.053	1.053	0.463	127%	1.053	1.053	0.134	885%
	LISINOPRIL	00093111501					1.555	1.555	0.692	125%	1.555	1.555	0.581	168%
	LOVASTATIN	00093092805	4.271	4.271	1.808	137%	4.271	4.271	1.431	198%	4.271	4.271	1.344	218%
	MEGESTROL ACETATE	00093963487									0.600	0.600		
	METFORMIN HCL	00093104801					0.704	0.704	0.423	67%	0.704	0.704	0.137	414%
	METFORMIN HCL	00093104805					0.704	0.704	0.457	54%	0.704	0.704	0.351	101%
	METFORMIN HCL	00093721401									1.461	1.461		
	METOPROLOL TARTRATE	00093073310	0.644	0.615	0.037	1817%	0.644	0.644	0.035	1447%	0.644	0.644	0.035	1457%
	MIRTAZAPINE	00093720656									2.715	2.715	1.744	56%
	MIRTAZAPINE	00093720756									2.797	2.797	1.836	52%
	NUPIRDIN	00093101042									1.943	1.943	1.322	47%
	NIFEDIAC CC	00093102101	1.081	1.081	0.738	47%	1.154	1.109	0.715	55%	1.154	1.154	0.720	60%
	NIFEDIAC CC	00093102201	2.032	2.032	1.404	45%	2.168	2.084	1.307	60%	2.168	2.168	1.307	66%
	NIFEDIAC CC	00093102301					2.565	2.565	1.939	32%	2.565	2.565	1.905	35%
	NIFEDIAC CC	00093527201									1.154	1.154		
	OXYCODONE HCL	00093603301												
	PENTOXIFYLLINE	00093511601	0.595	0.595	0.096	517%	0.595	0.595	0.102	485%	0.595	0.595	0.096	519%
	PENTOXIFYLLINE	38245067210	0.594	0.594			0.594	0.594			0.594	0.594		
	POTASSIUM CHLORIDE	00093531101									0.529	0.529		
	PROPOXYPHENE NAPSYLATE W/	00093089005	0.535	0.535	0.113	374%	0.535	0.535	0.116	361%	0.535	0.535	0.106	406%
	SUCRALFATE	00093221001	0.730	0.730	0.168	334%	0.730	0.730	0.168	333%	0.730	0.730	0.171	327%
	TAMOXIFEN CITRATE	00093078201									3.792	3.792	0.675	462%
	URSODIOL	00093938001	2.578	2.578	1.850	39%	2.578	2.578	1.828	41%	2.578	2.578	1.852	39%
WARRICK	ALBUTEROL	59930156001	1.259	1.259	0.384	228%	1.259	1.259	0.353	257%	1.259	1.259	0.250	405%

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
WARRICK	ALBUTEROL SULFATE	59930150008	0.403	0.403	0.257	57%	0.403	0.403	0.219	84%	0.403	0.403	0.196	106%
	CLOTRIMAZOLE	59930157002	0.447	0.447	0.069	543%	0.447	0.447	0.186	140%	0.447	0.447	0.168	166%
	CLOTRIMAZOLE	59930157003	0.361	0.361	0.087	313%	0.361	0.361	0.136	165%	0.361	0.361	0.145	149%
	ISOSORBIDE MONONITRATE	59930150201	1.116	1.116	0.164	624%	1.116	1.116	0.071	1465%	1.116	1.116	0.055	1938%
	ISOSORBIDE MONONITRATE	59930154901	1.174	1.174	0.084	1292%	1.174	1.174	0.061	1831%	1.174	1.174	0.055	2042%
	POTASSIUM CHLORIDE	59930171401	0.505	0.505	0.283	79%	0.505	0.505	0.247	105%	0.505	0.505	0.200	152%
	POTASSIUM CHLORIDE	59930171402	0.502	0.502	0.268	87%	0.502	0.502	0.214	134%	0.502	0.502	0.175	186%
	POTASSIUM CHLORIDE	59930171403	0.493	0.493	0.258	91%	0.493	0.493	0.206	140%	0.493	0.493	0.150	229%
WATSON	AFEDITAB CR	00591319301									1.258	1.258	0.684	84%
	AFEDITAB CR	00591319401							1.259		2.241	2.241	1.295	73%
	BUPROPION	00591398560												
	BUPROPION HCL	00591083960												
	BUSPIRONE HCL	00591065801			0.849		1.345	1.345	0.209	542%	1.345	1.345	0.089	1413%
	BUSPIRONE HCL	52544065801	1.345	1.345	0.841	60%	1.345	1.345	0.536	151%	1.345	1.345		
	CALCIUM CARBONATE	00536341410	0.016	0.016	0.006	171%	0.016	0.016	0.006	144%	0.016	0.016	0.006	145%
	CARISOPRODOL	00364047502	0.525	0.525	0.065	710%	0.525	0.525	0.051	920%	0.525	0.525		
	CARISOPRODOL	00591551301	0.596	0.342	0.070	391%	0.596	0.596	0.060	887%	0.596	0.596	0.056	991%
	CARISOPRODOL	00591551305	0.573	0.573	0.066	765%	0.573	0.573	0.056	931%	0.573	0.573	0.049	1062%
	CARISOPRODOL	00591551310	0.525	0.525	0.063	731%	0.525	0.525	0.051	929%	0.525	0.525	0.046	1044%
	CLINDAMYCIN HCL	00591312001									3.717	3.717		
	CLONAZEPAM	52544074501	0.749	0.749			0.749	0.749			0.749	0.749		
	CLONAZEPAM	52544074701	0.855	0.855			0.855	0.855			0.855	0.855		
	CLONAZEPAM	52544074705	0.812	0.812			0.812	0.812			0.812	0.812		
	CLONAZEPAM	52544074801	1.184	1.184			1.184	1.184			1.184	1.184		
	CLORAZEPATE DIPOTASSIUM	52544003601	1.597	1.597	0.201	450%	1.597	1.597	0.168	850%	1.597	1.597	0.147	990%
	COLCHICINE	00364007402	0.174	0.174			0.174	0.174			0.174	0.174		
	CYCLOBENZAPRINE HCL	00591565810	0.879	0.879	0.027	3110%	0.879	0.879	0.027	3170%	1.091	1.049	0.106	888%
	DAILY-VITE	00536354710	0.021	0.021			0.021	0.021			0.021	0.021		
	DIAZEPAM	00591562010	0.247	0.247	0.034	638%	0.247	0.247	0.029	757%	0.247	0.247	0.027	810%
	ENALAPRIL MALEATE	00591067005					1.072	1.072	0.072	1399%	1.072	1.072	0.081	1219%
	ENALAPRIL MALEATE	00591087101	1.525	1.525	0.080	1918%	1.525	1.525	0.085	1700%	1.525	1.525	0.153	898%
	ESTROPIPATE	52544041401	0.432	0.432			0.432	0.432			0.432	0.432		
	FERRLECIT	00364279123	8.600	8.600			8.600	8.600			8.600	8.600		
	FERRLECIT	52544092226			5.128				5.334		8.600	8.600	5.508	56%
	FOLIC ACID	00591521610	0.026	0.026	0.010	157%	0.078	0.031	0.014	120%	0.078	0.078	0.059	32%
	GLIPIZIDE ER	00591084401									0.407	0.407	0.272	50%
	GLIPIZIDE ER	00591084501									0.805	0.805	0.549	47%
	HYDROCODONE W/ACETAMINOPH	00591038705	0.409	0.409	0.056	637%	0.409	0.409	0.055	643%	0.409	0.409	0.045	815%
	HYDROCODONE W/ACETAMINOPH	00591050305	0.909	0.909	0.069	1209%	0.909	0.909	0.068	1221%	0.909	0.909	0.065	1303%
	HYDROCODONE W/ACETAMINOPH	00591054001	0.533	0.533			0.533	0.533	0.168	217%	0.533	0.533	0.157	236%
	HYDROCODONE W/ACETAMINOPH	00591054005	0.506	0.506			0.506	0.506	0.156	224%	0.506	0.506	0.148	242%
	HYDROCODONE W/ACETAMINOPH	52544038701	0.438	0.438	0.067	556%	0.438	0.438	0.066	565%	0.438	0.438		
	HYDROCODONE W/ACETAMINOPH	52544038705	0.409	0.409	0.064	655%	0.409	0.409	0.053	670%	0.409	0.409		
	HYDROCODONE W/ACETAMINOPH	52544050301	0.978	0.978	0.082	1095%	0.978	0.978	0.072	1251%	0.978	0.978	0.137	615%
	HYDROCODONE W/ACETAMINOPH	52544050305	0.909	0.909	0.060	1421%	0.909	0.909	0.094	867%	0.909	0.909		

REPORTED AWPs, MARKET PRICES AND SPREADS - 2001-2003 - HAWAII TARGETED DRUGS

Defendant	Drug	NDC	Year-end Reported FDB AWP 2001	Avg Reported FDB AWP 2001	Avg Market Price 2001	AWP Mkt Price Spread 2001	Year-end Reported FDB AWP 2002	Avg Reported FDB AWP 2002	Avg Market Price 2002	AWP Mkt Price Spread 2002	Year-end Reported FDB AWP 2003	Avg Reported FDB AWP 2003	Avg Market Price 2003	AWP Mkt Price Spread 2003
WATSON	HYDROCODONE W/ACETAMINOPH	52544054001	0.533	0.533	0.187	219%	0.533	0.533	0.157	238%	0.533	0.533		
	HYDROCODONE-ACETAMINOPHEN	00591038701					0.438	0.438	0.058	650%	0.438	0.438	0.054	710%
	HYDROCODONE/ACETAMINOPHEN	00591034905					0.465	0.465	0.039	1103%	0.465	0.465	0.034	1276%
	HYDROCODONE/ACETAMINOPHEN	00591085301					0.699	0.699	0.267	161%	0.699	0.699	0.233	200%
	HYDROCODONE/ACETAMINOPHEN	00591085305	0.675	0.675			0.675	0.675	0.241	180%	0.675	0.675	0.216	212%
	HYDROCODONE/ACETAMINOPHEN	52544034905	0.465	0.465	0.042	1016%	0.465	0.465	0.036	1190%	0.465	0.465		
	HYDROXYCHLOROQUINE SULFAT	00591069805	1.190	1.190	0.170	600%	1.190	1.190	0.206	479%	1.190	1.190	0.197	503%
	INFED	00364301247	18.852	18.852	11.870	59%	18.852	18.852	12.092	56%	18.852	18.852		
	LORAZEPAM	00591024101			0.082		0.880	0.880	0.070	1164%	0.880	0.880	0.063	1291%
	LORAZEPAM	00591024110			0.071		0.843	0.843	0.058	1357%	0.843	0.843	0.054	1461%
	LORAZEPAM	52544024110	0.843	0.843	0.083	920%	0.843	0.843	0.131	542%	0.843	0.843	0.356	137%
	METFORMIN HCL	00591245501					1.443	1.443	0.188	626%	1.443	1.443	0.172	736%
	METFORMIN HCL	00591245505					1.414	1.414	0.178	696%	1.414	1.414	0.137	933%
	METFORMIN HCL	00591271301					0.700	0.700	0.133	427%	0.700	0.700	0.109	541%
	METFORMIN HCL	00591271305					0.704	0.704	0.124	466%	0.704	0.704	0.115	613%
	METFORMIN HCL	00591277501					1.191	1.191	0.155	668%	1.191	1.191	0.131	811%
	METFORMIN HCL	00591277525					1.167	1.167	0.176	564%	1.167	1.167	0.552	111%
	MORPHINE SULFATE	00591061701					4.896	4.896	3.175	54%	4.896	4.896	3.187	54%
	MULTIVITAMIN	00536404610	0.019	0.019	0.009	105%	0.019	0.019	0.009	103%	0.019	0.019	0.009	102%
	OXYCODONE	00591350301												
	PRIMIDONE	00591532101	0.996	0.567	0.279	103%	0.996	0.996	0.412	142%	0.996	0.996	0.417	139%
	PROPAFENONE HCL	00591058201	1.636	1.540	0.922	67%	1.636	1.636	0.703	133%	1.636	1.636	0.492	233%
	SODIUM BICARBONATE	00536454410	0.014	0.014	0.009	57%	0.014	0.014	0.008	62%	0.014	0.014	0.008	68%
	THEREMS-B	00536466110	0.039	0.039			0.039	0.039			0.039	0.039		
	TRAMADOL HCL	00591046601					0.834	0.834	0.212	283%	0.834	0.834	0.093	795%
ZLB BEHRING	GAMMAR-P I.V.	00053748810	650.000	650.000			1000.000	702.740	440.000	60%	1250.000	1130.137	344.637	228%
	HELIXATE FS	00053813001	1.388	1.388			1.630	1.424			1.630	1.630		
	HELIXATE FS	00053813002	1.388	1.388			1.630	1.424			1.630	1.630		
	HELIXATE FS	00053813004	1.388	1.388			1.630	1.424	1.348	6%	1.630	1.630		
	HUMATE-P	00053752010	0.938	0.938			1.250	0.990			1.250	1.250		
	HUMATE-P	00053752020	0.938	0.938			1.250	0.990			1.250	1.250		
	MONOCLATE-P	00053765504	0.950	0.950			1.050	0.965			1.050	1.050		
	MONONINE	00053766001												
	MONONINE	00053766002	1.180	1.180			1.250	1.191			1.250	1.250		
	MONONINE	00053766004	1.180	1.180			1.250	1.191			1.250	1.250		

IN THE CIRCUIT COURT OF THE FIRST CIRCUIT

STATE OF HAWAI'I

State of Hawaii, Plaintiff, vs. Abbott Laboratories Inc.; Alpharma USPD, Inc.; Apothecon, Inc.; AstraZeneca Pharmaceuticals LP, AstraZeneca LP; Aventis Pharmaceuticals, Inc.; Aventis Behring LLC n/k/a ZLB Behring LLC; Barr Laboratories, Inc.; Baxter Healthcare Corporation; Ben Venue Laboratories, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Roxane, Inc. f/k/a Roxane Laboratories, Inc.; Bristol-Myers Squibb Co.; Centocor, Inc.; Dey, Inc.; Forest Pharmaceuticals, Inc.; SmithKline Beecham Corporation d/b/a GlaxoSmithKline; Hoffman-LaRoche, Inc.; Hospira, Inc.; Ivax Corporation; Ivax Pharmaceuticals Inc.; Janssen, LP f/k/a Janssen Pharmaceutica, LP; Johnson & Johnson, Inc.; McNeil-PPC, Inc.; Merck & Co., Inc.; Mylan Laboratories, Inc.; Mylan Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, LP; Par Pharmaceutical Cos., Inc.; Pfizer, Inc.; Pharmacia Corporation; Purepac Pharmaceutical Co.; Roche Laboratories, Inc.; Sandoz, Inc.; Schering-Plough Corporation; Sicor Pharmaceuticals, Inc. f/k/a Gensia Sicor Pharmaceuticals, Inc.; TAP Pharmaceutical Products, Inc.; Teva Pharmaceuticals USA, Inc.; Warrick Pharmaceuticals Corporation; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Doe Corporations 1-100; Doe Entities 1-100. Defendants.	Civil No. 06-1-0720-04 EEH (Complex Litigation) SUMMONS TO ANSWER SECOND AMENDED COMPLAINT

SUMMONS TO ANSWER SECOND AMENDED COMPLAINT

STATE OF HAWAII

To the above-named Defendants:

You are hereby summoned and required to serve upon Plaintiff's attorney, Price, Okamoto, Himeno & Lum, whose address is 707 Richards Street, Suite 728, Honolulu, Hawaii 96813, an answer to the Second Amended Complaint, which is attached. This action must be taken within twenty (20) days after service of this summons upon you, exclusive of the day of service.

If you fail to make your answer within the twenty (20) day time limit, judgment by default will be taken against you for the relief demanded in the Complaint.

This summons shall not be personally delivered between 10:00 p.m. and 6:00 a.m. on premises not open to the general public, unless a judge of the above-entitled court permits, in writing on this summons, personal delivery during those hours.

A failure to obey this summons may result in an entry of default and default judgment against the disobeying person or party.

DATED: Honolulu, Hawaii _____.

SUMMONS
DENIED

_____
CLERK OF THE ABOVE-ENTITLED COURT

In accordance with the Americans with Disabilities Act, and other applicable state and federal laws, if you require a reasonable accommodation for a disability, please contact the ADA Coordinator at the First Circuit Court Administration Office at PHONE NO. 539-4333, FAX 539-4322, or TTY 539-4853, at least ten (10) working days prior to your hearing or appointment date.

IN THE CIRCUIT COURT OF THE FIRST CIRCUIT

STATE OF HAWAI'I

State of Hawaii, Plaintiff, vs. Abbott Laboratories Inc.; Alpharma USPD, Inc.; Apothecon, Inc.; AstraZeneca Pharmaceuticals LP, AstraZeneca LP; Aventis Pharmaceuticals, Inc.; Aventis Behring LLC n/k/a ZLB Behring LLC; Barr Laboratories, Inc.; Baxter Healthcare Corporation; Ben Venue Laboratories, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Roxane, Inc. f/k/a Roxane Laboratories, Inc.; Bristol-Myers Squibb Co.; Centocor, Inc.; Dey, Inc.; Forest Pharmaceuticals, Inc.; SmithKline Beecham Corporation d/b/a GlaxoSmithKline; Hoffman-LaRoche, Inc.; Hospira, Inc.; Ivax Corporation; Ivax Pharmaceuticals Inc.; Janssen, LP f/k/a Janssen Pharmaceutica, LP; Johnson & Johnson, Inc.; McNeil-PPC, Inc.; Merck & Co., Inc.; Mylan Laboratories, Inc.; Mylan Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, LP; Par Pharmaceutical Cos., Inc.; Pfizer, Inc.; Pharmacia Corporation; Purepac Pharmaceutical Co.; Roche Laboratories, Inc.; Sandoz, Inc.; Schering-Plough Corporation; Sicor Pharmaceuticals, Inc. f/k/a Gensia Sicor Pharmaceuticals, Inc.; TAP Pharmaceutical Products, Inc.; Teva Pharmaceuticals USA, Inc.; Warrick Pharmaceuticals Corporation; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Doe Corporations 1-100; Doe Entities 1-100. Defendants.	Civil No. 06-1-0720-04 EEH (Complex Litigation) DEMAND FOR JURY TRIAL

DEMAND FOR JURY TRIAL

Plaintiff State of Hawaii, through its counsel, Price Okamoto Himeno & Lum, hereby demands a jury trial on all claims in this action that are triable of right by a jury.

Dated: Honolulu, Hawaii, JUL 3 - 2007.

RICK J. EICHOR
ATTORNEY FOR PLAINTIFF

CHARLES BARNHILL, JR.
SPECIAL DEPUTY ATTORNEY GENERAL

GEORGE F. GALLAND, JR.
ROBERT S. LIBMAN
W. DANIEL "Dee" MILES, III
CLINTON C. CARTER
P. JEFFREY ARCHIBALD
MICHAEL WINGET-HERNANDEZ
WARREN PRICE, III
KENNETH T. OKAMOTO

ATTORNEYS FOR PLAINTIFF

IN THE CIRCUIT COURT OF THE FIRST CIRCUIT

STATE OF HAWAI'I

State of Hawaii, Plaintiff, vs. Abbott Laboratories Inc.; Alpharma USPD, Inc.; Apothecon, Inc.; AstraZeneca Pharmaceuticals LP, AstraZeneca LP; Aventis Pharmaceuticals, Inc.; Aventis Behring LLC n/k/a ZLB Behring LLC; Barr Laboratories, Inc.; Baxter Healthcare Corporation; Ben Venue Laboratories, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Roxane, Inc. f/k/a Roxane Laboratories, Inc.; Bristol-Myers Squibb Co.; Centocor, Inc.; Dey, Inc.; Forest Pharmaceuticals, Inc.; SmithKline Beecham Corporation d/b/a GlaxoSmithKline; Hoffman-LaRoche, Inc.; Hospira, Inc.; Ivax Corporation; Ivax Pharmaceuticals Inc.; Janssen, LP f/k/a Janssen Pharmaceutica, LP; Johnson & Johnson, Inc.; McNeil-PPC, Inc.; Merck & Co., Inc.; Mylan Laboratories, Inc.; Mylan Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Ortho Biotech Products, LP; Par Pharmaceutical Cos., Inc.; Pfizer, Inc.; Pharmacia Corporation; Purepac Pharmaceutical Co.; Roche Laboratories, Inc.; Sandoz, Inc.; Schering-Plough Corporation; Sicor Pharmaceuticals, Inc. f/k/a Gensia Sicor Pharmaceuticals, Inc.; TAP Pharmaceutical Products, Inc.; Teva Pharmaceuticals USA, Inc.; Warrick Pharmaceuticals Corporation; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc., f/k/a Schein Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Doe Corporations 1-100; Doe Entities 1-100. Defendants.	Civil No. 06-1-0720-04 EEH (Complex Litigation) CERTIFICATE OF SERVICE

CERTIFICATE OF SERVICE

Pursuant to Case Management Order No. 1, entered by the Court in this case on January 5, 2007, the undersigned certifies that a copy of the SECOND AMENDED COMPLAINT was served on all counsel of record through the LexisNexis File and Serve® system on July 3, 2007.

Dated: Honolulu, Hawaii, July 3, 2007.

RICK J. EICHOR
ATTORNEY FOR PLAINTIFF

CHARLES BARNHILL, JR.
SPECIAL DEPUTY ATTORNEY GENERAL

GEORGE F. GALLAND, JR.
ROBERT S. LIBMAN
W. DANIEL "Dee" MILES, III
P. JEFFREY ARCHIBALD
MICHAEL WINGET-HERNANDEZ
WARREN PRICE, III
KENNETH T. OKAMOTO

ATTORNEYS FOR PLAINTIFF